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Abstract
Equine grass sickness is a primary dysautonomy of unproven aetiology that is
mainly fatal, untreatable and unpreventable. Much circumstantial evidence has
been demonstrated that supports the hypothesis that the disease is caused by a
toxicoinfection with Clostridium botulinum type C/D. Further evidence
supporting this hypothesis and an understanding of the immune response of the
horse to this organism and its toxins will facilitate vaccine research and design.
Serum samples from 6-month old ponies (n = 26) were assayed for antibodies
against botulinum neurotoxins type C and D (BoNT/C & D) and against
surface antigens (SA). Statistically significant rises in specific lgG levels against
all three antigens were shown across the sampling period, demonstrating
specific antibody acquisition with age. Adult horses (n = 40) were sampled
fortnightly for twelve months and assayed for specific IgG against the same
antigens. In this group fluctuations in specific IgG levels were observed that
corresponded with changes in management.
Seven acute cases of grass sickness that went to postmortem within 36h of onset
of clinical signs and four control horses that went to post-mortem had both
serum and gut samples taken. Specific IgA was assayed and cases demonstrated
significantly more specific IgA against BoNT/C in the jejunum, ileum and
caecum (P = 0.04, 0.02 and 0.006 respectively). Against BoNT/D, cases
demonstrated significantly more IgA in the pharynx, duodenum and jejunum (P
= 0.01, 0.01 and 0.02 respectively) and against surface antigens cases
demonstrated significantly more specific IgA in the duodenum (P = 0.01).
Serum samples from these acute cases were assayed for specific IgG and IgG
subclasses against the same antigens and compared to co-grazing controls.
Cases demonstrated lower specific IgG against surface antigens than co-grazing
controls (P = 0.06).
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Sera from twelve chronic cases of grass sickness were assayed for specific IgG.
Six horses that were subsequently euthanased demonstrated significantly lower
initial IgG levels against SA (P = 0.05) than those that survived and almost
significantly lower IgG levels to BoNT/C (P = 0.06) indicating that immune
status at disease onset may be important in survival / prognosis. Longitudinal
analysis showed that rising or falling levels of specific IgG had no influence on
disease outcome.
An outbreak of feline dysautonomia was investigated by bacteriological and
serological techniques. BoNT/C was detected in faeces in seven of eight affected
cats after enrichment and also detected in their food. No toxin was detected in
the faeces of controls. Specific IgA was also present in significantly higher
amounts in cases than in controls (P = <0.001) against BoNT/C and SA. In
serological studies, associations were found between low antibody levels and
disease in cats but not in dogs, which lacked an age-matched control group.
EGS and dysautonomias of other species appear to be associated with
toxicoinfections with C. botulinum types C and/or type D. As such, a vaccine,
consisting of both surface antigen and toxin components, would play a vital role
in protecting animals against this distressing disease.
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Chapter 1
Introduction
1.1 Equine Grass Sickness (EGS)
Equine grass sickness is a primary dysautonomia of equids which is generally fatal
and unpreventable. Although first recognised in 1909 at an army camp in Scotland
the aetiology of the disease remains unproven. The disease has spread throughout
Great Britain, with a higher incidence in Scotland (Milne et al, 1994), and also
occurs in Scandinavia and other Northern European countries (Obel, 1955, Gilmour,
1987). An equine dysautonomia, known as mal seco (dry sickness), occurs in
Argentina and Chile and is accepted as being the same as EGS (Uzal and Robles,
1993). Other documented cases include cases in the Falklands (Wood and Gilmour,
1991) and Australia (Stewart, 1977). Although previously rare in Southern Ireland,
incidence there appears to be increasing (U. Fogarty, personal communication).
Primary dysautonomias are characterised by severe neuronal degeneration and
neuronal loss in the enteric and autonomic nervous systems. The clinical,
pathological and epidemiological features of the disease are now well defined and it
is widely accepted that the disease is caused by a toxic insult (Scholes et al, 1993;
Griffiths et al, 1994; Doxey et al, 1995) with severity of clinical signs reflecting the
extent of neuronal damage (Doxey et al, 1992).
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1.1.1 Clinical signs and diagnosis
Classified on the basis of clinical signs and duration of the disease, EGS can present
in four overlapping forms-per acute, acute, sub acute and chronic (Doxey et al,
1991). Mortality rate approaches 90% (Pogson et al, 1992) with all but a few of the
milder chronic cases dying or being euthanased. Per acute cases, the most severe
form of EGS, demonstrate sudden onset of clinical signs with death or euthanasia
within 24 hours, and acute cases within 48 hours. Subacutes can survive up to seven
days with chronic cases lasting for several months before euthanasia or recovery.
The disease can present with a wide range of clinical signs which reflect the extent of
neuronal damage. EGS is characterised by gastrointestinal (GI) dysfunction, the
significance ofwhich is thought to be responsible for the high mortality rate (Scholes
et al, 1993). Depending on the form of EGS, animals present with varying states of
GI stasis/dysfunction, dysphagia and colic. No one clinical sign is diagnostic of one
form of EGS and many of the clinical signs can indicate other conditions/diseases,
making diagnosis difficult for the inexperienced, particularly in acute/early stages of
disease.
Some clinical signs typical of acute, subacute and chronic cases include GI
stasis/reduced gut motility, dysphagia, ptosis, muscle tremors and patchy sweating
(Doxey et al, 1992). Large fluxes ofwater and electrolytes occur across the walls of
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the equine alimentary tract and stasis and the subsequent inability to regulate these
fluxes can swiftly compromise the horse's health (Cottrell, 1999). Acute cases can
demonstrate complete GI stasis with impaction in the large colon, fluid accumulation
in the small intestine and stomach and gastric reflux is a characteristic of AGS.
Acute cases can be depressed, tachycardic and exhibit hypersalivation although this
may be attributable to the inability to swallow rather than true hypersalivation
(Cottrell et al, 1999).
Dehydration is also demonstrated, brought about by the inability/inefficiency of
swallowing. The inability of an animal requiring 10-15 litres ofwater daily to drink
could lead to the preferential transfer of fluid from the rest of the body to the
stomach and small intestine (Doxey et al, 1991Cottrell et al, 1999) resulting in severe
dehydration.
Signs in the subacute form are less severe, though similar to those demonstrated in
the acute form. Disease progression is accompanied by a rapid loss of weight and
condition. A 'tucked up' abdomen which can be especially pronounced in chronic
cases and which has been likened to that of an emaciated greyhound (Edwards, 1987;
Gilmour, 1987; Pinsent, 1989). Chronic cases can also develop rhinitis sicca, base
narrow stance-muscle tremors and patchy sweating can be observed in all forms of
the disease.
A definitive, non-invasive diagnostic test for EGS is not yet available despite much
research effort. Diagnosis is based on clinical signs with confirmation post-mortem
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histopathological examination of autonomic ganglia. There has been some level of
disagreement between research groups as to the accuracy of diagnosis based upon
clinical signs. Scholes et al (1993) held the view that ileal biopsy is essential for
accurate diagnosis and Doxey et al (2000) having the view that histological diagnosis
is not essential. This latter view was supported by examination of ganglia of
recovered chronic grass sickness cases that had later died or been euthanased due to
unrelated causes. Not only had the initial diagnosis of GS been correct, it also
demonstrated that these horses had suffered neuronal loss to such an extent, it cannot
be understood how such cases were able to lead relatively normal lives (Doxey et al
2000).
Research into non-invasive diagnostic tests include the use of barium swallows
(Greet and Whitwell, 1986); analysis of peritoneal fluid (Milne et al, 1990); clinical
signs in conjunction with biochemical testing (Doxey et al, 1991); detection of acute
phase proteins from serum (Milne et al, 1991); the use of phenylephrine to correct
ptosis in GS cases (Hahn and Mayhew, 2000) and urinalysis (Fintl et al, 2002).
No pathogonomic outcome was identified in any area although most are useful in
conjunction with clinical signs and case history. Of twenty-five suspected cases of
EGS given a barium swallow to help detect abnormal oesophageal motility, eighteen
that demonstrated impaired motility were histopathologically diagnosed as having
EGS (Greet and Whitwell, 1986). Parallel studies in cats with feline dysautonomia
(FD) have demonstrated abnormal motility in clinically normal cats, suggesting that
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more work is required to identify what constitutes normal oesophageal movement
(Cave et al, 2003).
Peritoneal fluid of a high specific gravity and total protein concentration but without
blood-staining or marked alkaline phosphatase activity can help differentiate the
acute or subacute GS case from a surgical colic. The high protein concentrations and
specific gravity ofGS peritoneal fluid may be accounted for in part by dehydration,
which is common in GS cases although total serum protein does not show such a
marked increase. The colour of peritoneal fluid in GS cases is often orange/dark
yellow, thought to be caused by increased serum bilirubin levels demonstrated in GS
cases (Milne et al, 1990). Doxey et al (1991) examined clinical signs and
biochemical testing including tests to show if proposed possible vitamin or mineral
deficiencies may be implicated in GS. Both magnesium and selenium deficiency was
ruled out and levels of vitamins B12 and E were within normal ranges, supporting
evidence that GS occurs in horses in good bodily condition rather than those that are
run down.
The presence of certain acute phase proteins detected in the sera of GS cases was
first reported by Johnson et al (1983) who demonstrated that GS cases had a two to
three fold increase in serum haptoglobin, a protein whose role as an acute phase
protein is thought to be involved in inhibition of lysosomal endopeptidase (Milne et
al, 1991), compared to a four to five fold increase in horses with acute inflammatory
conditions. However cases were grouped together with no consideration for
differences in severity of clinical signs or time line of the disease. Milne et al (1991)
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evaluated levels of four acute phase proteins - haptoglobin, orosomucoid,
ceruloplasmin and a2-macroglobulin - in cases grouped into acute, subacute and
chronic cases of grass sickness. Controls consisted of clinically normal animals, colic
cases and those horses with acute inflammatory disorders such as cellulitis and post-
surgery cases. Levels of all four proteins were elevated at different disease stages but
ceruloplasmin and a2-macroglobulin levels may have been elevated due to
dehydration. Further work was required to evaluate levels of the other proteins in
colic cases and a new study is in the planning stage (E. Milne, personal
communication).
Phenylephrine eye drops are used to diagnose Horner's Syndrome in small animals
and humans. Horner's syndrome leads to ptosis of the upper eyelid due to paralysis
of the cervical sympathetic nerve supply (Blood, 1999). Phenylephrine is an a-
adrenergic stimulant used to induce mydriasis (Blood, 1999). In GS cases, low
concentrations of phenylephrine drops can help correct ptosis for extended periods of
time in GS cases as opposed to controls and demonstrates a sensitivity and specificity
of 75% (Hahn and Mayhew, 2000).
Urinalysis showed that acute EGS cases demonstrated significantly higher protein
and creatinine concentrations, higher blood and urine glucose concentrations, higher
specific gravity and lower pH than controls (Fintl et al, 2002). However, none of
these findings are pathogonomic for EGS, all occurring in other disorders and
therefore are only useful in supporting a diagnosis of EGS used in conjunction with
clinical signs.
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1.1.2. Treatment and recovery
Per acute, acute and subacute cases of GS are invariably euthanased on humane
grounds although certain selected cases of chronic grass sickness do recover and
return to full work, something thought impossible previously
(Greig,1942;Pinsent,1989). Cases are selected on the basis of demonstration of
comparatively milder symptoms, particularly in reference to appetite, dysphagia,
colic, gut motility and rhinitis, those cases having a better chance of survival (Milne
et al, 1994). The foundation of treatment is intensive nursing care with lots of human
contact and certain relapsed cases that have been discharged and readmitted can be
attributed to a lack of the intensive nursing required (Doxey et al, 1999). The feeding
ofmoistened, palatable hard feed is also utilised to facilitate swallowing, stimulate
appetite and help with nutrition. Cases usually take many months to recover and are
hospitalised until their weight is stabilised. Often the animal will undergo periods of
recovery followed by temporary periods of ill health (Doxey et al, 1995) and it is
important not to work the animal too hard too soon. The nursing and management
regime at Easter Bush Veterinary Centre has increased the survival rate to 70% of
selected cases.
Cisapride is a prokinetic drug that did demonstrate some therapeutic benefit in the
treatment of CGS cases (Milne et al, 1996). The drug worked by facilitating
acetylcholine release from postganglionic nerves of the myenteric plexus in the gut.
Unfortunately the drug was withdrawn from the market.
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Certain supplementary treatments have been assessed (Fintl and McGorum, 2002)
namely Brotizolam, a potential appetite stimulant; acetylcysteine, to correct the
reduced levels of plasma cysteine found in cases and aloe vera, which has laxative,
antioxidant and anti-inflammatory properties. The study was inconclusive mainly
due to the mix of severity of the chronic GS cases used and the lack of a more
stringent trial such as a blinded placebo-controlled trial which was not considered on
humane grounds.
1.1.3. Epidemiological studies
The first recognised outbreak of GS occurred in a Scottish army camp in 1909
(Tocher et al, 1923) although it is possible that the disease occurred unrecognised
and unreported before this (McKay, 1958). The lack of an identified aetiological
agent has led to many epidemiological studies that have confirmed/disproved many
observations about the disease.
After the outbreak described in the Barry Camp, the disease spread throughout
North and South Eastern Scotland (McCarthy et al, 2001) and from 1911, the disease
had been reported in the majority of counties in England and Wales (Greig, 1942). It
was well reported in Northern Europe including Sweden and France (Bendixen 1946;
Lhomme et al, 1996 referenced in McCarthy et al, 2001) and Denmark (Obel, 1955)
among others. Apart from the pathologically identical disease, mal seco, in South
America (Uzal et al, 1993) worldwide histopathologically confirmed cases have only
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been reported in Australia (Stewart, 1977) and the Falkland Islands (Woods et al,
1991).
Epidemiological publications involving interviews/questionnaires date back to 1958
(McKay 1958) although only those from 1974 onwards use statistical analysis
(McCarthy et al, 2001). Among those risk factors found to be relevant are younger
age (Greig, 1942; Gilmour and Jolly, 1974; Doxey et al, 199; Barrett et al, 1992;
Wood et al, 1998; Newton et al, 2004), horses kept outdoors (Doxey et al, 1991;
Wood et al, 1998), time on pasture/premises (Greig,1942; McKay 1958; Gilmour and
Jolly, 1974; Wood et al, 1998), association of the pasture with previous cases (Doxey
et al, 1991; Wood et al, 1998; Newton et al, 2004), spring (Begg 1936; Guthrie,
1940; Doxey et al, 1991; Wood et al, 1998; Newton et al, 2004).
EGS was long believed to be a disease mainly of working horses and ponies and
research suffered from a lack of funding due to this misconception. The prevalence
of the disease in such animals is more related to the fact that these types of horses
spend more time at grass than sports horses and thoroughbreds. Wood et al (1998)
found that draught horses were seemingly more at risk from the disease when using a
univariate analysis but that the relationship was no longer significant following
adjustment for confounding variables, such as time spent at grass. Certainly another
centre of high incidence in the UK is in the Eastern Counties of the UK, Newmarket
in particular, due in part to the high concentration of horses and mares visiting studs
and thus being subjected to change of pastures and conceivable stress. Certainly,
some high profile cases such as the racehorses Mr Baileys, who recovered from
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chronic grass sickness and Dubai Millenium, who was euthanased due to acute grass
sickness, have demonstrated that this disease can affect any horse, even those with
limited access to grass.
Certain weather conditions are thought to have been conducive to GS outbreaks,
namely warm dry weather with ground frosts whereas wet weather was associated
with a decrease in incidence (Tocher, 1924; Pool, 1928; Greig, 1942). Greig (1942)
found no association of weather conditions with the disease although Doxey et al
(1991), emphasising the local character of Scottish weather, found that the disease
was associated with cooler, dry weather with intermittent ground frosts. In a UK-
wide study Wood et al (1998) demonstrated that 66% of cases occurred following
predominately dry weather.
More recent epidemiological studies have utilised case-control studies and have
concentrated on the risks of certain premises (McCarthy et al, 2004a). The McCarthy
(2004b) study will be further discussed in section 1.2.1. McCarthy (2004a) identified
two novel risk factors for increased EGS risk at certain premises with soil
disturbance and increased soil nitrogen, as well as premises with previous cases of
GS-previously reported by Wood et al (1998). McCarthy et al (2004) hypothesize
that a high level of soil nitrogen influences the amount of herbage available to the
horses present, which may be analogous to dietary change and may even be the long
sought after dietary trigger.
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Epidemiological findings indicate an infectious aetiology. The increased risk in
younger animals, decreased risk in those horses having had prior contact with a GS
case and those having spent longer periods of time on a certain premises/pasture and
the increased incidence of the disease at certain times of year all imply that a
protective immune response to the aetiological agent occurs.
1.1.4 Aetiology
Identification of the causal agent ofEGS is imperative to enable treatment,
intervention strategies and its prevention. Many possible putative agents have been
investigated since the disease was first recognised including fungi, chemical toxins,
poisonous plants and toxin-producing bacteria.
Plants
Due to the obvious association with grazing, toxic plants were investigated very early
in the history of the disease. Tocher et al (1923) did not find any plant known to be
toxic to horses on any GS associated premises. Alsike clover was thought to be
involved but extracts of the plant were not toxic when fed to horses (Tocher, 1924;
Greig, 1942). Botanical surveys found no association of any one plant common to all
GS pastures (Greig 1942; Robb et al 1997). Uzal et al (1996) tried reproducing the
disease by feeding Festuca argentina, a plant found in the diet of nine mal seco
cases, but failed to reproduce clinical signs or pathology.
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Fungi
Cultures of fungi found on GS pastures have also been tested and failed to reproduce
the disease (Greig, 1942) and no one particular species of fungi has been isolated
from GS cases (Doxey et al, 1990). It was thought that an endophytic fungus of
Festuca argentina might be responsible but these fungi have not been found on all
GS pastures and were identified in less that 20% of plants from GS and mal seco-
associated pastures (Robb et al, 1997a).
Robb et al (1997a) identified Fusarium species on all GS associated pastures in the
UK and in Patagonia that are capable of producing mycotoxins that were found to be
cytotoxic to equine nerve cells in vitro (Robb et al, 1997b). Dosing horses in
Patagonia with cultures of these fusaria isolates failed to produce clinical signs or
pathological changes (Uzal and Robles, 1997). They hypothesised that exposure to
fusarial toxins could be a predisposing factor to GS as they are known to alter GI
flora, affect the immune system and affect vitamin metabolism. As they had also
demonstrated that fusaria can out-compete other fungal species in dry weather
conditions the evidence supporting their hypothesis was promising encompassing
presence of the agent, cytotoxicity and a possible association with the weather
patterns associated with GS outbreaks.
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Abnormal plant biochemistry and oxidative stress.
The role of oxidative stress in GS cases has been under investigation for several
years. Oxidati ve stress can result from an excess of free radicals or from a depletion
of antioxidants and neurons are particularly sensitive (McGorum et al, 1998).
McGorum et al (2000) hypothesised that EGS is associated with ingestion of plants
under metabolic stress-due either to abnormal climatic conditions or fungal
colonisation. Plants immediately collected from a pasture after an outbreak of GS
demonstrated reduced antioxidant and weak pro-oxidant properties when compared
to control plants which consisted of plants from GS pastures out ofGS season and
plants from GS pastures grown in optimal conditions. However, these biochemical
changes could not be reproduced under experimental drought and chilling conditions.
Although the authors thought it unlikely that the levels ofmetabolites or the
pro-oxidant levels detected could be responsible for neuronal damage directly, it was
suggested that the stressed plants might play a part in onset of the disease by altering
the equine intestinal environment thus allowing overgrowth of some pathogen; in
conjunction with a neurotoxic metabolite not detected in the study; or if the
metabolic stress is caused by a plant pathogen capable of producing a neurotoxin. A
further study (McGorum et al, 2003) showed that EGS horses demonstrated no
evidence of systemic macromolecular damage although the involvement of oxidative




Grass sickness has been linked to ingestion of cyanogens either from white clover or
linseed (Gordon, 1934; Greig, 1942; Lannek et al, 1961) but had not been proven
(McGorum and Anderson, 2002). Following their previous work which
demonstrated that plasma amino acid profiles in EGS cases resemble those found in
of subacute and chronic cases of cyanide toxicity (McGorum and Kirk, 2001), a
further study measuring whole blood cyanide and plasma and urinary thiocyanate
showed that co-grazing controls demonstrated higher levels of these compounds than
other controls, indicating increased exposure to cyanogens. These increased levels
were not found in clinical cases although they could have been exposed before the
onset of anorexia-thiocyanate is rapidly eliminated. The animals also may be unable
to synthesise thiocyanate from cyanide. Further investigation to elucidate any causal
relationship between cyanogens and GS is required.
Bacterial
Several potential bacterial causes of GS have been investigated following detection
of specific organisms/toxins from clinical cases. Gaiger (1922, cited in Greig, 1942)
isolated a diplostreptococcus from the CNS of an acute case. Attempts to reproduce
the disease by injection of the organism failed. Clostridium perfringens type D was
also investigated following detection of the toxin in several acute cases however,
both a challenge and a protection study failed.
Ochoa and de Valendia (1978) demonstrated a positive relationship between
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C. perfringens type A and sera from recovered CGS cases using seroneutralisation
techniques. However, Gilmour et al (1981) did not reproduce these findings using
sera from Scottish cases of GS indicating that the disease in Columbia was not the
same due to certain clinical and pathological differences.
Tocher et al (1923) hypothesised a link between C. botulinum and GS, with
botulinum neurotoxin produced in vivo and this hypothesis is further detailed in
section 1.2.1
Others
A review by Greig (1942) was able to disregard plant poisoning, anaphylaxis, toxic
chemical production at pasture and poisonous products of intestinal origin as the
cause ofEGS. The same study also disregarded invasive and/or toxin producing
bacteria and protozoal causes. Viruses have also been suggested as a possible cause
of EGS-the nature of the initial spread of the disease was suggestive of some sort of
insect vector-however investigations into an insect vector was negative (Greig, 1942)
and a virus has not been isolated.
Selenium deficiency in cattle can be a problem in Scotland, leading to muscular
dystrophy. It was suggested that selenium deficiency was indicated in GS when it
was noted that cases often occurred on farms where selenium deficiency was a
problem. Selenium levels were found to be low in cases and controls from the same
premises (MacPherson, 1978).
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1.1.5 Evidence of a toxic aetiology
It is now widely accepted that EGS is caused by a toxin that is probably produced
enterically rather than ingested (Scholes et al, 1993; Griffiths et al, 1994; Doxey et
al, 1995). Peritoneal injection of serum and serum fractions from acute GS cases
have resulted in pathological changes in healthy horses although not in clinical
disease (Gilmour, 1973; Gilmour and Mould, 1977).
Gel filtration and saturated ammonium sulphate precipitation were used to prepare
plasma fractions of acute serum that was then injected intraperitoneally into
experimental ponies (Gilmour and Mould, 1977). Another pony was given an oral
dose of serum with known neurotoxicity and the same preparations were also
administered to laboratory small animals. No clinical disease was demonstrated in
any animal and histopathological changes were only observed in ponies, not in the
small animals. No pathology was observed in the pony that was dosed orally. The
lack of changes in this pony was attributed to inactivation/non-absorption in the
alimentary tract, too small a dose or that the toxin is acquired by another route or is
the result of the disease process. They established that the toxin is proteinaceous
and/or bound to a protein in the high molecular weight (greater than 30 kDa)
category. Every acute serum tested proved neurotoxic reproducing the
histopathology typical of grass sickness.
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Griffiths et al (1994) injected acute GS serum into the parotid salivary gland of
ponies. The salivary gland was chosen due to ease of administration and because this
gland receives its sympathetic innervation from the ipsilateral cranial cervical
ganglion. The contralateral gland and ganglion was used as a control. Clinical
disease was not reproduced but 4 out of 5 batches of acute sera reproduced
chromatolytic changes in the ganglia with the most dramatic changes produced from
sera from cases that were sampled within 12 hours of onset of clinical signs. One
batch of the neurotoxic serum was fractionated and the filtrate and retentate
(containing components ofmore that 30kDA) were injected into the same pony, into
opposite glands. Only the retentate produced chomatolytic lesions. They
hypothesised that the putative neurotoxin in GS gains access to the axon terminal and
is then retrogradely transported to the neuronal perikaryon. An inflammatory reaction
was observed in the ganglion of the pony that received sera from a chronic grass
sickness case of three weeks duration. The lack of any similar lesions elsewhere in
this pony was suggested to be due to some serum component - possibly due to
antibodies produced to the toxin component by the donor animal. The authors go on
to suggest that the majority of damage to neurones could happen within 1 to 2 days
from exposure to toxin.
Johnson (1985) discovered a small molecular weight compound in sera of acute GS
cases using solvent extractions and thin-layer chromatography. Extraction was
carried out on serum samples that had known in vivo toxicity but no toxicity was
demonstrated following treatment of the samples. A follow-up study using similar
methods by Pemberton et al (1990) identified the compound as Cortisol.
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In vitro studies have also demonstrated the neurotoxicity of plasma from GS cases.
John et al (1997a) used sera from previous in vivo studies to examine toxicity in
equine-derived autonomic nerve cell lines. Concentration-dependent toxicity was
found from all serum samples, even from those samples that had not produced
in vivo changes, although this was much less pronounced in sera from this group.
The authors suggested that this was due to immunity of the recipient horses in this
group or due to a genetic resistance. The plasma also exhibited a more general toxic
effect as demonstrated by toxic-mediated damage in liver and lung cells. Further
work demonstrated differing susceptibility in different cell lines (John et al, 1997b).
The results could not rule out possible differences caused by the presence of non-
neuronal cells in the cultures; by cell lines derived from foetal, neonatal or mature
animals; thoracic chain ganglia and cranial cervical ganglia; the presence of cell lines
derived from GS cases that may have led to the most resistant cell lines being
established in culture; the retroviral gene vector stimulating growth of other host
genes, leading to the variable growth stimulation of the different cell lines by control
plasma. They also raised the possibility that there could be a genetic susceptibility
among different breeds.
Although this has long been suggested, specific breed susceptibility has never been
demonstrated in epidemiological studies (Wood et al, 1998) There is anecdotal
evidence that increased incidence can be linked to particular stallions (John et al,
1997b). Similar anecdotal evidence exists suggesting a genetic susceptibility in feline
dysautonomia (Symonds et al, 1995).
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1.1.6 Pathology
Early histopathological reports on the neuropathology ofEGS failed to identify any
lesion that would account for the clinical manifestation of the disease (Whitwell,
1997). Obel (1955) was the first to describe severity and distribution of neuronal
lesions in affected animals and these lesions were later confirmed by various authors
including Mahaffey (1959) and Gilmour (1973), among others.
Neuropathology
A characteristic neuronal lesion demonstrates a lack ofNissl substance resulting in a
form of chromatolysis which is often accompanied by nuclear eccentricity, pyknosis
and karyorrhexis (Whitwell, 1997). Neuronophagia follows cell death and neuronal
damage in EGS is present in all autonomic ganglia and the enteric plexuses to
different extents. Other frequent features include cytoplasmic vacuolation either in
the form ofmultiple small vacuolations or single, larger ones and smooth,
eosinophilic spheroids within/adjoining perikarya.
Historically there was some disagreement between researchers as to whether the
degree of damage to the peripheral autonomic nervous system corresponded to the
extent of clinical disease (Brownlee, 1959). A study that severed the nerve supply to
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the large colon in ponies did not produce significant changes in colonic function
(Sellers et al, 1979) and damage to the peripheral ganglia did not result in clinical
signs (Gilmour, 1973a; Pogson et al, 1992). Attempts to correlate the degree of
enteric neuron damage to level of intestinal dysfunction and/or severity of clinical
signs did were not carried out until the 1990s (Doxey et al, 1995). Scholes et al
(1993) demonstrated a relationship between neuronal damage and clinical signs.
Chronic cases exhibited the majority of neuronal loss in the terminal small intestine
(particularly the ileum) whereas acute cases showed severe neuronal degeneration
and loss at most sample sites. These authors also suggested that discrepancies
described previously i.e. when chronic cases were found to have more severe
neuronal damage than acute cases where either attributable to a misdiagnosis of the
form of GS seen or not using consistent GI sampling sites.
Doxey et al (1995) carried out an extensive study to build upon the data published by
Scholes et al (1993). The study was designed to discover the sites of neuronal
damage, its severity and distribution throughout the small and large intestine and to
compare cases of differing clinical severity. They demonstrated that the ileum was
subjected to a high level of neuronal damage in all presentations ofGS. Acute cases
had neuronal loss and damage to the jejunum and small colon as well as the ileum.
However, not all cases showed the same pattern of neuronal damage with some
acutes and subacutes demonstrating more damage in the jejunum than the ileum or
comparative amounts of damage in both. The correlation therefore appears to lie in
severity of neuronal damage and loss rather than where the lesions occur
(Doxey et al, 1995).
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The lack ofGI motility observed in GS cases has also been investigated. When the
cholinergic activity of equine intestinal muscle was measured in vitro, it was found
that tissue from EGS cases released less endogenous acetylcholine than tissue from
controls when stimulated with physostigmine (Murray et al, 1994). Following
identification of interstitial cells ofCajal (ICC) in the equine GI tract, Hudson et al
(1999) investigated numbers of in EGS and demonstrated diminished numbers of
these cells in EGS cases (Hudson et al, 2001). ICC cells initiate slow wave activity in
the GI tract that is central to the synchronization ofGI motility. Similar findings
were found in horses with large colon obstructive disorders (Fintl et al, 2004) leading
to the question ofwhether the lack of ICC cells was the cause or the effect of severe
colic.
Other pathology
Other non-neuronal lesions are generally secondary lesions that reflect the severity
and/or duration of the disease (Whitwell, 1997). Oesophageal ulcers are often seen
and probably the result of regurgitation due to oesophageal malfunction. The small
intestine can be distended with fluid whereas the caecum and large intestine are
generally impacted to various degrees. The nasal mucosa of longer duration cases
can be dry and recent findings by Prince et al (2003) demonstrate that rhinitis sicca,
often associated with chronic grass sickness, may have an underlying cause of a
decrease in expression of sensory neuropeptides. Some inflammatory changes are
sometimes observed in the livers of affected horses and spleens of longer duration
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cases can be enlarged / engorged with blood (Whitwell, 1997). Lymphoid tissues are
generally normal although lymph nodes at the chest entrance are frequently inflamed
and /or haemorrhagic.
1.2.1 Clostridium botulinum
First isolated from an outbreak of botulism in Belgium in 1895 (Hathaway, 1989),
the species C. botulinum encompasses a phenotypically and genotypically
heterogenous group of organisms that are classified as one species due to production
of immunologically distinct neurotoxins (BoNTs) that possess the same
pharmacological action. The antigenicity of the neurotoxins has enabled the division
of the species into seven types, designated A through to G in chronological order of
discovery (Hunter and Poxton, 2002).
Nomenclature is further complicated due to isolation of strains capable of expressing
combinations of toxins, with organisms demonstrating the production of both
BoNT/A and BoNT/F (Hathaway and McCrosky, 1987; Barash and Arnon, 2004)
and BoNT/A and BoNT/B (Collins and East, 1998; Kobayashi et al, 2003). Isolates
of C. barati and C. butyricum have been found that produce BoNT/F and BoNT/E
(Hall et al, 1985; McCrosky et al, 1986).
C. botulinum has been divided into four groups based on characteristics such as
volatile fatty acid production. Group I contains type A and proteolytic strains of
types B and F; Group II contains type E and non-proteolytic/saccharolytic strains of
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B and F; Group III consists of types C and D; Group IV consists of type G (Hunter
and Poxton, 2002) and this species has now been renamed B. argentiense. These
groups also include phenotypically related, non-neurotoxigenic organisms such as
C. sporogenes in Group I and C. novyi type A in Group III.
Nucleic acid hybridisation and 16S ribosomal RNA sequencing studies have
supported the division of the species into the four groups with four distinct
phylogenetic groups demonstrated (Hutson et al, 1993; Collins and East, 1998).
There is evidence of lateral gene transfer as nucleotide sequences of the neurotoxin
genes do not support the phylogenetic groupings and BoNT/E and G have been
found on plasmids (Eklund et al, 1988; Hauser et al, 1992) and BoNT/C and D are
bacteriophage encoded (Eklund et al, 1972; Eklund et al, 1974).
1.2.1 Group III organisms
C. botulinum type C and D and C. novyi type A are phenotypically similar and
cannot be distinguished by culture methods, biochemical profiles or by gas liquid
chromatography. Their surface antigens are immunologically cross-reactive (Poxton,
1984; Poxton and Byrne, 1984) and non-neurotoxigenic Group III organisms are
effectively identical (Hunter and Poxton, 2002).
16S ribosomal RNA analysis demonstrates that these organisms can be grouped
together as a separate phylogenetic lineage although a 1% sequence divergence
suggests that types C and D are different species. C. novyi type A demonstrates a 2 %
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sequence divergence again indicating that it is a different species (Hutson et al,
1993).
Group III organisms therefore can only be identified to the species level by detection
of the major toxin produced with BoNT/C and BoNT/D produced by C. botulinum
types C and D correspondingly and the novyi alpha toxin for C. novyi type A. Each
of these toxins is encoded on separate pseudolysogenic bacteriophages with
consequently unstable host-phage relationships. Cycles ofphage loss and reinfection
are thought to occur in vivo (Eklund et al, 1974) and phage loss can occur in the
laboratory due to repeated subculture. Loss of the phage is associated with a loss of
toxicity. When phage loss was induced, the organism could be re-infected with the
original phage reinstating its original toxicity, or by phages encoding BoNT/D or the
novyi alpha toxin (Inoue and Iida, 1971; Eklund et al, 1974; Eklund and Poysky,
1974).
1.2.2 Group III toxins
C2 and C3 exotoxins.
C. botulinum types C and D can produce up to three toxins including the neurotoxins
and two ADP-ribosylating toxins, C2 and C3. C3, an exo-enzyme with ADP-
ribosylating activity, is encoded on the same bacteriophage as the neurotoxins and is
divided into two groups according to antigenicity (Moriishi et al, 1993) and there is
evidence that suggests that the toxin is encoded on a transposon (Hauser et al, 1995).
C2 is a binary ADP-ribosylating toxin that is chromosomally encoded and produced
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by the majority of type C strains and by a number of type D strains although it has
not been detected in other BoNT-producing strains. The C2 toxin is produced during
sporulation (Nakimura et al, 1978) and is thought to be part of the structural proteins
of the spore coat (Yamakawa et al, 1983). The genes for both C2 components have
been detected by PCR in non-neurotoxigenic isolates (A. Heffron, unpublished data).
The C2 toxin consists of two components (Barth et al, 2000) an enzymatic
component designated C2I, which is the ADP-ribosyltransferase which modifies G
actin, and the binding component designated C2II that mediates entry of the toxin
into the cell (Simpson, 1982; Ohishi and Miyake, 1985; Aktories et al, 1986). Both
components are required for toxicity which also requires assembly of the two
components at the target cell surface (Barth et al, 2000). Binding is via asparagine-
linked glycans on the cell surface (Eckhardt et al, 2000) and following binding the
toxin is taken up by receptor-mediated endocytosis (Simpson, 1989). Blocker et al
(2000) demonstrated that receptor binding is mediated by the C terminus ofC2II, in
particular the last seven amino acid residues.
C2 ADP-ribosylates G - actin at arginine 177 (Aktories et al, 1986) causing the
inhibition of actin-polymerisation (Vanderkerckhove et al, 1988). Certain amino
acid residues are conserved among prokaryotic and eukaryotic arginine-modifying
ADP-ribosylating toxins and Barth et al (1998) identified these amino acid residues
in C2I and showed that they were fundamental for activity of the enzymatic
component. The inhibition of actin polymerisation causes depolymersiation of actin
filaments and the breakdown of the actin cytoskeleton (Barth et al, 2000).
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C2 is able to cause substantial morbidity and mortality in experimental animals
(Hunter and Poxton, 2002) although little is known of its pathophysiological role in
naturally - occurring infection. It is a lethal toxin that demonstrates enterotoxicity by
increasing vascular permeability (Ohishi et al, 1980), causing fluid accumulation in
intestinal loops (Ohishi, 1983) with accompanying histological damage to the
epithelial surfaces of the intestines (Ohishi and Odagiri, 1984). Visceral smooth
muscle presents a potential target to the C2 toxin as they are high in y-actin but
relatively poor in a-actin (Mauss et al, 1990). This toxin also has effects on the
immune system, demonstrating inhibitory effects on neutrophil migration (Aktories
et al, 1992) and increasing the production of oxygen-free radicals (Aktories et al,
1992) and granule protein release in neutrophils (Norgauer et al, 1988) and such
stimulation of a premature respiratory burst may assist immune response evasion
(Hunter and Poxton, 2002).
Very few published reports exist of the identification ofC2 toxin from clinical cases
of botulism apart from in birds (Hunter and Poxton, 2002). It has been suggested that
C2 was implicated in some outbreaks of type C botulism in broiler chickens, where
cases presented with diarrhoea and enteritis, as well as the signs pathogonomic for
botulism (Ohishi and Gupta, 1987). An outbreak of type C botulism in horses in the
US led to detection of C2 in the GI tract of one animal, with intramuscular oedema
found in five other animals in the outbreak (Kinde et al, 1991).
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It is unknown if the exoenzyme C3 play any role in the pathogenesis of disease
(Hunter and Poxton, 2002) although it has demonstrated some effects in vitro that
could be important in disease such as the ability to depolymerise the actin
cytoskeleton in the vicinity of tight junctions leading to increased permeability of the
epithelium (Nusrat et al, 1995). This toxin has also demonstrated some
neurocytotoxicity in vitro albeit non-specific to neurones and only at high
concentrations (Williamson and Neale, 1998).
Type C and D neurotoxins.
BoNT/C and D have a sequence identity of 52.2% (Oguma et al, 1981; Oguma et al,
1982) and have both common and specific antigenic sites as well as strain-specific
epitopes (Oguma et al, 1984; Moriishi et al, 1993). It is thought that the cycles of
curing and reinfection that happen naturally in the environment may be responsible
for the heterogeneity that is demonstrated in types C and D (Sunagawa et al, 1991).
Botulinum neurotoxins inhibit the release of acetylcholine from cholinergic
synapses. They are synthesised as a single 150kDa polypeptide chain that is cleaved
by host/bacterial proteases to form the active dichain which is covalently linked by a
single disulphide bond. The dichain consists of a lOOkDa heavy chain and a 50kDa
light chain (Hunter and Poxton, 2002). Crystallographic structure ofBoNT/A has
determined the presence of three functional domains that were previously proposed
by biochemical analysis (Lacy et al, 1988).
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It has been proposed that botulinum neurotoxins act in a four step model involving
cell binding, internalisation, membrane translocation and target modification in the
cytosol (Montecucco and Schiavo, 1993; Montecucco et al, 1994) although the first
three steps of this proposed model are less experimentally defined than the last
(Hunter and Poxton, 2002).
Botulinum neurotoxins are produced as complexes called progenitor toxins which
exist in three forms ranging from 300 to 900kDa, having sedimentation constants of
12S, 16S and 19S (Schiavo et al, 2000). BoNT/C and D can form the 12S and 16S
complexes, the 12S consisting of the neurotoxin and non-toxic haemaglutinin
component (NTNH) and the 16S consisting of the neurotoxin, NTNH component and
a haemaglutinin component (HA) in the ratio 1:1:2 (Ohiishi et al, 1980; Fujinaga et
al, 1997). The genes encoding the NTNH and HA components are immediately
upstream of the neurotoxin gene (Hauser et al, 1995) although the NTNH
components of C. botulinum type C and D do not share the same phylogeny as the
neurotoxins- demonstrated by their identical antigenicity (Oguma et al, 1980) and
nucleotide sequence (Inoue et al, 1999) compared to the antigenically distinct
neurotoxins. The larger progenitor complexes are associated with higher oral toxicity
(Fujinaga et al, 1997), and so it is thought that the non-toxic components are
important in the pathogenesis of botulism, possibly protecting the neurotoxin from
proteases and acidity in the GI tract (Ohiishi et al, 1980).
The HA component of the 16S type C progenitor toxin binds to
glycolipids/glycoproteins in the small intestine of guinea pigs although the type C
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neurotoxin or the NTNH component does not (Fujinaga et al, 1997). The 16S
complex did not dissociate in the small intestine and it is thought that due to a higher
binding affinity for intestinal epithelial cells, that the 16S progenitor toxin possesses
a higher oral toxicity (Fujinaga et al, 1997). Inoue et al (1999) demonstrated that the
16S type C and D toxins do not bind to neutral glycolipids or asialoglycoproteins but
do bind to sialylglycolipids and sialglycoproteins. Mahmut et al (2002) demonstrated
that immunisation of the non-toxic component of the 16S complex could lead to a
protective immune response in mice immunised nasally and then challenged orally
with both BoNT/C and BoNT/D, indicating that mucosal antibodies may reduce
absorption of the toxins from the small intestine.
BoNT/A and BoNT/B have been shown to be bound to human intestinal cells and the
toxins transcytosed but BoNT/C was not transcytosed in the same study
(Maksymowych and Simpson, 1998). Uncomplexed toxin was used so it is not
known if the 16S progenitor toxin would be bound and transcytosed although the
lack of an efficient mechanism for transcytosis in humans may explain why BoNT/C
has not been implicated with human botulism (Maksymowych and Simpson, 1998).
M cells may take up the toxin (Schiavo et al, 2000). BoNT/C is highly toxic in
humans via inhalation (I.R. Poxton, personal communication).
BoNT/C has been shown to bind with higher affinity to mouse neuroblastoma cell
lines than to human and to bind to both cholinergic and adrenergic cells in vitro
(Yokosawa et al, 1989; Kurokowa et al, 1997).
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The C terminal domain is composed of two subdomains, HcN and HcC the latter of
which is concerned with binding and is poorly conserved between the different
botulinum toxins (Schiavo et al, 2000). These authors have proposed a two-receptor
model of binding of neurotoxins involving a polysialoganglioside receptor that is
similar for the different botulinum toxins and a neurotoxin-specific glycoprotein
receptor. Preincubation ofBoNTs with gangliosides has been shown to inhibit
binding - the extent of inhibition depending upon the type of ganglioside (Schiavo et
al, 1993). Yokosawa et al (1989) demonstrated that BoNT/C was inhibited from
binding by pre-incubation with neuraminidase, trypsin or pronase which points
towards a glycoprotein containing sialic acid as a BoNT/C receptor.
Internal isation of BoNTs is thought to be by receptor-mediated endocytosis via
clathrin coated pits (Niemann, 1991) and is temperature and energy dependent
(Black and Dolly, 1986). The He domain is sufficient for internalisation (Schiavo et
al, 2000) and neurotoxins of different strains of type B have demonstrated different
binding affinities due to mutation of amino acid residues in this region (Ihara et al,
2003. Exit from the vesicle is though to be initiated by acidification of the
compartment - the low pH induces a conformational change in the toxin's structure
enabling both the heavy and light chains to penetrate the hydrocarbon core of the
vesicular membrane (Donovan and Middlebrook, 1986) with the N terminal of the
heavy chain forming the channels (Blaustein et al, 1987) and refolding of the toxin
occurring in the cytosol following translocation of the light chain (Schiavo et al,
2000).
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BoNTs are zinc-dependent metalloproteases which cleave the protein components
involved in neuroexocytosis (Schiavo et al, 1992; Blasi et al, 1993a and 1993b;
Schiavo et al, 1993a and 1993b). Zinc plays an essential role in peptide bond
hydrolysis and the light chains of the neurotoxins possess a zinc-binding motif
(Schiavo et al, 1993c). BoNT/C and BoNT/D cleave syntaxin and SNAP-25 and
synaptobrevin/VAMP respectively (Blasi et al, 1993a; Schiavo et al, 1993b; Schiavo
et al, 1995). The neurotoxins cleave a single site in their respective target proteins
which results in a sustained blockage in neurotransmitter release (Hunter and Poxton,
2000).
Syntaxin and SNAP-25 proteins are both bound to the presynaptic membrane and
synaptobrevin/VAMP is a synaptic vesicle membrane protein. These three proteins
together form the synaptic SNARE complex, central to the neuroexocytosis process.
The proteins interact with soluble factors to bring about membrane fusion and
exocytosis (Sollner et al, 1994) and when assembled are highly stable and unaffected
by BoNTs (Hayashi et al, 1994).
Peptides of the target proteins containing only the cleavage site are not cleaved by
the neurotoxins (Montecucco and Schiavo, 1994) indicating that recognition of the
substrate by the toxin is twofold; interaction of a region A which is a structural motif
common to all three protein targets-common to all is the SNARE motif, a region of 9
amino acids (Schiavo et al, 2000) and region B that contains the peptide bond to be
cleaved (Rossetto et al, 1994).
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Uniquely among botulinum neurotoxins, BoNT/C has demonstrated cytotoxicity to
murine neurones in vitro (Kurakawa et al, 1987; Williamson et al, 1995; Osen-Sand
et al, 1996; Williamson and Neale, 1998) in both mature and developing neurones
(Williamson and Neale, 1998) and it is thought that the effect of BoNT/C on syntaxin
in the synapse mediates neuronal death. However, the use of BoNT/C in humans to
treat dystonias did not result in neuronal death (Eleopra et al, 1997). No work has
been published on the cytotoxic effects, if any, of BoNT/D.
1.2.3. The involvement of C. botulinum type C/D in the
aetiology of EGS
C. botulinum was first implicated as the aetiological agent of EGS in 1919 (Tocher et
al, 1923) following isolation of a large, anaerobic bacillus from clinical samples. By
1924, Tocher and his colleagues had collated a body of evidence that supported his
hypothesis including recovery of the organism from the spleens of subacute GS and
neutralisation of toxin from these isolates with antitoxin from known strains of
Bacillus botulinus. The isolates and their toxin were toxic in experimental animals
and apparently reproduced GS symptoms and antitoxin to BoNT/A was detected in
chronic and recovered cases but not in acute cases (Tocher 1923; 1924). Tocher also
hypothesised that the disease was caused by toxin production in vivo rather than
ingestion of toxin as in classical botulism as evidenced by the detection of specific
complement-binding antibodies against botulinum types A and B in subacute cases
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and the lack of such antibodies in clinical normal animals or those vaccinated by
toxin alone (Tocher et al, 1923).
In 1922-1923 a protection study was carried out in 1433 horses utilising a toxin-
antitoxin mixture prepared from known strains. The mortality rate in vaccinated
horses compared to unvaccinated controls was 2.8% versus 9.3% in 1923 and 1.5%
compared to 8.2% of controls in 1923. Wood et al (1999) calculated the significance
of the reduction ofmortality as P = <0.0001 - highly statistically significant.
Tocher's work was strongly criticised at the time for not using a toxin-antitoxin
mixture from equine isolates (human isolates were used) and because it was thought
that the organism was not conclusively C. botulinum (Gaiger in Tocher et al, 1923).
Toxicoinfectious botulism was not known at this time-infant botulism was not
described until 1976 (Midura and Arnon) and toxin production within a living animal
was not thought possible (Anon, 1927; Greig, 1942). Tocher thought that a
predisposing factor, possibly a nutritional or metabolic disturbance that would lead to
gastric irritation, would lead to toxin production within tissue as opposed to toxin
production in the gut.
The botulinum hypothesis failed to gain support among the veterinary community
and further experimental work, whereby type B toxin was stomach tubed into horses
leading to classical botulism, was thought proof enough that GS could not be caused
by C. botulinum.
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In the early 1990s the botulinum hypothesis was revisited, namely that EGS is
caused by a toxicoinfection by C. botulinum type C, with toxin production in the gut
of susceptible animals. C. botulinum type C/D was suggested due to the cytoxicity of
the type C neurotoxin and the pathology that can be caused by the C2 toxin - C.
botulinum type C was not reported until 1922 (Bengston,1922; Seddon,1922) and so
it is unlikely that this was the strain that Tocher used in his protection study. Pilot
serological studies at Edinburgh University (JK Miller et al, unpublished data),
implied that a serum IgG response was made against C. novyi type A, used as a
surrogate marker for safety.
On the basis of the initial study, further work was carried out to determine the role of
C. botulinum type C/D in the aetiology of EGS. Much circumstantial evidence has
been found including toxin detection from clinical samples (Hunter et al, 1999);
analysis of serum IgG and mucosal IgA from cases and controls (Hunter and Poxton,
2001; Hunter 2002); bacteriological studies of the equine GI tract in health and
disease (Garrett et al, 2002); and epidemiological studies (McCarthy et al, 2004).
Using a mixture of direct detection and enrichment culture techniques, Hunter et al
(1999) detected BoNT/C in 74% of acute cases, 67% of subacute cases and 67% of
chronic cases. Using the same combination of methods toxin was also detected in
10% of controls, albeit in much lesser amounts. However, only 4% (3/77) controls
demonstrated toxin via the direct method-one of these horses was a recovered
chronic case from 16 months before and the other was a surgical colic. It is known
that numbers of Clostridia increase during ileus/colic (Garrett et al, 2002) and this
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may explain the very low levels of toxin in non-EGS horses. The detection of toxin
in healthy controls reinforces Tocher's view that spores of C. botulinum are
transiently associated with the equine GI tract and that they can pass through without
causing disease. The difficulty associated with isolation of the organism was also
illustrated; not all samples positive for toxin via the direct method were positive after
enrichment or vice versa, illustrating the instability of the toxin-encoding
bacteriophage. Therefore the detection of toxin after enrichment was not necessarily
producing the toxin and the opposite is also true. Isolates identified as Group III
organisms by GLC and biochemical testing have been isolated from EGS cases
(Hunter 2001; F.G. Nunn, unpublished data) but all have proved negative for type C
toxin by ELISA and PCR methods and negative for other BoNTs using PCR
methods. Enrichment methods could be responsible for loss of the prophage due to
inhibition of organism growth/toxin production by faster growing organisms,
bacteriophage instability or simply that the organism was not present in the enriched
sample (Hunter et al, 1999). Based upon these results Hunter et al (1999) proposed
that the toxin was produced locally, with axonal transport responsible for the varying
degrees of neuronal damage in peripheral ganglia, preventing the clinical signs being
consistent with classical botulism. However, although the circumstantial evidence
was compelling, it is impossible to state whether C. botulinum type C/D was the
causal agent ofEGS, a cofactor or even that toxin production is a secondary event,
facilitated by ileus and consequential overgrowth of Clostridium spp.
Immunity at the mucosal level is likely to be more important than systemic immunity
and specific IgA has been detected from clinical samples (Hunter, 2001). Detection
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of specific IgA suggests recent exposure to the organism as the mucosal immune
response is thought to be comparatively short-lived (Pierce and Cray, 1982). Hunter
(2001) found that higher levels of specific IgA were demonstrated in subacute cases
and proposed that this was due to subacute cases were exposed to an intermediate
dose of toxin, sufficient to stimulate IgA production, but not so high as to lead to the
onset of acute grass sickness. Detection of anti-BoNT/C IgA in acute cases gives
strong evidence supporting the causal/co-causal role in EGS: if BoNT/C was
produced after GI stasis it is thought unlikely that IgA to BoNT/C would be detected
in AGS cases (Hunter, 2001).
At the time of the study, reagents for the detection and quantification of equine
immunglobulins were not readily available and so only OD values were obtained for
all specific IgG and IgA detection. Although large differences are easily perceived as
being significant in vivo, the significance of small fluctuations are more difficult to
ascertain and it was not possible to quantify specific IgA as a ratio of specific to total
IgA recovered. Due to degradation of IgA by proteases in the GI contents, total IgA
may be highly variable and a more robust study was required before definite
conclusions could be drawn.
Further investigation of the systemic immune response (Hunter and Poxton, 2001)
demonstrated that horses with EGS possessed lower levels of specific IgG (as
measured by OD level) to BoNT/C and surface antigens than control horses but no
difference was demonstrated between mean IgG levels between different EGS
groups. However, a large range of values was observed for each data set and
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although controls were grouped into contacts and non-contacts analysis could not
account for ages of the animals, known to be a risk factor in development of EGS
(Doxey et al, 1996). No information was available as to 'normal' levels of specific
IgG at the time so only relative comparisons could be made. It is very interesting that
those controls classed as contacts or at high risk in this study, had the highest median
OD levels of all the groups, implying that these clinically healthy controls had
mounted a possibly protective immune response. It is not known however, whether
low antibody levels in cases is due to naivety or to IgG being bound to antigen.
Longitudinal analysis ofCGS cases revealed that recovery from CGS did not follow
an increase in specific IgG levels. This has possible implications for intervention
strategies such as the use of hyperimmune sera as although serum IgG may be
protective, levels of IgG do not appear to change the outcome of the disease. On the
other hand, these results do support the use of a vaccine.
A large epidemiological study was carried out by Liverpool University (McCarthy et
al, 2004a; 2004b) that built on Hunter and Poxton's initial study. The authors used a
case-control study that was premises-matched and that utilised univariate and
multivariate analysis that could account for ages of the horses and other confounding
variables. Based upon their findings, the authors propose that low antibody levels to
surface antigens enable proliferation of C. botulinum C/D in the gut leading to toxin
production. Other interesting findings included the importance of age in assessing
antibody levels, a recent change in diet of affected horses and the use of the
antihelminthic, ivermectin, which requires further investigation.
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1.2.4 Dysautonomias of other species
Primary dysautonomias, sharing clinical and pathological similarities to EGS have
been reported in cats, dogs, hares and rabbits since the early 1980s (Key and Gaskell,
1982; Rochlitz and Bennet, 1983; Whitwell, 1991; Whitwell andNeedham, 1996).
The similarities suggest a common aetiological agent (Pollin and Griffiths, 1992) and
although none has been definitively identified, similar circumstantial evidence exists
for feline dysautonomia as in EGS (Hunter, 2001; Nunn et al, 2004). A full
description of feline and canine dysautonomia can be found in Chapter 7.
Leporine dysautonomia has been reported on premises that have previously been
associated with EGS (Whitwell, 1991). Histopathology demonstrates striking
similarities in Golgi disappearance and endoplasmic reticulum distension as found in
EGS cases although some changes, such as stacks of parallel smooth membranes and
lectin-staining cytoplasmic inclusions are not seen in EGS but have been seen in
feline dysautonomia (Sharp et al, 1984; Griffiths and Whitwell, 1993). Rabbit
mucoid enteropathy (RME) was demonstrated to be a dysautonomia in 1996
(Whitwell and Needham, 1996). The rabbit therefore has the potential for use as a
small animal model for EGS.
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1.2.5 Botulism in animals and humans.
Classical botulism
Classical botulism, also called forage poisoning in animals, results from the ingestion
of pre-formed toxin in contaminated foods. Whilst botulinum types A, B, E and F are
mainly involved in human botulism, types C and D seem only to affect animals with
only four poorly substantiated cases being attributed to type C in humans (Jensen and
Price, 1987). It is thought that humans lack the receptors for BoNT/C
(Maksymowych and Simpson, 1998) as BoNT/C can block neurotransmitter release
in isolated human neuromuscular junctions (Coffield et al, 1997) although lack of
exposure to the organism could also account for the lack of disease (Hunter, 2001).
Botulism has been reported in a wide range of species, both domestic and wild.
Large outbreaks of botulism occur in birds (Lamanna,1987) with type C responsible
for many cases in wild and farmed avian species. There are differing susceptibilities
between species with horses being more susceptible than cattle, dogs and humans
(Lewis and Metzger, 1980 cited in Whitlock and Buckley, 1997). Outbreaks of type
C botulism have been reported in cats (Elad et al, 2004), mink and foxes (Lindstrom
et al, 2004), cattle (Jean et al, 1995; Main and Gregory, 1996; Galey et al, 2000;
Cobb et al, 2002), dogs (Darke et al, 1976; Barsanti et al, 1978; Richmond et al,
1978; Farrow et al, 1983), horses (Kinde et al, 1991;Mackay and Berkhoff, 1992;
Schoenbaum et al, 2000), bighorn sheep (Swift et al, 2000), ferrets and pigs (Mitchell
and Rosendal,1987). Botulism in cattle caused by type D has also been reported
(Heider et al, 2001).
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Botulism has been reported in horses in conjunction with feeding big bale silage
(Ricketts et al, 1984; Broughton and Parsons, 1985). As the practice of feeding
haylage and related products to horses increases, cases of botulism may also
increase. It is thought that bales become contaminated with dead wildlife and that the
bales can reproduce an environment favourable for the growth of anaerobes in
microniches.
Further examples of changing husbandry practices causing disease in domestic
animals can be found in the beef and dairy industry. It is increasingly difficult to
dispose of increasing amounts of poultry litter. Poultry litter used as feed or bedding
for cattle or used as fertiliser is known to be a source of botulism in cattle (Smart et
al, 1987; Jean et al, 1995; Ortolani et al, 1997; McLoughlin et al, 1998; Neill et al,
1989; Livesey et al, 2004; D. Graham, personal communication).
Rotting carcases are the most common source of botulinum toxins for animals and
birds. Maggots containing BoNT/C have been found in rotting carrion (Haagsma,
1973 cited in Haagsma 1987). Smith and Turner (1987) found high levels of BoNT/C
for more than 28 days in carcases ofmice that had been inoculated with spores
before euthanasia demonstrating the risk of scavenging by other species or
contamination of feedstuffs. It is thought that C. botulinum can invade the tissues
from the gut post-mortem (Hunter, 2001). Landfill sites are another major source of
botulism for avian species such as gulls and spores of C. botulinum types B, C and D
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were found in the majority of sites examined (Ortiz and Smith, 1994) and it is
thought that such contamination comes from the gulls themselves.
Toxicoinfectious botulism.
Intestinal colonisation of humans with C. Botulinum spp. is rare, the most common
form being infant botulism, which is also the most common form of human botulism
in the US (Hatheway, 1990). It generally occurs in infants of less than 12 months,
probably due to a lack of an established gut flora that facilitates growth of botulinum
spores in the GI tract. It is very rare in adults and always associated with
immunosuppression following surgery or after antibiotic use (Chia et al, 1986).
In horses, a toxicoinfection of foals With C. botulinum exists known as Shaker foal
syndrome. It occurs in foals between two weeks and eight months of age (Whitlock
and Buckley, 1997) again due to the lack of a mature gut flora - vaccination of the
dam around one month prior to partuition is sufficient to give protection to the foal.
Toxicoinfectious botulism in the GI tract of adult horses has not been reported
(Whitlock and Buckley, 1997).
Toxicoinfection with C. botulinum type C can occur in broiler chickens with the high
energy diet of these birds thought to enhance the rate of toxin produced (Eklund et al,
1987). Poultry used as bedding for cattle or used as fertiliser is known to be a source
of botulism in cattle (Ortolani et al, 1997; McLoughlin et al, 1998; D. Graham,
personal communication).
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Wound botulism is rare in horses and associated with infection of injection sites
(Mitten et al, 1994) or post surgical infection (Bernard et al, 1987) and has not been
reported as a naturally - occurring disease.
1.3 Equine serology / immunology
The horse played a key role in the early years of immunological research (Marti et
al, 2003) with the disparate immunoglobulin isotypes and subclasses being common
fields of research for scientists interested in immunoglobulin structure (Sandor et al,
1964; Weir et al, 1966). Equine anti-lymphocyte serum was used in studies of
cellular immunity (Mosedale et al, 1968; Stewart and Bell, 1970) but the introduction
ofmonoclonal antibodies removed horses from the vanguard of immunological
investigation (Marti et al, 2003).
Many immunological mechanisms are conserved within the evolution of the immune
system but interspecies diversity is significant and systematic evaluation of
mechanisms and reagents is required (Steinbach et al, 2002).
1.3.1 Equine cytokines
Given the importance of cytokines in an immune response, it is imperative to
determine their functions. However, reagents such as antibodies for detection which
are raised in other species only cross-react very rarely (Steinbach et al, 2002). Both
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the cytokine and its receptor has to be conserved across species in order for
bioactivity to occur and this is not the case for major cytokines such as IFN-y and
IL-4. Where cross-reactivity does occur, activity is often much reduced and antibody
production is a risk during in vivo use (Steinbach et al, 2002a; 2002b).
Cloning and expression of the T helper cytokines, IL-4 and IL-2 was reported in
2000 (Dohman et al, 2000) and the homology of equine and human IL-4 was found
to be just 65% and of horse and mouse just 55% (Steinbach et al, 2000a). IL-6 was
also cloned, sequenced and expressed (Swiderski et al, 2000) as was IL-5
(Cunningham et al, 2003). This molecular research has greatly facilitated the
understanding of immune responses in horses against both infectious agents such as
parasites and viruses (Klei et al, 1989; Nelson et al, 1998), and in understanding
recurrent airway obstruction (Foster et al, 1997 cited in Horohov (2000). Some work
has been published on the detection of cytokine RNA in the equine gut in response to
inflammatory conditions and parasites (Davidson et al, 2002; Davidson et al, 2005)
none has yet to be published on cytokine production in response to enteric bacterial
pathogens.
There is strong evidence of Thl and Th2 responses in horses (Hooper-McGrevy et al,
2003) in response to the respiratory pathogen, Rhodococcus equi but again there is
nothing published on immune responses to enteric pathogens.
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1.3.2 Equine immunoglobulins
Although different immunoglobulin (Ig) classes viz. IgM, IgG, IgE, IgA and IgD, are
conserved between mammalian species (Wagner et al, 2004) the number of Ig
subclasses/ isotypes differs among mammals. As an example rabbits express 13 IgA
isotypes whereas most other species express just one or two (Knight et al, 1985;
Wagner et al, 2004). The horse possesses seven IgH chain constant (IGHC) genes,
the most found in the IGH locus of any species (Wagner et al, 2004). A duplication
event occurred leading to the IGHG4 and IGHG7 and these genes have been found in
all individual animals and breeds examined, including those that have been bred in
isolation such as Icelandic horses (Overesch et al, 1998; Wagner et al, 1998) and
those used in production of a variety ofmore modern breeds such as the
Thoroughbred. The authors conclude that due to the high sequence homologies and
the lack of gene conversion between these two genes and the other IGHG genes, this
duplication occurred most recently during the evolution of these genes in the horse.
In early immunological investigations, the equine Ig isotypes were studied using
serological and biochemical analysis. More recently, monoclonal antibodies (Mabs)
have been used (Lunn et al, 1995; Sheoran et al, 1998). These studies led to the
identification of five IgG subclasses designated IgGa, IgGb, IgGc and IgG(T) and
IgG(B) (Wagner et al, 2004) and so discovery of seven IGHG genes suggested that
equine antibodies were more complicated although two subspecies of IgG(T) had
been reported - demonstrated by their different binding properties to Proteins A and
G (Sheoran and Holmes, 1996). Wagner et al (2004) confirmed these two subspecies
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by identification of the isotype genes IgG3 and IgG5. The genes of the subclasses
have been identified as follows; IgGl (IgGa), IgG3 (IgG(T)), IgG4 (IgGb), IgG5
(IgG(T)) (Wagner et al, 2004). IgG2 and IgG6 have been expressed in mammalian
cells but not identified as yet. IgG7 has been detected at the mRNA level and the rate
of its expression apparently suggests that it could be present in adult equine serum in
high concentrations - in comparable levels to IgG4 (IgGb) and so it is possible that
IgGb as detected by antibodies, consists of two similar isotypes. Sheoran et al (2000)
used Mabs to quantify the levels of the different subclasses in serum, nasal secretions
and colostrum in adult animals and in foals. IgGb was found to be significantly more
abundant in serum, consisting ofmore than 60% of serum IgG and IgGc as the least
abundant (less than 1%).
Studies of IgG subclass responses to infection have been reported to intracellular
pathogens such as equine influenza virus (Nelson et al, 1998), equine herpesvirus
(Mizukoshi et al. 2002) as well as Rhodococcus equi (Hooper - McGrevy et al,
2003).
In addition to the seven IgGHG genes, IGHC region in horses consists of one of each
of IGHA, IGHE, IGHMand IGHD genes. Although previously found only in
primates and rodents, genes encoding IgD have been described in cattle, sheep and
pigs (Zhao et al, 2002) indicating that evolution of this gene occurred early on in
evolution of the mammalian immune system.
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IgA is the most abundant immunoglobulin class in saliva, milk and colostrum
(Vaerman et al, 1970; Sheoran et al, 2000). Once again, studies of production of
specific IgA are limited to the same pathogens as mentioned previously with no
published work found on enteric bacterial pathogens. Until recently, quantification of
equine IgA was difficult due to the lack of commercial reagents. Hunter (2001) could
not investigate the possible differences in IgA recovery from different sample sites or
between horses due to this problem.
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Aims of thesis
Although a substantial body of evidence has been collated supporting the
hypothesis that equine grass sickness is caused by a toxicoinfection with
Clostridium botulinum type C/D, the aetiology of equine grass sickness is still
unproven. Serological evidence strongly suggested that a systemic immune
response to toxins and surface antigens of the organism may indicate protection
from the disease and possibly demonstrate and/or influence recovery from the
disease. Initial studies of the mucosal immune response have also been
encouraging, with recent exposure to the organism leading to higher specific
IgA levels in AGS cases. However, controls were often not appropriate to enable
useful comparisons between groups and little is known of specific antibody
fluctuations in clinically normal animals. In addition, equine specific reagents
are now commercially available that facilitate the quantification of IgG levels,
allowing researchers to judge if fluctuations in OD levels are significant in vivo.
The aims of this thesis were as follows:
1) To examine IgG levels against extracellular and surface antigens of C.
botulinum Group III organisms in clinically healthy animals, in order to
establish 'normal' levels or to examine differences between groups, i.e.
age or geographic location.
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2) To compare specific systemic IgG levels in affected animals; both acute
cases and premises-matched controls and also in chronic cases. This
would enable comparisons of specific IgG levels in cases as well as those
seemingly immunologically protected. To establish whether fluctuations
in IgG were significant and to look at immune response in chronic cases.
3) To study the mucosal immune response in the gut by examining IgA
levels in affected and non-affected animals and to improve on qualitative
studies carried out previously





Full descriptions of the animals studied and the type of samples used in each
study can be found at the beginning of the relevant chapters. Briefly;
Horses
Healthy horses and ponies used were from E & O Laboratories, Bonnybridge and the
Animal Health Trust, Newmarket respectively. Serum from the adult horses was
excess sample from routine bleeds under the premises' own Home Office Licence.
Samples from the ponies were likewise excess serum used in conjunction with a
study run under an AHT-held licence.
Cases of grass sickness and those animals referred to as non-GI controls (Chapter IV)
were all patients at the Easter Bush Large Animal Hospital, Edinburgh and samples
were taken by clinicians employed there with the owner's consent.
Cats and Dogs
Sera used from cases of canine dysautonomia were all retrospective samples.
Serum samples from healthy cats were library samples used in routine screening by
the FELV and FIV unit at Glasgow University Veterinary School (GUVS). Faecal
samples from healthy cats were donated by cat owners, all ofwhich were staff of
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GUVS. Clinical samples from cases of feline dysautonomia were all taken by
clinicians at GUVS.
The feline work undertaken during my PhD made up a substantial part ofmy first
eighteen months of study. I therefore decided that the feline and canine
dysautonomia studies would be treated as a separate chapter, Chapter VII.
2.2 Samples.
Samples consisted ofwhole blood or serum; GI contents which could include tissue
and/or contents.
2.2.1 Treatment of blood and serum samples
Samples received were either blood or serum. Sera were stored at -20°C until
assayed. Blood samples from clinical cases were collected in sterile vacutainers with
no additives and allowed to clot overnight at 4°C. Serum was collected after
centrifuging at 1000 g for 15 min and stored at -20°C until assayed.
2.2.2 Treatment of equine GI contents for IgA extraction
All reagents were stored at -20°C and kept on ice during the procedure. Two parts
protease inhibitor solution (soybean trypsin inhibitor lmg/ml in PBS, 50mM EDTA
containing 0.05% Tween 20) were added to one part weighed sample (~lg).
Phenylmethylsulphonyl fluoride (PMSF; Sigma-Aldrich, 0.1M in ethanol) was added
to a final concentration of ImM. The mixture was vortex mixed for 30-60 sec and
50
then centrifuged at 3800g for lOmin.The supernate was removed and PMSF was
added to a final concentration of 1% (v/v). After mixing well it was allowed to stand
for 15min on ice. Heat inactivated foetal calf serum (FCS) was added to a final
concentration of 4% (v/v) and centrifuged at 15700g for 5min. The supernatant was
removed and stored at -70°C.
2.2.3 Treatment of equine Gl tissue for IgA extraction
Antibody extraction from tissue was achieved with saponin as described by Berquist
(2000) with some modifications. One to three grams of frozen tissue was aseptically
removed and thawed for 8 h at 4°C in PBS containing 2% saponin (w/v), soybean
protease trypsin inhibitor (lmg/ml), EDTA; 0.05M, Tween 20 (0.05%), PMSF
(2mM), sodium azide (0.2mg/ml) and 4% FCS (v/v). A 2ml volume was added per
gram of tissue. Samples were vortexed for 30s. After thawing, samples were agitated
using sterile forceps, vortexed for 30s and then placed in a sonicating water bath for
2min. After further vortexing, samples were centrifuged at 15,000g for 5 min and the
supernatants collected and stored at -70°C until used. All reagents and samples were
kept on ice between steps.
2.3 ELISA
ELISAs were optimised by chequerboard titrations of sample and conjugate.
Standard curve of IgG can be seen in Chapter 3 and IgA ELISA optimisation can be
found in Chapter 4.
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2.3.1 Preparation ofEDTA extracts of surface antigens
Lyophilised cultures of strains were inoculated into pre-reduced cook meat broth and
incubated for 24-48h in an anaereobic cabinet to prepare stock cultures. These were
subcultured into 3ml ofmedium and overnight cultures of these were used to
inoculate 20ml cultures of the same medium. These 20ml cultures were incubated
overnight before cell harvesting.
EDTA extracts were prepared as by Poxton (1984). Cells were harvested by
centrifugation at 3,800g for 20 min and the pellet then resuspended in 10ml cell
washing buffer (0.05M sodium phosphate buffer pH7.4 with 0.15M NaCl). The cells
were then washed twice by centrifugation as above. Cells were then resuspended in
lml EDTA buffer (0.05M sodium phosphate buffer pH7.4 with 0.15M NaCl and
0.01M EDTA) and incubated for 90 min in a 45°C water bath before treating in an
ultrasonic water bath for 60sec. Cell suspensions were then transferred to
microcentrifuge tubes and centrifuged at 13000g for 2 min. Supernatants were
collected and centrifuged as before and the surface extracted antigens collected,
assayed for protein content by the method of Lowry (1951) before being stored at -
20°C.
2.3.2 Coating ofplates
Equine IqG standard curve
A standard curve of equine IgG was constructed using Bethyl
Plates were coated with affinity purified goat-anti equine IgG
Laboratories reagents.
(A70 - 121A) diluted
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at 1 in 100 in 0.05M sodium carbonate buffer (0.05M sodium carbonate buffer,
pH9.6, 0.02% w/v sodium azide) (100 pl/well) and incubated for 90 min at room
temperature.
ELISA to detect total specific IgG
Surface antigens were diluted to 30pg/ml in 0.05M sodium carbonate buffer (0.05M
sodium carbonate buffer, pH9.6, 0.02% w/v sodium azide), CI and type D toxoid
complexes (Metabiologicals Inc,) were diluted to 5pg/ml, TetNT toxoid (List
Biologicals) diluted to 0.5pg/ml and added to Nunc Polysorb plates (lOOpl/well).
Plates were incubated overnight at room temperature and 4°C respectively.
ELISA for the detection of specific IqGa, IqGb and IqG(T)
Coating was as described for total specific IgG ELISA (as above).
ELISA to detect IqA
Standard curve of IgA and total IgA detection
A standard curve of equine IgA was constructed using a Bethyl Laboratories Equine
IgA Quantification kit (E70 - 116). Plates were coated with affinity purified goat-
anti equine IgA diluted at 1/100 in 0.05M sodium carbonate buffer (0.05M sodium
carbonate buffer, pH9.6, 0.02% w/v sodium azide) (100 pl/well) and incubated for
90 min at room temperature.
ELISA to detect specific IgA
Coating was as described for total specific IgG ELISA (as above).
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2.3.3 Blocking ofplates
All plates were washed four times between each stage with ELISA wash buffer (1 x
PBS BR14a 5mg tablet/litre Oxoid, Basingstoke, U.K. 15mM/l NaCl, 2mM/l KCL,
Tween 20 0.05%) pH7.3 between each stage.
All plates were blocked with PBS-TG for 90 min with PBS-TG (0.05M phosphate
buffer pH7.4 with 2% teleostean gelatine and 0.1% Tween 20, final pH7.4)
(200pl/well) at 37°C with the exception of both surface antigen ELISA, where
blocking was found to be unnecessary.
Plates were either used straight away or stored in sealed plastic bags at -20°C for up
to one month.
2.3.4 Addition of samples
Equine IqG standard curve
Reference serum was diluted in PBS-TG to concentrations recommended by the
manufacturer (1000, 500, 250, 125, 62.5, 31.25 ng/ml) and added (lOOpl/well).
ELISA to detect total specific IqG
Samples were diluted 1 in 300 in PBS-TG and added in duplicate (100 pl/well).
Samples were repeated at 1 in 600 or 1 in 100 if necessary to fall within the linear
portion of the standard curve of total IgG. Plates were incubated for 90 min at 37°C
with shaking. OD values were converted into concentrations of ng/ml by Prism.
These were then multiplied by the appropriate dilution factor and converted to pg/inl.
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EL1SA for the detection of specific IqGa, IgGb and IqG(T)
Samples were diluted 1 in 50 in PBS-TG and added in duplicate (100 pl/well). Plates
were incubated for 120 min at 37°C with shaking.
ELISA to detect total IqA
The reference serum was diluted according to the manufacturer's instructions and
added (lOOpl/well). Samples were diluted 1 in 500 for faecal extractions and 1 in
1000 for saponin extractions. Samples and reference sera were assayed in
quadruplicate at 1 OOpl/well and incubated overnight at room temperature. Plates
were washed six times between steps.
ELISA to detect specific IqA
Samples were assayed in quadruplicate and averages of these OD values used for
IgA quantitation. Optimal dilution was at 1 in 8 for the majority of samples although
some were repeated at 1 in 4 and 1 in 16.
2.3.5 Conjugates
Equine IqG standard curve
Goat anti-equine IgG (H+L) chain HRP conjugate was diluted 1 in 10000 in PBS-TG
and added 1OOpl/well. Plates were incubated for 90 min at 37°C with shaking.
ELISA to detect total specific IqG
Conjugate was as for IgG standard curve.
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ELISA for the detection of specific IgGa, IgGb and IqG(T)
Goat anti equine IgGa, IgGb or IgG(T) was diluted 1 in 2000 in PBS-TG. Plates were
incubated for 120 min at 37°C with shaking.
ELISA to detect total IqA
Goat anti-equine IgA alkaline phosphate conjugate was diluted 1 in 10000 in PBS-
TG and added 1 OOpl/well. Plates were incubated for 4h at 37°C with shaking.
ELISA to detect specific IgA
2.3.6 Substrates
Horse radish peroxidase (HRP): One tablet (lmg) 3'3',5'5' - tetramethylbenzidine
(TMB) (Sigma - Aldrich) was dissolved in 0.05M phosphate-citrate buffer pH5.0
with 0.006% hydrogen peroxide and added at 100 pl/well. The colour was allowed to
develop for 30 min for total and specific IgG and for 60 min for IgG subclasses.
Development was stopped by addition of 100 pl/well of 2M H2SO4. Plates were read
on an Anthos 2001 plate reader at 450nm, referenced at 620nm.
Alkaline phosphatase: alkaline phosphatase substrate tablets (Sigma 104-105
phosphatase tablets, p-nitrophenyl phosphate 5mg) were diluted 1 in 10000 with
substrate solvent (0.05 mol/1 sodium carbonate solution, pH 9.8, with lmmol/1
magnesium chloride) to give a concentration of lmg/ml. Plates were then incubated




Blank wells, consisting of coating buffer were included on each plate. Negative
controls, consisting of antigen diluent in place of sample, to control for nonspecific
binding of conjugate to the antigen, were included on plates in initial assays but were
found to be negligible and were not included on further plates.
The Bethyl Laboratories standard reference serum was found to be positive against
all antigens in IgG assays. This was included on all subsequent plates and used to
normalise all readings between plates.
2.3.8 Statistical analysis
IgG and IgA quantitation was carried out using non-linear regression (curve-fit)
using a 4 parameter logistic equation on GraphPad Prism version 3.0 software.
Concentration of IgG or IgA from clinical samples was an estimation obtained by
comparing OD values of samples with OD values of known concentrations of IgG or
IgA which were assayed under the same conditions.
Correlation and all other statistical analyses were also carried out with this software.
IgG subclasses were not quantified and are expressed in OD units.
Prism software was used to check for Gaussian distribution of data within groups.
Where a Gaussian distribution was demonstrated, parametric tests such as unpaired t-
tests for means comparison and Pearson's correlation and One-Way ANOVA with
Tukey's comparisons were used (Motulsky 1996). Where a Gaussian distribution
was not observed, data was either transformed (X = LogX) so that it did or if that
were not successful, non-parametric tests were used such as Mann-Whitney U test
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for comparison ofmedians or Spearman's correlation and Kruskal-Wallis test for
multiple comparisons. However, no P value became significant due to the use of one
test or another unless stated.
2.4 Culture of type strains and identification of toxin genes using PCR
2.4.1 Strains used
MPRL* number NCTC** number description
2778 5413 neurotoxin negative
2779 9569 neurotoxin positive
4564 8548 neurotoxin positive, C2 positive
2510 3732 neurotoxin negative, C2 positive
3923 8265 neurotoxin positive, C2 positive
*Microbial Pathogenicity Research Laboratory, University of Edinburgh.
** National Collection of Type Cultures, Colindale Ave., London.
2.4.2 DNA extraction
DNA extraction was carried out using the chelex method of de Lamballerie et al
(1992).
Pre-reduced media was inoculated with 1ml of stock culture and incubated
anaerobically at 37°C overnight. Cultures were checked for purity by plating on
blood agar aerobically and anaerobically (48h) and also by Gram film and wet film.
1.5ml of culture was centrifuged (5min at 13.000 g) and the pellet resuspended using
100 pi of 5% Chelex suspension (suspended in sterile, pyrogen free water,
Bioconnections- BC2090). The suspension was then boiled for 10 min before
centrifugation at 13,000 g for 2 min. Supernatant was collected and frozen at











Fujii et al, (1996)
C2 Component 2 •
C2CII-F 5' -GCAGAAGTTTCAGGTAGTTTACAAC-3'
C2CII-R 57 -CGCATTCTATAACGACCTTCTGGA-31








Halpern et al (1990)
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2.4.4 PCR reaction mixtures and cycling conditions
Reaction mixes (all 50jj.1) with 5 jxl DNA :
C2I. C2II and BoNT/D



















Initial cycles cycling conditions final extension
denaturation




C2CI 3min at 94°C 35 45s at 94°C
2min at 45°C
lmin at 72°C
5min at 72 °C
C2CII 3min at 94°C 40 45s at 94°C
lmin at 53°C
3min at 72°C
5 min at 72 °C
BoNT/D 1 Omin at 94°C 25 lmin at 94°C
lmin at 55°C
lmin at 72°C
3 min at 72 °C
TetNT 5min at 94°C 25 2 min at 94°C
3 min at 30°C
10 min at 67°C
5 min at 67°C
2.4.6 Controls
Positive controls were the DNA extractions from toxin positive strains. Negative
controls consisted of 5pl H2O in place of the template DNA.
Visualisation of PCR products
10pl portions of amplification products are run on 1% ethidium bromide stained
agarose gels. All products from PCR were run on 1.5% gels.
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Chapter III
Immunity to Group III protein antigens: longitudinal studies
of clinically healthy horses and ponies.
Results
3.1 Longitudinal study of healthy ponies
Specific antibody acquisition against C. botulinum type C toxoid and surface
antigens have been shown to plateau at seven years of age (HE McCarthy, personal
communication) which correlates with the physical maturity that horses reach around
the same age. An opportunity arose to assay a herd of young ponies that had recently
been moved from a premises not associated with GS to one that had. IgG levels to
BoNT/C and BoNT/D toxoids, EDTA extracted type C surface antigens were
assayed as well as levels of specific IgG subclasses (IgGa, IgGb and IgGT). Ratios
of specific IgG subclasses were also examined to see if younger animals
demonstrated any bias towards a Thl or Th2 response to these antigens.
3.1.1 Samples and study
Twenty six ponies from the Animal Health Trust (AHT) were sampled on three
occasions in a 10-month period between October 2001 and August 2002. All of the
ponies were 6 months old at the time of first sampling and therefore -16 months old
by end of the study. The animals were all clinically healthy and samples donated
were surplus from a study carried out under an AHT held licence.
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The ponies had previously been barn kept and fed large-baled hay with no
concentrate. They were moved to Newmarket 2 weeks before date of first sampling
and subsequently kept on land previously associated with grass sickness cases.
All data had a Gaussian distribution with unequal SD. One-way ANOVA was used
with Tukey's post-test for multiple comparisons. Un-paired t-tests with Welsh's
correction were also used to test for significant differences in antibody level between
sampling dates. Correlation between specific antibody levels and specific IgG
subclass levels were calculated using Pearson's correlation coefficients.
3.1.2 Specific IgG to neurotoxins and surface antigens (SA).
Levels of antibodies to all three antigens were examined and all rose over the
sampling period. Each is described separately:
BoNT/C
Boxplots of the three sampling times are shown in Fig. 3.1a with the P values
resulting from one way ANOVA. Significant differences were seen between levels
at 6 and 16 months (P=0.0001) and almost significant differences between 6 and 13
months and 13 and 16 months (P=0.06 and P = 0.05 respectively). ANOVA results
demonstrated an overall P value of 0.005 while the Tukey's post-test only showed a
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BoNT/D
Similar results were observed for this neurotoxin. Unpaired t-tests demonstrated
significant differences between all data points and these are illustrated of Fig.3.1b.
ANOVA results demonstrated an overall P value of 0.0001 while the Tukey's post-
test showed a significant difference between levels at 6 months and 16months
(P=<0.001) and between 13 and 16months (P = 0.01). The P value between 6 and 13
months was >0.05.
SA
Results of this analysis are shown in Fig.3.1c. Unpaired t-tests demonstrated
significance between 6 and 16 months (P=<0.0001) and 13 and 16 months
(P = 0.006) but none between 6 and 13 months (P = 0.13). ANOVA results
demonstrated an overall P value of <0.001 while the Tukey's post-test only showed a
significant difference between levels at 6 and 16 months (P=<0.001) and between
levels at 13 and 16 months (P = <0.01). Using this test P= >0.05 between 6 and 13
months.
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3.1.3 Correlation of specific IgG to different antigens
Results from this analysis can be seen in Fig. 3.2.
Anti-SA, anti-BoNT/C (Fig. 3.2a)
Using Pearson's correlation a positive correlation was observed between anti-SA and
anti-BoNT/C antibodies at 6 and at 16 months (Pearson's r = 0.41, r2 = 0.17,
P = 0.03: Pearson's 0.4, r2= 0.16, P = 0.04 respectively) but not at 13 months
(Pearson's r = -0.34, r2 = 0.11, P = 0.1).
Anti-SA, anti-BoNT/D (results not shown)
No correlation was observed between anti-SA antibodies and anti-BoNT/D
antibodies with Pearson's r = 0.24, r2 = 0.06, P = 0.21: Pearson's 0.2, r2= 0.04,
P = 0.3: Pearson's r = 0.41, r2 = 0.017, P = 0.03: Pearson's 0.05, r2= 0.002, P = 0.8 at
6, 13 and 16 months respectively.
Anti-BoNT/C and anti-BoNT/D (Fiq. 3.2b)
No correlation was demonstrated between anti-BoNT/C and anti-BoNT/D levels at 6
or 16 months (Pearson's r = 0.21, r2 = 0.04, P = 0.3: Pearson's r = 0.08, r2 = 0.18,
P = 0.69 respectively). A positive correlation was seen at 13 months (Pearson's r =
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3.1.4 IgG subclasses to antigens
These results are graphically represented as boxplots in Fig.3.3a-c.
BoNT/C
IgGa
Overall a significant increase in specific IgGa was demonstrated over the sampling
period with ANOVA P value =0.004. Tukey's post test showed significant
differences between levels at 6 and 16 months (P = <0.05) but not between 6 and 13
months or 13 and 16 months (P =>0.05 for both).Unpaired t-tests showed
significance between 6 and 16 months between (P=0.02) and approaching sigificance
between 13 and 16 months (P = 0.08).
IgGb
Specific IgGb showed an overall increase in level with ANOVA P value at P =
0.005. Tukey's post tests showed significant differences between 6 and 13 months
only (P = <0.01). Between 6 and 16 months and 13 and 16 months P = <0.05.
Unpaired t-tests with Welsh's correction demonstrated P values of P = 0.002 between
6 and 13 months and P = 0.06 between 6 and 16 months and P = 0.13 between 13
and 16 months.
igGT
Overall, an increase in specific IgGT was observed (P = 0.006) with the post tests
showing P=>0.05, P =<0.01 and P = <0.05 between 6 and 13 months, 6 and 16
months and 13 and 16 months respectively. Unpaired t-tests demonstrated P values
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of P = 0.43 between 6 and 13 months. The P value for levels between 6 and 16
months and 13 and 16 months were P = 0.003 and P=0.03.
BoNT/D
IgGa
A significant increase in specific IgGa was observed over the sampling period with
ANOVA P value of 0.01. Post tests demonstrated significant differences between 6
and 13 months and 6 and 13 months (P = <0.05) but not between 13 and 16 months
(P => 0.05). Unpaired t-tests showed P values of <0.002, 0.006 and 0.3 respectively.
IgGb
No significant increase was seen in specific IgGb using ANOVA (P = 0.1, multiple
comparisons all >0.05). Using unpaired t-tests a significant difference was observed
between 6 and 16 months (P = 0.03) but not between 6 and 13 months (P= 0.2) and
13 and 16 months (P = 0.4).
igGT
No significant increase was seen overall in specific IgGT with an overall ANOVA P
value of 0.56 and all comparisons at P = >0.05. Unpaired t-tests gave P values of
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SA
IgGa
No significant increase in specific IgGa was seen using ANOVA (P = >0.05)
although a significant difference was seen between levels at 6months and 16months
using unpaired t-tests (P = 0.05). P values between levels at 6 and 13 months and 13
and 16 months were P =0.62 and 0.15 respectively.
igGb
No significant increase between data points of specific IgGb was seen with an overall
ANOVA P=0.77 and post-tests all P = >0.05. Unpaired t-tests were insignificant at P
= 0.65, P = 0.79 and P = 0.47 at 6 and 13 months, 6 and 16 months and 13 and 16
months respectively.
igGT
No significant increase between data points of specific IgGb was seen with an overall
ANOVA P=0.61 and post-tests all P = >0.05. Unpaired t-tests were insignificant at P
= 0.6, P = 0.27 and P = 0.7 at 6 and 13 months, 6 and 16 months and 13 and 16
months respectively.
3.1.5 Correlation between IgG subclasses
No relationship was demonstrated between specific IgG subclass levels at any data
point (using Pearson's correlation).
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3.1.6 IgG subclass ratios against neurotoxins
Ratios between IgG subclass ratios were analysed singly (i.e. IgGa/IgGb or IgGT) or
with IgGb and IgGT combined. These results can be seen in Fig. 3.4a-c.
BoNT/C
IgGa/IgGb
An overall increase was observed in specific IgGa/IgGb ratios across the sampling
period with ANOVA P value at 0.03 and Tukey's post-tests at P = >0.005 between 6
and 13 months and 6 and 16 months. Between 13 and 16 months P = <0.05.
Unpaired t-tests gave P values of P = 0.02, P = 0.07 and P = 0.03 between 6 and 13
months, 6 and 16 months and 13 and 16 months respectively.
IgGa/lgGT
An overall increase was observed in specific IgGa/lgGT ratios across the sampling
period with ANOVA P value at <0.0001. Multiple comparisons using Tukey's post-
tests gave P values of P = <0.001 between 6 and 13 months and 6 and 16 months.
P = >0.05 between 13 and 16 months. Unpaired t-tests gave P values of P =< 0.0001
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IgGa/lgGb+lgGT
One way ANOVA demonstrated a significant overall increase in the ratio of
IgGa/lgGb+lgGT over time-with P=< 0.0001. Tukey's post-tests gave P=>0.01
between 6 and 13 months and 13 and 16 months, P = <0.001 between 6 and 16
months. Unpaired t-tests gave P values of P=0.004 and P=0.01 between 6 and 13
months and 13 and 16 months and P =<0.001 between 6 and 16 months.
BoNT/D
IgGa/lgGb
No significant change was demonstrated between specific IgGa/lgGb ratios over the
sampling period with ANOVA P=0.97 and all Tukey's post tests at P =>0.05.
IgGa/lgGT
Overall ANOVA for specific IgGa/lgGT levels demonstrated a P=<0.001 with
Tukey's post tests giving P= <0.001 between 6 and 13 months and 6 and 16 months
and P = >0.05 between 13 and 16 months. Unpaired t-tests gave P=<0.0001 between
6 and 13 months and 6 and 16 months but no significant difference between 13 and
16 months (P = 0.7).
IgGa/lgGb+lgGT
One way ANOVA demonstrated no significant overall increase in the ratio of
IgGa/lgGb+lgGT over time-with P= >0.15. Tukey's post-tests gave P=>0.05.
Unpaired t-tests demonstrated an almost significant increase between 6months and
(P = 0.07) and a trend toward an increase in level between 6 and 13 months
(P = 0.11).
77
3.1.7 IgG subclass ratios against surface antigens
IgGa/lgGb
No significant difference was observed in specific IgGa/lgGb using ANOVA
(P= 0.7).
IgGa/lgGT
ANOVA demonstrated an overall increase in ratios of specific IgGa/lgGT with
P = <0.0001 and Tukey's post-tests P = <0.001 between 6 and 13 months and 6 and
16 months and P = >0.05 between 13 and 16 months.
Unpaired t-tests showed P=<0.0001 between 6 and 13 months and 6 and 16 months
and P = 0.7 between 13 and 16 months.
IgGa/lgGb+lgGT
ANOVA demonstrated an overall increase in ratios of specific IgGa/lgGb+lgGT
with P = <0.0001 and Tukey's post-tests P = <0.001 between 6 and 13 months and 6
and 16 months and P = >0.05 between 13 and 16 months. Unpaired t-tests showed
P=<0.0001 between 6 and 13 months and 6 and 16 months and P = 0.8 between 13
and 16 months.
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3.2.1 Longitudinal study of adult horses
Very little is known about IgG levels in healthy horses against clostridial antigens
and neurotoxins. This study was designed to examine the IgG levels of a herd of
clinically healthy horses over the course of 12m-to determine if there was any
seasonal difference or if different management practices affected IgG level.
3.2.2 Samples and study
Forty horses (from a herd of 144) were used from a herd kept specifically for
bleeding for blood products-samples received were excess from these samples and so
no licence was required. Horses were sampled at two weekly intervals over the
course of a year, from the end of September 2002 to the beginning of September
2003. Horses were not bled if they were on antibiotics, of poor body condition or in
the same week as their tetanus and equine flu vaccinations, given every other year.
Animals at the premises were retired or recuperating from surgery or lameness.
Horses were chosen for this study by the staff, on the basis that they would probably
be there for the duration of the study and that they were 'good doers' and would
therefore provide regular samples. The full set of samples was not obtained every
fortnight, either for the reasons given above, due to staff changes and in the summer,
when fewer horses were needed to be bled due to the increase in packed cell volume
(PCV). Due to holidays, samples were not taken over the Christmas break (between
16th December and 16th January, or the first week in February).
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Horses were out at grass part-time from the end of February and all horses turned out
full-time from the middle ofMarch. When housed indoors, horses were barn kept
and fed big-bale horsehage ad liberatum and hard feed when necessary. Horses had
access to the barns in the summer although no horsehage was fed during the months
May through to September.
Age of horses
The ages of the horses were normally distributed with mean = 11.53, median = 11.50
and a range of 5 - 19.
3.2.3 Analysis ofmedian IgG levels of the herd over time.
Median values of IgG levels against the neurotoxins and SA can be seen in Fig.3.5
and descriptive statistics are detailed in Table 3.1.
Differences between medians of sample sets were calculated using Mann-Whitney
test as data was not normally distributed before or after transformation.
BoNT/C
Significant increases were demonstrated in median anti-BoNT/C IgG levels between
samples 7-8, 8-9, 11-12, 14-15 and 20-21 (P = <0.05 for each, P = <0.0001 between
11-12).
Significant decreases were demonstrated between samples 3-4, 9-10, 10-11, 13-14,
16-17, 17-18 and 19-20 (P = <0.05 for each).
81
Fig.3.5a
Sept. Oct. Feb. Mar. Jul. Aug. Sept.
Fig.3.5b
Sept.Oct. Feb. Mar. Jul. Aug. Sept.
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Fig.3.5c
~i 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 r
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Sept.Oct. Feb. Mar. Jul. Aug. Sept.
Graphs depicting Boxplots of herd titres against a) BoNT/C b) BoNT/D
and c) SA. See Table 3.1 for dates of samples.
Boxplots depict the 5th and 95th percentiles, mean (red lines) and median
values for each data set.
Samples 1 and 2 were taken when the horses were still out at grass and
they were bought in and barn-kept from October (sample 3) until the end of
January (sample 6), part-time at grass from Sample 7and all horses were
kept at grass fulltime from the middle of March (sample 9).
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Table3.1Descriptivestatisticsfromlongi udinalanalysifherdI Gevelgai st DateJuneJulyAugust Sample1718192021 N=201413522 a) Range0.55-0.32-0.18-0.06-0.10- 0.070.030.030.010.04 Mean0.170.110.080.040.07 Median0.130.080.070.040.06 b) Range0.27-0.24-0.21-0.15-0.11- 0.050.050.040.040.04 Mean0.130.140.090.070.07 Median0.110.130.060.060.07 c) Range0.48-0.57-0.32-0.13-0.23- 0.090.120.080.090.08 Mean0.220.220.160.110.14 Median0.210.19523
BoNT/D
Significant increases demonstrated between samples 10-11, 13-14 (P = 0.001 and
<0.001 respectively). Significant decreases observed between samples 7-8, 12-13
(P = < 0.001 for each).
SA
Significant increase were observed between samples 1-2, 5-6 (P = 0.03 and 0.07
respectively) and an almost significant increases between samples 15-16 (P = 0.06).
Significant decreases were observed between samples 2-3 and 7-8 (P = 0.03 and
0.0001).
The increase in anti-BoNT/C IgG coincided with the horses beginning to be turned
out and corresponds with a drop in level of anti-SA IgG and the subsequent fall in
anti-BoNT/C levels corresponds with an increase in anti-SA IgG level although the
increases are not statistically significant. Other increases between samples 14-15 and
20-21 also correspond with increases of IgG to SA and BoNT/D although these are
not significant rises in level against the latter two antigens. A decrease in IgG to
BoNT/C between samples 9-10 corresponds to a slight increase of IgG to SA.
3.2.4 Correlation between age and specific IgG level
Results of this analysis is shown in Table 3.2 and Fig.3.6. Some positive and
negative correlation was demonstrated between different samples and age against
BoNT/C. No correlation was observed between age and anti-BoNT/D IgG level and
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only two instances of positive correlation was demonstrated between age and anti-SA
IgG level.
All correlations were calculated using the non-parametric Spearman's correlation
coefficient.
Table 3.2. Results of age-specific IgG level in all animals sampled
Sample no. P value Spearman's r positive/negative
BoNT/C
5 0.04 -0.36 negative
6 0.04 0.38 positive
9 0.04 -0.42 negative
10 0.01 0.47 positive
13 0.007 0.51 positive
SA
1 0.03 0.36 positive
12 0.02 0.48 positive
It is interesting to note that negative correlations are demonstrated between age and
anti-BoNT/C level when levels are comparatively low (sample 7) or high (sample 9).
Positive correlation is again demonstrated when levels fall. This is also demonstrated
in IgG to SA to a lesser extent and no negative correlation is observed with
comparatively low or high levels. The lack of any sort of correlation between age
and IgG to BoNT/D may be due to the much lower levels to this neurotoxin, which
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3.2.5 Correlation between specific IgG levels
In order to identify any correlation between fluctuations of specific IgG levels was
carried out on each data set showing significant differences. Levels were not
normally distributed before or after transformation so the non-parametric Spearman's
correlation was used.
Sample 7
The results of this analysis can be seen in Fig. 3.7a. A positive correlation was
demonstrated between anti-BoNT/C and anti-BoNT/D IgG levels (P = 0.007,
Spearman's r = 0.5) and anti-BoNT/D and anti-SA IgG (P = 0.0006, Spearman's
r = 0.6) but not between anti-BoNT/C IgG and anti-SA levels (P = 0.13, Spearman's
r = 0.30).
Sample 8
A positive correlation was demonstrated between anti-BoNT/D and anti-SA IgG
level (P = <0.001, Spearman's r = 0.7) but not between anti-BoNT/C and anti-SA
IgG or anti-BoNT/C and anti-BoNT/D IgG levels (P = 0.5, Spearman's r = 0.12 and
P = 0.6, Spearman's r = -0.09 respectively.
Sample 9
No significant correlation was demonstrated between any IgG levels for this sample
point.
Sample 10
A positive correlation was demonstrated between anti-BoNT/D and anti-SA IgG
level (P = <0.007, Spearman's r = 0.44) but not between anti-BoNT/C and anti-SA
IgG or anti-BoNT/C and anti-BoNT/D IgG levels (P = 0.33, Spearman's r = -0.2 and
P = 0.13, Spearman's r = 0.2 respectively.)
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Sample 14
No correlation was demonstrated between any IgG level.
Sample 15
A positive correlation was demonstrated between anti-BoNT/D and anti-SA IgG
level (P = 0.03, Spearman's r = 0.41) but not between anti-BoNT/C and anti-SA IgG
or anti-BoNT/C and anti-BoNT/D IgG levels (P = 0.9, Spearman's r = -0.2 and P =
0.14, Spearman's r = 0.14 respectively.)
Sample 16
The results of this analysis can be seen in Fig.3.7b. A positive correlation was
demonstrated between anti-BoNT/C and anti-BoNT/D IgG levels (P = 0.03,
Spearman's r = 0.53) and anti-BoNT/D and anti-SA IgG (P = 0.008, Spearman's
r = 0.53) and between anti-BoNT/C IgG and anti-SA levels (P = 0.05, Spearman's
r = 0.49).
Sample 17
A positive correlation was demonstrated between anti-BoNT/D and anti-SA IgG
level (P = 0.01, Spearman's r = 0.6) but not between anti-BoNT/C and anti-SA IgG
or anti-BoNT/C and anti-BoNT/D IgG levels (P = 0.7, Spearman's r = 0.15 and
P = 0.13, Spearman's r = 0.14 respectively).
Before IgG level to BoNT/C rises between samples 7-8, there is a positive
correlation between IgG to both neurotoxins and between IgG to SA and BoNT/D
although not between BoNT/C and SA. The correlation is lost between the
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only positive correlation demonstrated between all combinations is at sample 16
(Fig. 3.7b) when all levels are comparatively high.
3.2.6 Analysis of IgG levels in selected horses
With such a large data set, specific levels were not analysed for every horse over the
12m sampling period. An anti-tetanus ELISA was developed to depict IgG levels in
horses against a known encountered antigen and to demonstrate that the ELISAs
were representative. Nine horses were chosen on the basis of tetanus vaccinations
occurring during the sampling period and encompassing the age range. Table 3.3 lists
ages and breed of the selected animals.
3.2.6.1 IgG levels against TetNT
IgG levels against TetNT can be seen in Fig.3.8. An anti-tetanus ELISA was used to
demonstrate that the ELISA methodology was representative of what was happening
to IgG levels. These samples were assayed three times, in duplicate and error bars
on the graphs depict the SEM. The two week period that the vaccination was given
was known, but not the exact date. Large peaks of specific IgG were demonstrated in
the two weeks after the vaccination and horses took varying times for the level to






Graph depicting anti-tetanus IgG in animals following vaccination. Horses
were split into two random groups a) and b).
Arrows depict the sample before vaccination-except for 1337 which had been
vaccinated at the beginning of September. Animals were not sampled the
week they received their vaccinations. Error bars demonstrate the SEM.
These samples were assayed three times, in duplicate. Horses shown were
chosen on the basis of vaccinations occurring during sampling.
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Table 3.3. Ages and breeds of animals used in specific IgG analysis
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3.2.6.2 Age-specific IgG level correlation
No correlation was demonstrated between age and anti-BoNT/D level in the nine
selected animals. Results of correlation analysis with BoNT/C and SA can be seen in
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Age-IgG correlation between nine selected animals and anti-BoNT/C IgG
level. Of the 21 samples, positive correlation was demonstrated between age
and IgG titre in samples 6, 8, 10 and 13. No correlation was observed in




Table 3.4. Results of age-specific IgG level in all animals sampled
Sample no. P value Spearman's r positive/negative
BoNT/C
6 0.03 0.82 positive
8 0.05 0.79 positive
10 0.05 0.77 positive
13 0.02 0.83 positive
SA
12 0.02 0.93 positive
Positive correlation between age and IgG to BoNT/C was again demonstrated at
samples 6, 10 and 13 and additionally at sample 8.
3.2.6.3 Longitudinal analysis of IgG levels
Longitudinal analysis of individual horses is illustrated in Fig.3.10a-f.
Horse 1159
Little correlation is demonstrated between IgG levels of this horse. An increase in
IgG to SA at sample 12 does correspond with an increase in anti-BoNT/D IgG but no
increase is observed in anti-BoNT/C t the same sample point. An increase in anti-




A peak of IgG to BoNT/C at sample 6 is followed by a peak of anti-BoNT/D and
anti-SA at sample 7. There are further peaks of anti-BoNT/C IgG at samples 8 and
12 with a corresponding peak of anti-BoNT/D also at sample 12. Further analysis
showed a significant correlation between BoNT/D and SA IgG levels but not
BoNT/C and SA levels (Table 3.5).
Horse 1442
An increase in IgG to BoNT/C is demonstrated at sample 10 along with a peak in
anti-SA. IgG to BoNT/D remains fairly constant and further analysis demonstrated a
strong correlation between anti-BoNT/C and anti-SA IgG levels (Table 3.5).
Horse 1468
Comparatively high levels against all BoNT/C and SA were demonstrated initially
but a large peak of anti-BoNT/C at sample 13 has no corresponding peak of anti-SA
or anti-BoNT/D.
Horse 1481
Comparatively high initial levels of IgG against all three antigens are demonstrated
and a large peak of IgG against all three is also seen at sample 16. This animal




A peak of IgG to BoNT/C is demonstrated at sample 6, followed by peaks of IgG to
BoNT/D and SA at samples 7 and 8 respectively. A further peak of anti-BoNT/C and
BoNT/D is seen at sample 15 but no peak of SA is seen.
Horse 1579
A large peak in IgG to BoNT/C at sample 3 corresponds with a drop in IgG to
BoNT/D and SA. Likewise, a peak of anti-BoNT/C at sample 9 does not correspond
with peaks of anti-SA or anti-BoNT/D.
Horse 1602
Small peaks are demonstrated at sample 5 against all three
anti-BoNT/D at sample 18 corresponds with a drop in IgG
antigens.
Horse 1618
A peak of IgG to BoNT/D at sample 4 corresponds with a smaller peak of IgG to
BoNT/C. This animal demonstrated a strong correlation between anti-BoNT/C and
anti-BoNT/D (Table 3.5).
antigens. A small peak of
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3.2.6.4 Specific IgG-IgG correlation of horses over time
Results of this analysis are detailed in Table 3.5 and case 1481 is shown in Fig.3.11.
Table 3.5 Significant correlations between IgG levels over time
Horse antigens P value Spearman's r
1337 BoNT/D & SA 0.02 0.69
1442 BoNT/C & SA 0.005 0.87
1481 BoNT/C & BoNT/D 0.025 0.60
BoNT/C & SA 0.02 0.62
BoNT/D & SA 0.02 0.63
1618 BoNT/C & BoNT/D 0.01 0.66
3.2.6 Analysis ofmedian specific IgGT OD values
Median values of IgG levels against the neurotoxins can be seen in Fig.3.12 and
descriptive statistics are detailed in Table.3.6.
Differences between medians of sample sets were calculated using Mann-Whitney
test as data was not normally distributed before or after transformation.
BoNT/C
Significant differences were demonstrated between sample sets using Mann-Whitney
U-tests but only one significant difference was calculated using one way ANOVA
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against BoNT/C. Significant differences were demonstrated between each sample set
except samples 3-4, 13-14 and 17-18 onwards. All P values <0.005 except that
between sample 5-6 (P = 0.01).
BoNT/D
Significant differences were demonstrated (Mann-Whitney U-test) between samples
1-2, 5-6, 7-8, 10-11, 12-13, 16-17. P values were all <0.05.
There is no corresponding increase in IgGT to BoNT/C to the increase in IgG seen in
samples 7-9 although there is an increase in IgGT in samples 4-6.
3.2.7 Specific IgGT-lgGT level correlation
Results of these analyses are shown in Table 3.6. Strong correlation was observed
between most data sets.
3.2.8 Longitudinal analysis of specific IgGT levels of specific horses
Results of this analysis are shown in Fig.3.13. There is no correlation between IgGT
OD value and specific IgG level. IgGT accounts for only 13% of total IgG (Sheoran
et al, 2000) and was not quantified in this study. Large peaks of specific IgGT
occurred within two week periods in different animals against both neurotoxins
although the largest peaks occurred against BoNT/C. Peaks of anti-BoNT/C rarely
coincided with peaks of anti-BoNT/D. Exceptions to this are Horse 1481 at sample 9,
Horse 1159 at sample 15, Horse 1602 at sample 16 and Horse 1579 at samples 8 and
10. Horse 1442 showed little change in IgGT OD levels and also was one that
demonstrated correlation between IgG to BoNT/C and SA. The other horse to
demonstrate correlation between both neurotoxins and SA (1481) demonstrated a
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Boxplots showing IgG(T) OD values against a) BoNT/C b) BoNT/D.
Significant correlation was demonstrated between IgGT OD values in 16 out
of 21 samples.
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3.3 Discussion
3.3.1 Sampling and statistical analysis
Only three data points were obtained for the pony study. It is unfortunate that no
other samples were obtained as four data points would have been sufficient to carry
out correlation/linear regression of the levels with age (Motulsky, 1996). If the data
points had been equally spaced a relationship between age and antibody level could
have been calculated using linear correlation. These animals were still immature at
the time of last sampling and it would have been interesting to follow the serology
for a further year. However, given the difficulty in obtaining licensing for the
sampling of healthy animals, finding a suitable group of animals and the cost of
sampling such a group, such studies are difficult to organise and any samples are
therefore of use. As with all the statistics in this thesis, arguments can be made for
and against the use of parametric versus non-parametric tests. Unpaired t-tests were
used to examine any differences between data points that may not have been highly
significant using one - way ANOVA.
The study of adult horses would have been improved ifmore animals had been under
the age of five but the nature of the premises meant that animals were generally
recuperating from surgery or had retired from work. Access to such a large herd with
the added benefit of no licensing required was a good opportunity. A control group
on GS associated premises would have enabled further comparisons. However,
comparisons needed to be made between chronically affected horses, acutely affected
horses and co-grazing controls so some idea of normalcy was required i.e. IgG levels
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in animals not associated with GS. Additionally, the known vaccination status of
these horses enabled a control, in the form of a anti-TetNT ELISA, to be developed.
3.3.2 Specific IgG ofponies
The increase in specific IgG seen against all three antigens gives an indication that
antibody acquisition increase with age as found by McCarthy et al (2004). The
seemingly increased susceptibility of younger animals (those under 7 years of age) to
grass sickness has been taken as a sign of the infectious aetiology of the disease. The
horse is considered mature physically at ~6 years of age and therefore perhaps it is
not surprising that an adult level of immunity is reached by this time. However, a
level of immunity to different antigens would presumably be due to abundance of
that antigen in the environment and subsequent exposure to it. There is little work
published on the natural acquisition of antibody to environmental antigens, most of
the literature is concerned with exposure to organisms such as Rhodococcus equi
(Hooper - McGrevy, 2003), whereby exposure to the organism leads to clinical
disease and no work has been published on the sampling of healthy horses
longitudinally against enteric organisms. Although the means increase overall with
increasing age with this population, there is also some fluctuation within the ranges
of specific IgG levels between 13 and 16months - noticeably in anti-BoNT/D and
anti-SA. This indicates that levels can rise and fall within individuals, possibly due to
other factors such as exposure to other antigens/subclinical infection caused by other
organisms or by the (undisclosed) nature of the other study being carried out at the
time.
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Correlation between anti-SA and anti-BoNT/C did demonstrate a positive
relationship between exposure to C. botulinum type C and exposure and subsequent
immune response to BoNT/C. An inverse relationship has been demonstrated
between anti-SA and anti-BoNT/C level in adult co-grazing animals and a high anti-
SA level has been statistically shown to be protective against EGS (McCarthy et al,
2004).
The lack of correlation between anti-BoNT/C and anti-BoNT/D IgG suggests that
there is little/no detectable cross-reactivity between the two neurotoxins although
correlation in antibody levels has been found between the neurotoxins in adult
horses. Although some correlation was demonstrated at 13 months, this is not seen at
16 months when comparatively high levels of anti-BoNT/D are observed. Generally,
anti-BoNT/D levels are lower than BoNT/C indicating that BoNT/D producing
organisms are less prevalent in the environment. The relatively high anti-BoNT/D
levels of these ponies indicate greater exposure to the type D organism. These
premises were previously associated with cases of grass sickness (within five years
of the beginning of the study) which is known to increase the risk of grass sickness
(Doxey et al, 1991) and although type D has never been implicated in GS through
toxin ELISA this is due to the lack of reagents and the possibility of involvement of
the organism cannot be ruled out. These results may indicate that the Type D
producing strain is more prevalent at these premises whereas Type C or a
combination of the two may exist elsewhere.
114
IgG subclasses levels were measured by use ofOD values and not quantified as
specific IgG (mg/ml) so although some parallels between OD and IgG level can been
seen it would be misleading to draw too many parallels between IgG and IgG
subclass levels.
Specific IgGa increased with age with all three antigens although a decrease in the
lower ranges against BoNT/C and SA demonstrates that specific subclass levels can
fluctuate.
IgGb is the most abundant IgG subclass in equine serum (Sheoran et al, 2000) and
therefore any rise in specific IgGb would go some way in explaining a rise in total
specific IgG and this appears to be the case in both anti-BoNT/D and anti-SA IgGb
levels. A decrease in the median anti-BoNT/C IgGb level at 16m seems to be
cancelled out by a large increase in IgGa subsequently still leaving an overall
increase in total specific anti-BoNT/C IgG. The ranges of specific anti-SA IgGb
hardly changed across the sampling period and although the herd median decreased
against BoNT/C between 13m and 16m, the range did not change substantially. The
median anti-IgGb against BoNT/D increased between the same sampling points
although the higher range of the sample fell.
IgGT is the subclass thought to be involved in neutralisation of bacterial toxins
(Sheoran et al, 2000) and although IgGT increases with age against both SA and
BoNT/C it does not against BoNT/D. The increase in specific anti-BoNT/D IgG must
therefore be accounted for by increases in specific IgGa and IgGb. The strain used
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for the SA ELISA is positive for the C2 toxin by both PCR and immunoblot (data not
shown) although reagents are not currently available to assay directly for anti - C2
antibodies, so it is not know if the presence of the C2 toxin accounts for any rise in
IgG or which subclass reacts with it most.
The lack of either a positive or negative correlation between levels of specific
subclasses of IgG may possibly be due to the limits of the experimental design -
quantification of total subclass levels and then expressing specific IgG as a
percentage may help in this respect as it would with ratios of IgG subclasses. A Thl
response has been demonstrated to be effective in horses against R. equi (Hooper -
McGrevy et al, 2003). Although C. botulinum is not an intracellular organism, and as
such should produce a mixed Th1/2/0 response, it was decided to look at subclass
ratios as very young animals show a bias toward a Th2 response (IgGb, IgGT) over a
Thl response (IgGa) (Hooper - McGrevy et al, 2003). As IgGb and IgGT are both
Th2 type subclasses it is perhaps more relevant to look at the IgGa/IgGb + IgGT
ratios. A rise in the ratios of IgGa/IgGb + IgGT does occur overall against BoNT/C
and SA but not against BoNT/D, suggesting that the animals did develop more of a
Thl response with age. However, without knowing what the ponies were being used
for at the time or without quantifying the subclass levels, it is not possible to come to
any firm conclusion.
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3.3.3 Specific IgG of horses
The sampling period was chosen so that any seasonal differences in IgG level could
be observed, or the possible effect ofmanagement practices. Turnout of horses was
staggered in both terms of time and which horses were turned out but the overall
increase in IgG to BoNT/C over samples 7-9 and decrease in IgG to SA at samples 7-
8 interesting. It has been demonstrated (McCarthy et al, 2004) that higher levels of
IgG to SA associated with protection. A sudden increase in exposure to Group III
organisms due to turnout may have led to the drop in IgG to SA, allowing increased
exposure to BoNT/C. Hunter et al (2001) showed that toxin could be detected in
samples from controls, albeit at very low concentrations. Although not always
statistically significant, levels of IgG to SA did fall when levels of IgG against
BoNT/C increased and vice versa, indicating a relationship between the two within
this group of horses.
Correlation analysis is affected by outliers in a data set. Outliers were left in because
large fluctuations in specific IgG levels have been observed in CGS cases and it
needed to be determined if similar fluctuations would be observed in controls. Within
the data set certain levels of specific IgG correlate with age of the data set with two
of the three antigens (BoNT/C and SA) and these correlations become negative if
levels fall or rise too far beyond that level. There is no age-IgG correlation between
IgG to SA and BoNT/D. This may be because BoNT/D is a rarer antigen although
some animals do show higher IgG levels to BoNT/D than BoNT/C at certain data
points, indicating exposure. The age-IgG level correlation is repeated in the nine
horses chosen and a similar pattern demonstrated.
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Specific IgG-IgG correlation was examined to try and determine any relationship
between anti-SA IgG and anti-BoNT IgG. No significant inverse relationship was
demonstrated at any data point and correlation between IgG levels to SA and
BoNT/C was less common than correlation between the neurotoxins and BoNT/D
and SA. A certain level of correlation between IgG levels to the two neurotoxins
might be expected due to some cross-reactivity although this was not observed in the
pony study.
Longitudinal analysis shows that a peak in IgG against any of the antigens does not
always correspond with a rise or fall in the level of another. This independence may
be due to rarity of neurotoxin producing organisms in the environment, due to them
sometimes coexisting together and the detection of cross-reacting antibodies to other
non-neurotoxin producing Clostridia by the ELISA.
When looking at the individual animal's response to their tetanus vaccinations it is
clear that the ELISA methodology used is representative of the IgG response against
all of the antigens used. Clear lgG responses are observed after each animal's
vaccination against tetanus which then fall with time. Obviously immune responses
to environmental antigens are far more complex than against a standardised
parentally administered one but the assay served as a useful control in this study and
in studies of cases of chronic grass sickness.
118
Fluctuations in herd medians of specific IgGT levels were also demonstrated which
did not correlate with specific IgG level although this may be partly due to IgGT not
being quantified. These fluctuations were also observed in the 9 individual horses.
Immune responses in the horse are poorly understood with investigations being
involved with parasites and intracellular pathogens. No study involving the equine
immune reponse either to enteric pathogens or to environmental bacteria has been
published to the best ofmy knowledge. This study was a useful exercise in assessing
normal fluctuations of IgG levels against the main antigens of interest and is later
used as a comparison when studying the IgG responses of chronically affected
animals. A control in the form of an anti - tetanus toxoid assay was used to
demonstrate that the fluctuations in IgG levels to these environmental antigens were
real. However, immune responses to environmental antigens are complex and both of
the studies could have been improved upon by quantifying the IgG subclasses and
the pony study being for longer and having more data points.
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Chapter IV
Comparative serology of AGS cases and healthy co-grazing
controls
Results
4.1 Samples and study
A focused study was required to maximise the chance of isolating C. botulinum type
C/D and also to examine any possible differences between susceptible animals and
premises-matched controls. Samples were collected from healthy non-GI controls-
that is horses euthanased for conditions not related to the G1 tract- and also from
AGS cases and their co-grazers. As well as serological studies (both serum and
secretory IgA), samples were taken from the GI tract of cases at post-mortem for
bacteriology and histopathology. Environmental samples were also collected from
the pastures involved.
Seven horses with acute grass sickness went to post-mortem between August 2002
and August 2003. Cases were selected on basis of time between onset of clinical
signs and diagnosis of acute grass sickness; only those diagnosed and euthanased
within 36h of onset of clinical signs were selected for this study.
Serum was taken pre and postmortem from cases and serum from go-grazers was
taken within 24 h. Blood samples were collected in sterile vacutainers containing no
additives and allowed to clot overnight at 4°C. Serum was collected after
centrifugation at lOOOg for 6 min. The number of co-grazers varied from case to case










































































































































































Case 03-425 had no co-grazers and was omitted from any statistical comparisons.
However the sample was used in specific IgG-IgG correlation studies. A sample
from the seventh case was not received.
Specific IgG levels against BoNT/C, BoNT/D and C. botulinum type C (a neurotoxin
negative strain) surface antigens were compared between cases and controls as was
secretory IgA. Levels of IgG subclasses were also examined against these antigens.
As means of control, IgG levels against tetanus toxoid and surface antigens of a
C. tetani (TetNT negative strain) were also assayed. All of the cases and controls
were vaccinated with tetanus toxoid and the TetSA assay was used as an indicator of
soil exposure.
4.1.1 Comparisons of age groups
Ages of the two groups were compared as it is well established that animals of seven
years of age and under are more susceptible to GS (Doxey et al, 1991). Antibody
acquisition to SA and BoNT/C has also been shown to plateau at this age (H.
McCarthy, personal communication) and therefore it is important that the ages of the
control groups be taken into account. The analysis is summarized in Table 4.2.
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Table 4.2 Comparison of age groups.





Both age groups were normally distributed. The co-grazing control group were
significantly older (P = 0.014, Student's unpaired t-test).
4.1.2 Total specific IgG
Total specific IgG of the acute cases and their co-grazers are summarised in Table
4.3a and 4.3b. Values were computed using GraphPad Instat which tests for Gaussian
distribution using a variation of the Kolmolgorov and Smirnov test. Only levels
against BoNT/C&D were normally distributed among the co-grazers, anti-SA levels
were not normally distributed even after transformation. All levels were normally
distributed in the AGS groups.
Table 4.3a. Total specific (pg/ml) IgG of AGS cases.
Anti-SA Anti-BoNT/D Anti-BoNT/C Anti-tetSA
0.248 0.128 0.242 0.289
0.223 0.120 0.220 0.205
0.467- 0.184- 0.350- 0.576-




Table 4.3b. Total specific (pg/ml) IgG of co-grazing controls.
Anti-SA Anti-BoNT/D Anti-BoNT/C Anti-tetSA
Mean 0.448 0.160 0.205 0.467
Median 0.310 0.147 0.176 0.407
Range 2.170- 0.440- 0.522- 1.484-
0.099 0.027 0.025 0.031
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4.1.3 Comparison ofmedian specific IgG levels
No significant differences were observed between AGS and co-grazing controls for
any antigen although differences approaching significance were seen between levels
against SA and TetSA (P = 0.06 and P = 0.09 respectively). Outcomes of the median
comparisons can be seen in Table 4.4 and Fig 4.1.
The co-grazers demonstrated a range of specific IgG that reached below that of the
AGS cases against all antigens with the exception of SA.
Table 4.4 Group median comparisons
Antigen
Median
AGS Co-grazers test P value
SA 0.223 0.310 t-test, Welsh's 0.06*
BoNT/D 0.120 0.147 unpaired t-test 0.54
BoNT/C 0.220 0.176 unpaired t-test 0.77
TetSA 0.205 0.407 unpaired t-test 0.09
*SD of the two groups significantly different, P = 0.02
4.1.4 Comparison between different herds
There were some differences of the total specific IgG between herds. The herd of co-
grazers ofCase 02-351 had significantly higher levels of anti-BoNT/C than the herds
of co-grazers of case 02-376 and 02-392 and a higher level against BoNT/D than the
herd of case 02-352. The other significant results are detailed in Table 4 .5.
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Fig 4.1. Boxplots showing differences in specific IgG in AGS cases and co-












































Table 4.5. Significant differences in total specific IgG levels between herds
Antigen Herd P value












4.1.5 Comparison within herds
Due the range in specific IgG levels and the differences in level between herds, the
individual cases were compared to their respective herds and these can be seen in
Fig.4.2 a-e.Three of the five cases had lower level against BoNT/C, BoNT/D and SA
than their respective herd median (cases 02-409,02-392 and 02-351) and of these
cases the latter two had lower levels against TetSA. With the exception of the anti-
TetSA level of case 03-409, in no instance does the level of the corresponding case
go above the value of the upper range of the herd.
4.1.6 Correlation between age and IgG level
No correlation was demonstrated between age and specific antibody levels in this
group of healthy controls. However, only six of the co-grazers were below seven
years of age and none below 4y and this would have affected the analysis.
Statistics of this analysis can be seen in Table 4.6.
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Fig 4.2a-e.Comparisons between specific IgG levels between AGS cases
and their respective herds a) Case 03-409 b) Case 03-392 c) 03-376 d) 03-
352 e) 03-351.
All levels expressed as pg/ml except anti-TetNT, which are expressed as an
OD value.
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Table 4.6 Correlation between age and IgG level
-j
Antigen test r P value
BoNT/C Pearson's 0.065 0.145
BoNT/D Pearson's 0.002 0.8
SA Spearman's 0.116 0.54
tetSA Pearson's 0.021 0.145
4.1.7 Correlation between specific IgG levels.
In co-grazing controls, significant correlation was demonstrated between anti-
BoNT/C level and anti-BoNT/D level (Pearson's r = 0.5195; r2 0.2698; P = 0.0016).
(Fig.4.4) A significant inverse correlation was observed between anti-BoNT/C level
and anti-SA level (Spearman's r = -0.3782; P = 0.0274). No correlation was observed
between anti-BoNT/D and anti-SA level (Spearman's r = - 0.02995; P = 0.8665).
These results are graphically represented in Fig. 4.3a-c.
In the AGS group the only significant correlation was between anti-BoNT/C and
anti-BoNT/D IgG levels (Pearson's r = 0.05834; P = 0.02; r2= 0.07805). No
correlation was observed between anti-BoNT/D and anti-SA levels (Pearson's r =
0.494; P = 0.3192; r2 = 0.2441) or between anti-BoNT/C level and anti-SA levels
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4.2 IgG Subclasses
4.2.1 Comparison of subclasses between AGS and co-grazers
Collective data was transformed to give a normal distribution and median
comparisons were therefore calculated using Student's unpaired t-tests.
AGS cases demonstrated significantly less specific IgGa and IgG(T) against BoNT/C
(P = 0.006 in both instances) and significantly less IgGa and IgGb against BoNT/D
(P = 0.06 and P = 0.09 respectively). Against SA, AGS cases demonstrated a trend
towards lower IgGa levels (P = 0.2) and a trend towards higher IgG(T) levels
(P = 0.09).
4.2.2 Comparison between individual cases and herds
Results of this analysis can be seen in Fig. 4.4. Cases 03-409, 03-351 and 03-392 all
demonstrated lower IgGabT against neurotoxins than the median level of their
respective herd and these three cases also showed higher IgGb and IgGT against SA
than the median levels of their herds.
Case 02-352 had lower IgGabT against neurotoxins than the median level of its herd
but higher IgGb and IgGT against SA than the median levels of its herd.
Case 02-376 had higher levels of IgGabT against BoNT/D than the median level of
its herd but lower IgGabT against BoNT/C and lower IgGab against SA, although a
higher IgGT level than all of its co-grazers.
4.2.3 Specific IgG subclass correlation
No correlation was demonstrated between any subclass for any antigen.
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Case 02-352 (Fig. 4.4a) and Case 02-376 (4.4b) compared to herd medians
against i) BoNT/D ii) BoNT/C and iii) SA
135























































cP A A ^
IgGa IgGb IgGT
Case 03-409 (Fig. 4.4b) and Case 02-351 (4.4c) compared to herd medians










































Case 03-392 compared to herd medians against i) BoNT/D ii) BoNT/C and iii)
SA
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4.3 IgA detection: samples & study
Samples received from cases are detailed in Table 4.7.
In addition to the seven acute cases described in 4.1.1, a further 5 acute cases went to
post-mortem in the season of 2003. Ileum samples were taken from these for IgA
extraction and are included in analysis when mentioned. Four other horses that were
euthanased for reasons other than GI problems were sampled post-mortem in the
same way as the seven original acutes and are referred to as non-GI controls.
Eighteen faecal samples from the co-grazers of three of the seven acute cases were
also collected for IgA extraction, these samples are summarised in Table 4.7.
The samples consisted of tissue and/or contents. Samples from the small intestine
consisted of tied-off pieces of intestine. Samples of the intestinal wall and of the
contents (where there were contents) underwent saponin extraction or faecal
extraction respectively and these were also used to compare IgA yield extracted by
the two techniques. Samples from the large intestine and stomach consisted of
contents only.
All statistical analysis was performed on Graphpad Prism V3.03. This software tests
for Gaussian distribution using a variation of the Kolmolgorov and Smirnov test.
Normality testing could not be carried out on the control horse samples due to their
small number and so the non-parametric Mann-Whitney U test was employed to test
for differences between cases and group medians.
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against all antigens for the extraction technique involved. A sample was identified
and its dilution curve for total IgA can be seen in Fig.4.5c and for specific IgA in
Fig.4.5d. In initial assays this sample was assayed on three separate occasions and
error bars on the graphs depict SD. Samples were subsequently assayed in
quadruplicate and averages of these OD values used for IgA quantitation. Optimal
dilution was at 1 in 8 for the majority of samples although some were repeated at 1 in
4 and 1 in 16.
4.3.2 Total IgA: comparison between extraction methods
Cases
Significant differences were demonstrated within samples depending upon extraction
method used ie significantly more total IgA was obtained from duodenal tissue than
duodenal contents (P = 0.01) and between ileal tissue than ileal contents (P = 0.01).
No significant difference was demonstrated between jejunal tissue and jejunum
contents (P = 0.12).
Controls
The only samples that had sufficient numbers to allow this analysis were samples of
ileal tissue and ileal contents (P = 0.11).
Cases and control samples combined
No significant differences were demonstrated between IgA yield between like
samples of cases and controls. Descriptive statistics are outlined in Table 4.8.
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Comparisons could not be made between faecal and rectal samples between groups
due to insufficient numbers of samples. As some sample numbers were low, the
above analyses were combined. Significantly higher total IgA was obtained from
tissue samples rather than contents from the same part of the small intestine (SI). The
results of this analysis are detailed in Table 4.9.
Table 4.9 Statistics of comparison of extraction methods: total IgA(ug/ml/g sample)
duodenum duodenal jejunum jejunal ileum ileal
contents contents contents
N = 9 3 11 4 16 9
Range 2.852- 0.478- 4.044- 0.302- 4.127- 0.376-
0.566 0.009 0.067 0.025 0.087 0.012
Median 0.975 0.076 0.991 0.1208 1.022 0.077
Mean 1.314 0.188 1.270 0.1422 1.423 0.100
P = 0.009 0.02 0.0002
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4.3.3 Specific IgA: comparison between AGS cases and Non-GI
controls.
Descriptive statistics for specific IgA can be found in Tables 4.10. P values between
total specific IgA are shown in Table 4.11.
Table 4.11. Differences between total specific IgA from AGS cases and controls:
cases having more IgA than controls
BoNT/C BoNT/D SA TeTSA
Pharynx P = 0.11 P = 0.02 P = 0.2 P = 0.06
Stomach P = 0.004 P = 0.39 P= 1.0 T3 II O oo
Duodenum P = 0.07 P = 0.10 P = 0.09 II o
Jejunum P = 0.006 P = 0.006 p II pbo P = 0.5
Ileum P = 0.006 P = 0.03 P = 0.006 P = 0.25
Caecum P = 0.01 P = 0.07 P = 0.07 P = 0.65
Colon P = 0.02 P = 0.10 P = 0.64 P - 0.86
Rectum - - - -
Faeces _ _ _ _
4.3.4 Specific IgA: comparison between AGS cases and Non-GI
controls of specific IgA presented as percentage of total IgA
yield.
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4.3.5 Specific IgA: detection of IgA along the Gl tract ofAGS cases
Specific IgA concentration in the GI tracts of the seven acute cases is detailed in Fig
4.7a-d.
Case 02-352
The pharynx and stomach samples for this case were not analysed (due to insufficient
sample and sample missing). Similar levels of IgA against the two neurotoxins were
found throughout the GI tract with the highest levels of each detected in the ileum.
The highest amounts of anti-SA were detected in the ileum and caecum samples and
the highest amount of anti-TetSA detected in the jejunum and ileum.
Case 02-351
This case demonstrated higher levels of anti-BoNT/C than ofanti-BoNT/D IgA.
Specific IgA against neurotoxins were found in all samples present (rectal sample not
assayed) with the highest levels found in the caecum and colon samples and very low
levels were found in the ileum. However, the highest yield of total IgA was detected
in this animal's ileum, and amongst the lowest total IgA from the caecum and colon.
Likewise, the highest anti-SA and anti-TetSA IgA levels were also detected in the
caecum.
Case 02-376
This case showed higher levels of anti-BoNT/C IgA than anti-BoNT/D IgA and anti-
BoNT/C IgA was detected in every sample assayed (rectal and faecal samples
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missing from data). This case had the second highest anti-BoNT/C IgA levels in the
pharynx and the highest level of the whole group in the ileum with the corresponding
total IgA detected in the samples being near the median of the group. The case's
highest level of anti-BoNT/D IgA was also detected in the pharynx and ileum
samples. This case also demonstrated the highest levels of anti-TetSA of the case
group in ileal and pharynx samples and the highest anti-SA levels in the ileal sample.
Case 03-342
A similar pattern of anti-neurotoxin IgA can be seen in the samples of this case, with
the highest levels detected in the ileal and caecal samples- higher levels of anti-
BoNT/D than BoNT/C IgA is found in the caecum and colon. This case also
demonstrated higher levels of antiSA IgA than TetSA IgA, with the highest levels
detected in the jejunum.
Case 03-392
The highest percentage yield of anti-neurotoxin IgA was obtained from this case
from its faecal sample although this was also one of the lowest total IgA yields from
a sample to give a positive signal on a specific assay. Approximately 10 % and 45 %
of the IgA detected was anti-BoNT/C and anti-BoNT/D specific respectively. This
also accounts for the comparatively large percentage of specific IgA detected in the
stomach and possibly the amount of anti-BoNT/C IgA detected in the caecum.
Similar patterns are observed in levels of anti-SA and anti-TetSA IgA. Percentage
yield of IgA are not significant against any antigen in this case from pharynx
160
samples, probably due to a comparatively large amount of total IgA extracted from
this sample (upper range).
Case 03-409
This case demonstrated higher levels of IgA against BoNT/D than anti-BoNT/C with
the highest levels detected in the pharynx, jejunum, ileum and colon. However, with
the exception of the pharynx, these samples also demonstrate the lower end of the
total IgA levels of the group. Similarly, the highest levels of anti-SA and anti-TetSA
are also found in the pharynx and jejunum.
Case 03-425
This animal demonstrated higher levels of anti-BoNT/D overall, with the highest
anti-BoNT/D IgA levels of the whole case group in the pharynx, stomach and
caecum with total IgA from these samples being approximately around the median of
the case group. This animal also demonstrated the second highest anti-SA IgA level
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4.3.6 Specific IgA: detection of IgA along the Gl tract of Non-GI
controls
Data for specific IgA in the GI tracts of the four non-GI controls cases are detailed in
Fig. 4.8a-d.
Case 02-182
The highest anti-neurotoxin IgA levels are found in the pharynx of this animal with
other comparatively (to this case) high levels detected in the caecum. Increased
levels of anti-SA and anti-TetSA are also found in the jejunum and caecum. Total
IgA levels are unremarkable in the case of the pharynx and jejunum, but are at the
lower end of the range from the caecum. No specific IgA was detected in the
stomach, where a very low level of total IgA was detected.
Case 02-176
A high level of specific IgA against all four antigens was demonstrated in the
pharynx of this animal, which also gave a yield of total IgA on the lower range. High
levels of anti-BoNT/C was also detected in the caecum and ileum of the animal
which also gave comparatively lower levels of total IgA. The highest anti-SA IgA




This case demonstrated a low level of anti-neurotoxin IgA in the pharynx and higher
levels in the colon and faeces where very low amounts of total IgA were detected.
However, the highest amounts of anti-TetSA was detected in the stomach and faeces
of the whole group.
Case 02-537
Demonstrated the highest levels of anti-neurotoxin IgA from the jejunum of the
whole group and high levels of anti-BoNT/D were demonstrated in the caecum and
stomach. Total IgA levels were comparatively low in these samples. This case's level
of anti-SA IgA was the second highest of the case group and total IgA from this
sample was slightly above the median.
Overall, cases exhibited higher levels of specific IgA than non-GI controls although
data must be carefully examined to check for bias caused by extremes of total IgA
yield. Samples from the pharynx appear to be more representative due to most
samples falling around the median of the group. Total IgA extraction may be more
efficient and reproducible here due to the lack of gut contents that degrade IgA and
the uniformness of the sample, which helps eliminate the error produced by varying
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4.3.7 Specific IgA: detection of total and specific IgA from faecal
samples of co-grazing controls.
IgA from co-grazing controls was analysed collectively and on a herd-case basis.
Descriptive statistics can be found in Table 4.14 and 4.15a-c respectively.





Range 3697- 9.71- 8.03 14.86 4.40-
23.68 0.02 0.02 0.00 0.00
Median 506.10 0.26 0.34 0.02 0.15
Mean 724.30 1.27 2.35 1.37 0.99
Table 4.15 Descriptive statistics of IgA detection from co-grazing controls





Range 1322- 4.95- 4.30- 0.11- 0.24-
107.30 0.10 0.09 0.01 0.01
Median 470.10 0.26 0.78 0.08 0.13
Mean 592.40 1.64 1.73 0.07 0.13
* faecal sample not available-caecal sample used
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Range 1286.00- 8.03- 3.78- 4.19- 4.40-
23.68 0.08 0.01 0.01 0.00
Median 239.70 1.02 0.60 0.00 0.01
Mean 436.8 1.772 3.903 2.695 1.121





Range 3697.00- 0.08- 0.09- 0.11- 4.43-
381.10 0.00 0.02 0.01 0.12
Median 1003.00 0.05 0.05 0.02 0.39
Mean 1351.00 0.05 0.05 0.04 1.43
Significant differences were demonstrated between the different herds. The non-
parametric Kruskall-Wallis ANOVA test was used to allow multiple comparisons to
be made. The herd of case 03-392 had significantly more total IgA extracted from
samples than the other herds with Dunn's post test P = <0.05 against case 03-352,
but P =>0.05 against 02-376. In spite of this, the herd of case 02-392 also had
significantly more specific anti-BoNT/C IgA recovered than 02-352 (Kruskall-Wallis
ANOVA P = 0.007, post-tests P = <0.05 against case 03-352, but P =>0.05 against
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herds. No significant differences were demonstrated between the herds against anti-
SA IgA or anti-TetSA IgA. However, the caecal sample of case 02-376 was used for
comparison with its herd's faecal sample and this sample possessed a much higher
total IgA yield (824.5 pg/ml compared to a herd median of 470.1).
Comparisons between individual cases and their respective herds can be seen in Fig.
4.9. Case 03-352 has higher levels of specific IgA against the neurotoxins and SA
than the median value of its respective herd and case 03-392 has higher specific IgA
levels than all the horses in its herd to all antigens. Case 02-376 had less specific IgA
than the median of its herd.
4.4 Discussion
4.4.1 Study design and analysis
This study was a collaborative effort involving research centres around the UK and
the study design was agreed upon by all involved. Although the number ofAGS
cases was adequate, more non-GI controls would have been more useful, particularly
if they had been grazing animals. However, controls such as these are hard to come
by.
Likewise, it is probably preferable to obtain premises-matched controls rather than
purely age-matched ones. However studies have proved age is important in the
disease, horses under the age of seven years being more susceptible (Doxey et al,
1991). A previous study (McCarthy et al, 2004) demonstrated that affected horses
had significantly lower specific IgG levels than premises-matched controls,
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reinforcing data previously found by Hunter et al (2001) that was not age or premises
matched. While the lack of age-matched controls is not imperative it should be taken
into consideration when looking at the data. The data was analysed using a
multivariable model but nothing was found that could not be explained by the horses'
ages i.e. lack of disease in this data set was due to the control group's higher age, not
by a higher IgG titre (Tom Cave, personal communication).
4.4.2 Comparisons ofsystemic IgG between cases and co-grazing
controls.
No significant differences in anti-neurotoxin IgG was demonstrated when taken
collectively although three of the five cases had an IgG titre against BoNT/C and
BoNT/D below the median of their respective herds and 5/5 animals had a titre
below that of the upper range of their herd. The lack of significant differences may
be explained by the small number of cases involved and the differences demonstrated
between IgG levels of herds support the case for looking at the data on a case by case
basis as this could also skew the data in this small data set.
Age and specific IgG correlation analysis was not useful in this study - a lack of data
for horses under the age of 4y probably accounted for the lack of correlation with any
antigen. Specific IgG-IgG correlation was more interesting however, with positive
correlation demonstrated between anti-BoNT/C and anti-BoNT/D IgG titre and
inverse correlation observed between anti-SA and anti-BoNT/C IgG levels. The
extent of cross-reactivity between the two neurotoxins in not documented, although
some might be expected, this has not been demonstrated using this ELISA in other
studies (Chapter III). A strong correlation was found indicating that the neurotoxins
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may be found together i.e. the Group III organisms and their bacteriophages may be
encountered together in the environment and in the horses GI tract in health and
disease (a positive correlation was seen in AGS cases also, although not as
significant). However, the lack of correlation between anti-SA and anti-BoNT/D may
be due to BoNT/D being more rarely encountered in the environment (Ian Poxton,
personal communication). A significant inverse relationship between anti-SA and
anti-BoNT/C IgG in co-grazing controls suggests that these animals have been
exposed to the organism for longer and built up more of an immune response. This
may be enough to protect the animal from developing GS in itself or possibly the
lack of immunity coupled with the nutritional trigger causes the disease.
Significant differences in OD levels of IgG subclasses were demonstrated but no
correlation was observed between any combination. A reasonable body of work on
IgG subclasses in relation to respiratory pathogens has been published but nothing
has been published on bacterial pathogens or bacterial flora of the GI tract to the best
ofmy knowledge.
4.4.3 IgA extraction and detection.
IgA extraction from GI contents and faeces yielded less total IgA than GI tissue,
making comparison between parts of the GI tract difficult where some consisted
solely of contents. It is unlikely that those samples showing a high percentage of
specific IgA and a low total IgA are true representations of the amount of specific
IgA present in vivo.
Variation of thickness of the GI wall along the intestine also introduces experimental
error into the saponin method and removal of just mucosa would be a more accurate
method ofquantifying IgA. Pharynx samples, with one exception, gave a much more
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uniform amount of total IgA and therefore a potentially more representative account
of specific IgA. The presence ofhigher levels of anti-BoNT/D in cases and a trend
toward higher levels of anti-BoNT/C IgA in the pharynx is interesting. Some very
acute cases lack the distinctive pathology of the disease, leading pathologists to
hypothesize that toxin production may take place higher up the alimentary tract (KE
Whitwell, personal communication).
Unfortunately there is no working toxin assay presently to identify the presence of
BoNT/C and none exists for the detection of BoNT/D. Possibly, toxin production
occurs in the proximal alimentary tract in acute cases but not in chronic cases leading
to more severe disease and less typical pathology in the enteric nervous system.
All of the original seven AGS cases were confirmed as grass sickness by
histopathology (KE. Whitwell, personal communiction). Two animals in particular
(03- 409, 03 - 392) demonstrated interesting inflammatory changes and bacterial
colonisation in sections taken from the ileum and jejunum. Case 03 - 409 did
demonstrate relatively high levels of specific IgA against BoNT/D in the jejunum
and ileum and against SA in the jejunum. Specific IgA demonstrated by case 02 -
392 was unremarkable when compared with the rest of the group. The discovery of
bacterial colonisation warrants further investigation and fits in with the hypothesis of
Hunter (2001) that toxin production could be highly localised. A highly focused
study, allowing investigation by histopathology, gene detection from mucosa of
clostridial toxins, IgA and cytokine production could be highly useful: both in
identifying the species involved in the colonisation and in understanding the disease
process and immunology.
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Although significantly more specific IgA against BoNT/C was seen in cases from
jejunum and ileal samples this was not the case in duodenal samples. Duodenum
samples gave the lowest percentage yield against BoNT/C of all the samples in cases
and had the third lowest yield in controls: although one of the highest medians for
total IgA. Against BoNT/D, significantly more IgA was found in jejunal and
duodenal samples but not in ileal samples despite a large difference in medians when
looking at the data. However, if the medians are compared using an unpaired t-test
(with Welsh's correction, see Chapter III) a significant P value is demonstrated
(P = 0.009) Significance is not demonstrated between duodenal samples against
BoNT/C between samples and controls using either test. Discrepancies between large
intestinal samples may be due to the extraction technique not being representative.
Although no significant difference was seen between pharynx samples against
BoNT/C, the relatively high (when comparing to other samples) upper range
indicates that there may be an association between high levels of specific IgA at this
site in comparison with controls and this is supported by a significant difference
between specific IgA against BoNT/D between cases and controls. A much higher
upper range in specific IgA against SA in cases also indicates an association-
supported by a less clear association in anti-TetSA in the pharynx of cases versus
controls.
A significant difference was observed between specific IgA levels against SA in
duodenal samples and approaching significance in ileal samples but this was not
demonstrated in jejunum samples despite the higher upper range found in cases. A
significantly higher level of anti-TetSA was found in the stomach samples of cases of
cases and approaching significance in ileal samples.
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Hunter (2001) suggested that the presence of higher levels of IgA in cases also
indicates a degree of exposure to the organism prior to the onset of clinical signs and
therefore toxin production may be a cause of gut stasis rather than an effect. This
study was designed to allow comparisons between case and controls on the same
pasture. Only three of the cases had co-grazers that were faecal sampled and out of
these, cases 02-352 and 03-392 had higher levels of specific IgA against BoNT/C
than their respective herds. Some co-grazers (Fig. 4.9) demonstrated comparatively
high specific IgA levels and would have thus been exposed to the organism as well.
Subclinical cases ofGS are thought to occur (Doxey et al, 1998) or it maybe that
certain animals exposed to the organism without the hypothesised nutritional/stress
trigger, simply produce a normal immune response, clearing the infection.
In summary, no highly statistical significant differences were demonstrated between
systemic specific IgG levels between AGS cases and their controls but case numbers
were not very high. Interesting differences were observed between herds -
demonstrating that IgG levels may be relative within a herd and that these differences
may affect statistical analysis. Cases often demonstrated lower specific IgG or IgG
subclass levels than the median of their respective herds, indicating less exposure to
the organism of interest. Detection of IgA from GI contents is variable due to
proteases that degrade it and results were more satisfactory using a method of IgA
extraction from tissue rather than contents. However, significantly more specific IgA




Serology of chronic grass sickness cases.
Results
5.1 Samples and study
Previous longitudinal studies ofCGS cases demonstrated fluctuations in OD levels of
specific IgG (Hunter 2001). However, it was not possible to determine whether these
fluctuations were significant. EL1SA kits for the quantification of equine IgG are
now commercially available and these were used to quantify levels of specific IgG in
chronic cases by comparison against a standard curve of total IgG. Levels of IgG
would be measured against neurotoxins and SA thought to be involved in the disease
and compared to levels of IgG against TetNT and TetSA. As the vast majority of
horses in the UK are vaccinated with tetanus toxoid every other year an anti-tetanus
ELISA would provide an opportunity to determine if any fluctuations in IgG were
due to an immune response to involved antigens or non-specific immune responses.
Samples were assayed for total specific IgG against BoNT/C, BoNT/D and tetanus
toxoids (TetNT) and against EDTA extracted surface antigens of neurotoxin negative
strains of C. botulinum type C (SA) and C. tetani (TetSA). OD values of specific IgG
sublasses IgGa, IgGb and IgGT against BoNT/C and BoNT/D and SA were also
assayed.
Table 5.1 shows the chronic cases used in the study. Twelve chronic cases of grass
sickness, admitted to R(D)SVS in the season of 2003 were sampled longitudinally
and samples assayed for specific IgG against BoNT/C, BoNT/D, SA and TetSA.
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Four of the cases were euthanased at the hospital, two horses were euthanased at a
later date, after returning home, and the remaining six animals survived.
A form was devised with the aid of clinicians, to provide relevant clinical and
epidemiological information such as age, tetanus vaccination status and onset of
clinical signs. A copy of the form can be found in Appendix 1.
5.1.1. Analysis of the initial IgG levels of horses that were
euthanased and comparison with surviving cases.
Fig. 5.1 shows the IgG levels of animals that were euthanased, from Day 0 (onset of
clinical signs) until death. The cases are plotted on the same timeline to enable
comparison. The exception is Case 03-489 which was included in the analysis as the
horse was eventually euthanased due to recurrent choke. The premise was to examine
initial antibody levels of animals to look for a positive protective effect in the early
stages of the disease. The remaining course of Case 03-489 immune responses can be
seen in Fig.5.3c. Of the four horses sampled more than once, all demonstrated a rise
in IgG titre to BoNT/C except 03-359. All cases also demonstrated a rise in titre to
BoNT/D also, except case 03-315, which showed the most dramatic increase in anti-
BoNT/C IgG titre. Likewise, all animals demonstrated some increase in anti-SA IgG
over the course of sampling. Case 03-489 was sampled more than other cases and











Boxplots illustrating the difference between initial levels of those horses
euthanased (first plots of each set, n = 6) and those that survived (n = 6).
Red lines demonstrate the mean and black lines the median of each data set.
BoNT/C BoNT/D SA
P = 0.06 P=1.00 P = 0.05
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The results of the comparison of initial levels of the two groups are shown in
Fig.5.2. The non-surviving cases had significantly less initial specific IgG to SA
than surviving cases (Mann-Whitney U test, P = 0.05) and almost significantly less
IgG to BoNT/C than surviving cases (P = 0.06). There was no difference in levels to
BoNT/D (P = 1.0). Cases 03-139, 03-359 and 03-520 were initially sampled much
later during the course of the disease than the others (11 and 16 days respectively).
The first two show comparatively high IgG levels to BoNT/C than other euthanased
chronics although 03/520 does not.
5.1.2 Longitudinal analysis of specific IgG levels in CGS
cases that survived.
The results of these analyses are graphically represented in Fig.5.3. IgG was
quantified and plotted on the left hand axis as mg (specific IgG) /ml. IgG subclasses
were not quantified and are plotted on the right hand axis and expressed as OD units.
Case 03-513
This case was the youngest animal sampled in this study (3y) and was first sampled
at 7 days after the onset of clinical signs.
BoNT/C & TeNT
Anti-TeNT IgG increased very slightly after the first 18 days. The largest fluctuation




An overall initial increase is demonstrated in IgG at the end of sampling although
corresponding fluctuations in IgG subclasses are not.
SA & TetSA
IgG decreases over the first 17 days and thereafter remains fairly level. However,
large fluctuations are seen in the OD values of specific IgGa, IgGb and IgGT which
are not reflected in the total specific IgG level.
Case 03-497
BoNT/C & TeNT
A slight increase in anti-TeNT was observed over the first 14 days. A drop was seen
in anti-BoNT/C IgG and a corresponding fluctuation seen in IgGb.
BoNT/D
A peak in anti-BoNT/D IgG was demonstrated at 20 days. A drop in specific IgGb
was seen at day 10.
SA & TetSA
Fluctuations in anti-SA IgG with peaks occurring at ~ 5-7 day intervals. These were
largely mirrored by fluctuations in OD of IgGb and IgGa. A similar drop in anti-





-o-IgGa IgGb -O-IgGT BoNT/CI< TetNT
daysdaysdays










-IgGa -IgGb -IgGT BoNT/CIgG TetNTIgG
TetSAIgG SA-IgG
00



























1.25 1.00 0.75 0.50 0.25 O.OO
5105234 day
Graphsofcase03-356(5.3e)and7 fshowinglongitudinalI GevelsODfgsubcla s sag in t
i)BoNT/CandTetNTi)T/DiiSAtSA
Fig.5.3g Case03-624.Gr phsshowinglongitudinalIgGtit eandODifsubclas est)B NT/CanTe TiBoNT/Di) SAandTetSA.
Case 03-489
BoNT/C & TeNT
Peaks ofanti-BoNT/C IgG were demonstrated at 10 and 32 days. All three
subclasses showed an increase in OD at the last sampling. Anti-TeNT IgG remained
relatively level over the time of sampling.
BoNT/D
An overall increase in anti-BoNT/D IgG was observed between 7 and 32 days with a
further peak at 60 days. The IgG titre corresponds to the OD levels of the subclasses.
SA & TetSA
Fluctuations were seen in anti-TetSA IgG at the beginning and end of the sampling
period. Between day 7 and day 40 a higher level of anti-SA was demonstrated. This
case had high OD levels of IgGb and relatively high levels of IgG.
Case 03-448
BoNT/C & TeNT
Significant peaks of anti-BoNT/C IgG were demonstrated at day 52 and day 100 with
smaller peaks at day 15 and day 30. The major peak at day 52 corresponds with
peaks of OD levels of specific IgGa and IgGb. Anti-TeNT IgG remains largely
unchanged. This horse had a higher level of specific IgGa than IgGb to BoNT/C.
BoNT/D
An increasing titre of anti-BoNT/D IgG is seen, resulting in a large peak at day
80.This does not correspond with any other anti-BoNT/D IgG subclass.
SA & TetSA
Anti-SA IgG gradually decreases from day 7 until day 50 after which it begins to
increase. IgGa and IgGb mainly correspond to each other although not with anti-SA
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IgG. A high level of anti-SA IgGa is maintained in this horse. Anti-TeTSA increases
slightly between day 42 and day 57 but remains relatively constant after this.
Case 03-376
BoNT/C & TeNT
This animal was not vaccinated against tetanus. A significant peak of IgGT to
BoNT/C is demonstrated at day 29 to BoNT/C. A very slight increase in anti-
BoNT/C was seen although this had dropped at the time of last sampling.
BoNT/D
A peak of IgGa can be seen at day 29 which corresponds with a peak of IgG. A
subsequent peak of IgG at the end of sampling is not followed by an increase in any
of the subclasses.
SA & TetSA
Anti-TetSA IgG shows no fluctuations. A drop at day 15 of anti-SA IgG is followed
by a peak at 29 days, corresponding with a peak of IgGa and a peak of IgGb can be
seen at day 35.
Case 03-356
BoNT/C & TeNT
A small peak of anti-BoNT/C IgG is seen at day 62 and day 75. Anti-TetNT IgG
drops after day 40.
BoNT/D
Significant peaks of anti-BoNT/D IgG can be seen at day 28 and day 75. A
significant peak of IgGa can also be seen at day 27.
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SA & TetSA
Anti-TetSA IgG levels remain low and unchanged throughout the sampling period.
Anti-SA IgG demonstrates peaks and troughs in cycles of-20 days. An increase in
IgGa was observed up until day 70. This animal had relatively high levels of IgGb
throughout the sampling period with a large increase between day 7 and day 12 and
this appeared to be dropping at the end of sampling.
Case 03-634
This case had had suspected grass sickness since its arrival at the new owners and
had been treated at home for -42 days before being admitted to the LAH.
BoNT/C & TeNT
Anti-TeNT IgG does not fluctuate significantly throughout the sampling period. A
peak of anti-BoNT/C IgG, IgGb and IgGT can be seen at day 57 although IgGa rises
after this date.
BoNT/D
A large peak of total specific IgG and IgGb can be observed at day 57. After a drop
IgG titre continues to rise up until end of sampling. Specific IgGb and IgGT had also
risen at the last sampling.
SA & TetSA
A significant drop in anti-TetSA IgG is demonstrated at day 64. An overall increase




As discussed previously (Chapter IV) epidemiological evidence supports the
hypothesis that EGS may have an infectious aetiology and that a protective immune
response is demonstrated in older horses, those having prior contact with the disease
and those animals that have remained on a particular pasture (Doxey et al, 1991,
Wood et al, 1998). It is also accepted that the degree of pathology demonstrated in
the various disease presentations is representative of the degree of toxic insult
received (Scholes et al, 1993; Doxey et al, 1995). AGS is also associated with low
levels of systemic IgG to neurotoxin and SA (Hunter et al 2001; McCarthy et al,
2004) and subclinical cases of GS are thought to occur (Doxey et al 1995). The
importance of the state of the immune system at the time of exposure to the causative
agent and subsequent severity of the disease is unknown. Hunter (2001) showed that
CGS cases that did not survive had a lower specific IgG titre against SA than those
that recovered, although this was not statistically significantly lower. The results
presented here, that subsequently euthanased animals had significantly lower IgG
levels to SA and almost significantly lower (P = 0.06) IgG levels to BoNT/C, suggest
that the status of the immune system before infection may be important in the
animal's prognosis. All of the euthanased cases that had been sampled more than
once demonstrated rising levels against the antigens except one, suggesting that the
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subsequent immune response has no effect on disease outcome. The surviving
animals also demonstrate fluctuations in IgG levels to either BoNT/C or BoNT/D,
often having higher levels at the end of sampling than at the start. Disease
intervention treatments, such as passive immunisation may at best contribute some
sort of damage limitation if given early enough, but may have no effect at all. The
incubation period is unknown, although AGS cases do show higher levels of specific
IgA against the antigens than controls (Hunter 2001, Chapter IV, this thesis)
indicating that exposure happens some time before the onset of clinical signs.
Unfortunately, some of the horses in this analysis were not sampled quickly after the
onset of clinical signs (up until 42 days after) and when looking at the data from the
surviving animals, IgG levels often drop in the first 14 days of sampling. This may
be due to existing IgG being bound to free antigen (Hunter, 2001).There was no
difference between IgG levels against BoNT/D although subsequent fluctuations in
IgG indicate that low initial levels to this neurotoxin may be due to rarity of the
BoNT/D producing organism/bacteriophage in the environment and lack of exposure
to it beforehand. The extent of cross-reactivity of BoNT/C and BoNT/D is unknown
and some horses show much higher levels of IgA and IgG to BoNT/D than BoNT/C,
suggesting the presence of BoNT/D in some cases.
The serology ofCGS has been examined before (Hunter 2001) although IgG was not
quantified due to lack of reagents. Fluctuations in OD level alone give little evidence
as to the significance of the rise or drop in levels. When looking at specific IgG
(pg/ml) in different data sets (ie healthy horses, co-grazing controls, AGS and CGS
cases) it does imply that the fluctuations demonstrated are significant - some
192
fluctuations are at least double the initial level and therefore the IgG level to that
antigen is being affected in some way whether or not the organism has a causal role
in the disease. Why the fluctuations are transient is unclear - increasing levels of IgG
against the neurotoxins are only rarely observed although some CGS cases do
demonstrate high levels in subsequent seasons (I. Poxton, unpublished data).
However, this is the exception rather than the rule. That AGS cases produce IgA and
CGS cases demonstrate such fluctuations suggest that animals begin to mount an
immune response, but are subsequently immunosuppressed. It might be interesting to
correlate IgG fluctuations with clinical observations, in particular to see if the peaks
in specific IgG correspond with periods ofGI stasis and therefore re-exposure to SA
and or neurotoxin. An investigation into cytokine expression may also prove useful.
An assay against TetSA was established to look for IgG against another ubiquitous
soil organism and it is noteworthy that IgG to this antigen did not fluctuate as much
as IgG levels against the BoNTs or SA in any animal at any time. The fluctuations
would therefore not appear to be due to non-specific immune stimulation.
Little is known about the IgG subclass function in the horse. IgGa and IgGb are
involved in opsonisation and IgGT in parasite and bacterial exotoxins. All the
published literature is involved in viral diseases (Nelson et al, 1998; Mizukoshi et al,
2002) and intracellular bacteria such as Rhodococcus equi (Hooper - McGrevy et al,
2003). An infection involving an extracellular organism such as C. botulinum would
involve both a Thl and Th2 immune response and no differences / patterns were
observed in IgG subclass ratios (data not shown). Quantification of subclasses may
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be interesting if correlated with RNA expression of cytokines to try and establish the
mechanism behind the apparent immunosuppression.
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Chapter VI
Serology of challenge horses
6.1 Samples and study
This work is related to that in Chapter III and involves soil samples gathered from
those premises that had the cases ofAGS. This was part of a multi-centre research
project and the oral challenges consisted of soil samples positive for different
BoNTs. In Edinburgh, free toxin was detected before/after enrichment by toxin
ELISA and mouse bioassays were used in Goettingen, to detect A/B/E positive or
C/D positive enrichments. The challenge work was carried out in the Central
Veterinary Laboratory in Dubai.
An initial study demonstrated that horses in Dubai had specific IgG OD levels to
BoNT/C and SA comparable to British animals (data not shown). Several other
horses were selected (not on the basis of pre-bleeds) for challenge work and the
challenge protocols discussed and decided upon by the research groups involved. In
addition to soil, some animals were given one/combination of other oral substances
that were known/thought to be potential risk factors. These included ivermectin; oral
antibiotics to alter GI flora and make it more amenable to clostridial growth and
dextrin as a potential substrate for clostridial growth; iv corticosteroids to achieve
some level of immuno-compromise (in order to mimic stress); oral inulin to attempt
to mimic a seasonal increase in grass fructan levels; codeine phosphate to reduce GI
motility and induce ileus; apricot kernels to act as a cyanide source (to mimic
clover): omeprazole which is a proton pump to decrease gastric pH and thus
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possibly increasing toxin survival through the gut. The challenge protocols for each
horse are listed below in Table 6.1. Different soils/soil combinations were used and
these are detailed in Table 6.2 and the graphs of antibody levels in individual horses
in Figs 6.1-6.6.
Table 6.1 Challenge protocols for individual horses
Horse A
Week 1 2 3 4 5 6 7 8 9 10
Soil* 1 1 1 1 1 - 6 6 7 7
Antibiotics . + + + + + + _ _









1 3 - 4 4 4 6 6





Soil* ... 3 . 5 .. 6 6
Inulin + . +
Dextrin _._-_ + + + + +
Ivermectin -
Codeine - - = : : : : - + -
Horse E
Week 123456789 10





Ivermectin - - : - : : + -
Horse F
Week 123456789 10
Soil* 7 - 5 - - 6 6
Inulin + _ +
Dextrin
Kernels _









Antibiotics + ± ± ±
* soil samples described in Table 6.2
Table 6.2 Details of soil samples
Sample no. contents
1 soil mixture from 15 GS associated pastures
2 soil from a GS premises in Aberdeenshire
3 soil from a GS premises in Northumberland-BoNT/C
directly detected by ELISA
4 soil in which BoNTs A,B and E detected by bioassay
5 soil in which BoNTs C/D detected by bioassay
6 soil from GS premises in Perthshire
7 worm casts from premises in Perthshire*
*same premises as in 6
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6.2 Results
Graphs depicting longitudinal serological analysis are shown in Fig. 6.1-6.6. Specific
IgG was quantified and plotted on the left hand axes as specific IgG (pg/ml).
Specific IgG subclasses IgGa, IgGb and IgGT were not quantified and are therefore
expressed as OD values and plotted on the right-hand axes. The only animal to
demonstrate abnormal clinical signs was Horse G which was euthanased on Day 19
of the challenge. The results of this challenge are treated separately in section 6.3.
6.2.1 Analysis of challenge animal serology
Horse A
Horse A (Fig. 6.1) was given the soil mixture from a mixture ofGS premises (1) and
demonstrated an increase in IgG to BoNT/C during the sampling period following
the start of the challenge although changes in IgG to SA or BoNT/D were not as
apparent. IgG to BoNT/C dropped during administration of sample 6 until the
administration of a soil sample 7. Peaks of IgG to BoNT/D and SA are demonstrated
at the end of the initial sampling period.
Horse B
Horse B (Fig.6.2) was also given the soil mixture 1 and also inulin in the first week.
On Day 28 soil and steroids were given. Soil mixture number 4 and dextrin was
given from Day 40 and this is also followed by a drop in IgG to all three antigens.
Specific IgG increased against BoNT/C following administration of soil mixture 6,
which was given in conjunction with codeine phosphate and then dextrin. IgG to
BoNT/C and BoNT/D was higher at the end of the challenge period than at the
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Horse C
Horse C (Fig. 6.3) was given only oral inulin for the first and third weeks of the
challenge, with no soil given until -day 27 (soil sample 3). A peak of IgG to
BoNT/D was seen in the second week and a slight increase in IgG to BoNT/C
corresponds to an increase in IgGT and IgGb to BoNT/C. IgGa to BoNT/C
demonstrated no dramatic fluctuations in OD level throughout the challenge period.
A peak in IgGb and IgGT to BoNT/D corresponds to the peak of IgG. IgG to SA
remains unchanged although small peaks of IgGa and IgGT are seen. A peak of IgG
to BoNT/C is demonstrated following feeding of soil sample number 3, which was
the sample containing BoNT/C before enrichment. A further peak of IgG to BoNT/C
is seen after administration of soil sample number 6. Corresponding peaks of IgG to
BoNT/D or SA were not demonstrated.
Horse E
Horse E (Fig.6.4) demonstrated large peaks of specific IgGT against BoNT/C and
SA.
IgG levels to BoNT/C and BoNT/D were higher at the end of the challenge period
than at the beginning, anti-BoNT/D rising after the end of administration of soil
sample 4 (containing BoNTs A, B and E).
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Fig.6.7 GraphshowinglongitudinalserologyofH seovertchall ngeer du tileut asia.IgGI subclassl t a)BoNT/Cb)/Dandc)SA.
Horse F
A rise in IgG to BoNT/C was demonstrated (Fig. 6.5), although corresponding peaks
were not seen in IgG to BoNT/D or SA. IgG to all three antigens was at a higher
level at the end of the challenge period than at the start, with the largest increases in
IgG to BoNT/D.
Horse H
This horse showed little increase or decrease in specific IgG over the course of
sampling (Fig. 6.6). Initially only oral antibiotics were given, followed by a mixture
of soil 1 and antibiotics followed by soil 2 and soil 6, all with antibiotics.
6.3 Analysis of Horse G
Horse G was given soil mixture 1 three times daily over a period of 16 days and
antibiotics on day 15 (erythromycin and potentiated sulphonamides via stomach
tube). Colic signs were demonstrated later that day and the animal responded to
analgesics. Intra-venous gentamicin was given on day 16 when the horse failed to eat
concentrate feed containing potentiated sulphonamides. Colic signs consistent with
intestinal ileus were demonstrated and the animal was finally euthanased on the basis
of inability to provide adequate analgesia and the detection of small intestinal
obstruction upon rectal examination.
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6.3.1 Longitudinal IgG levels
Longitudinal IgG levels can be seen in Fig. 6.7. A peak of IgG to BoNT/D is
demonstrated at day 7 but apart from a rise in IgGT and IgGa to BoNT/C and SA
respectively, nothing significant is seen.
6.3.2 Mucosal IgA
Post-mortem samples were collected for bacteriology and serology. Mucosal IgA
was extracted and analysed as described in Chapters II and IV. Total IgA and total
specific IgA are shown in Table 6.3. Longitudinal analysis of specific IgA (from
faeces) is shown in Fig.6.8 and specific IgA detected in different GI locations is
shown in Fig.6.9.
Specific IgA against both neurotoxins demonstrated peaks - IgA against BoNT/C
after 5 days and to BoNT/D after 12 days. The TetSA assay was used as an indicator
of soil exposure in all studies and IgA against this antigen hardly varied. There was
little variation against SA. Samples contained a higher proportion of anti- BoNT/D




Longitudinal analysis of faecal IgA from Horse G. IgA is expressed as a percentage
of total IgA recovered which is extremely variable from faecal samples.
Interestingly, IgA to SA or to TetSA did not increase. IgA to TeTSA was used as an
indicator of soil exposure on the presumption that if horses are encountering
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Table 6.3 Total IgA extracted from samples from experimental Horse G: a
comparison of the two techniques. Specific IgA as a proportion of total IgA is












Faeces 1 4.31 1.36 0.42 0.04 0.10
Faeces 2 3.13 1.62 0.61 0.05 0.18
Faeces 3 7.98 0.54 3.11 0.01 0.03
Faeces 4 3.33 0.55 1.46 0.01 0.02
Faeces 5 19.2 0.48 1.34 0.01 0.02
Faeces 6 4.32 0.35 1.34 0.01 0.02
Stomach 12.6 0.48 0.84 0.01 0.08
Duodenum 32.0 0.53 1.35 0.01 0.03
Jejunum 39.6 0.74 1.14 0.01 0.02
Caecum (c) 26.7 0.38 0.93 0.01 0.02
Caecum (s) 23.9 1.34 5.90 0.06 0.17
L colon (c) 7.65 0.40 1.27 0.01 0.03
L. colon Is) 90.6 0.41 0.89 0.01 0.02
c- extraction from contents s- saponin extraction. See Chapter II for details
An initial rise in IgA to BoNT/C is followed by a rise in IgA to BoNT/D. IgA to SA
and TetSA remained the same.
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It would seem however, that something did affect the specific IgG levels of some of
the challenged horses. Horse C for example (Fig. 6.3) demonstrated fluctuations in
IgG levels against BoNT/C that appear to correspond to doses of the different soils
and was also given oral inulin as was Horse E, whose specific IgG remains
unchanged but whose specific IgGT demonstrates large fluctuations against BoNT/C
and SA but not against BoNT/D (Fig. 6.4). It is also interesting that IgG to BoNT/C
dropped in Horse B after being given soil containing BoNTs A/B/E. Whether the
trigger factor was missing, the dose insufficient or if the horses had too high an IgG
level, and therefore protection, to the organism (s) is not clear, although it maybe that
these animals are now too immunised against these clostridial antigens to be of any
further use. Horse G was more interesting in that certain clinical signs were
demonstrated but histopathology was incomplete at time ofwriting.
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6.5 General discussion
The serology of grass sickness with regards to the toxicoinfection hypothesis is
complex. The causative agent is unproven and exposure to the hypothesised
organism and / or toxin(s) does not necessarily lead to disease / clinical illness.
Rising levels of specific IgG to these antigens are not generally seen in chronically
affected animals and there is currently no way of knowing if low levels in AGS cases
are due to less exposure than their co-grazing counterparts or due to the disease
process. Some researchers have shown a statistical link between low IgG levels to
somatic antigens and to BoNT/C (Hunter et al, 2001; McCarthy et al, 2004)
indicating naivety, immuno-incompetence or lack of exposure among affected
horses. This could also be attributed to the disease process. This was not
demonstrated in the horses investigated in Chapter IV where the only difference
between specific IgG levels between cases and controls were against SA (Fig. 4.1c).
The lower range of specific IgG of the collective cases was also only lower than the
collective lower range of the controls against SA although no AGS case had a higher
level of specific IgG against any of the antigens than the higher range of the co-
grazers. Two animals had higher anti-BoNT/C IgG levels than the median of their
respective herds (02 - 376 & 02 - 352) and it seems that among this data set that
naivety is not the only factor in disease onset. Little is really understood about the
role of IgG subclasses in disease and both these animals have relatively low levels of
specific IgGb against SA: IgGb is the most abundant IgG subclass in serum (Sheoran
et al, 2000) and thought to be involved in opsonisation (Sheoran et al, 1997).
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McCarthy et al (2004) suggested that higher levels of IgG to SA may be protective
by prevention of the growth of C. botulinum type C and subsequent toxin production
but there is no evidence to suggest that this indicates anything other than IgG status
against SA possibly just indicates exposure to the organism. The co-grazing controls
were the only group studied to demonstrate a significant inverse relationship between
anti-SA IgG and anti-BoNT/C IgG. No inverse correlation was observed in twelve
months of sampling the healthy adult horses and although it is tempting to attribute
low anti-BoNT/C levels to high anti-SA IgG levels, it may just indicate a higher level
of exposure.
The work on CGS cases (Chapter V) does suggest that IgG levels to the organism at
the start of the disease may influence disease outcome: significant differences were
observed in initial specific IgG levels between horses that survived and those that did
not. Taking into account the apparent lack of immune response to these antigens in
chronic cases either inappropriate antigens are being used in assays or the animal
experiences immunosuppression. One way forward, removing the bias of looking for
involvement of C. botulinum type C/D, especially if inflammatory mechanisms or
tissue necrosis might be involved would be to look for cytokine production in cases
and controls. This would preferably be in mucosal tissue samples at the site of toxin
production.
Fluctuations in longitudinal specific IgG studies had been demonstrated before
(Hunter, 2001) but there is no published data on the specific IgG levels of clinically
healthy horses. Studies were designed to try and supply data that could be used in
comparisons between EGS cases and controls. Such studies are difficult to set up,
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relying on goodwill and existing licensing. The pony study (beginning of Chapter III)
showed increasing IgG levels across the sampling period but unfortunately that lack
of further samples and sample from regular time points restricted the amount of
statistical analysis that could be employed. The adult horse study (later in Chapter
III) showed that specific IgG may have been affected by changes in management
practice (although fluctuations were observed later on in the study that did not
coincide with any change in practice) even though the premises were not associated
with cases ofGS. An anti-TetNT assay was used to show that the ELISA technique
and analysis worked - showing classical IgG responses to a parentally administered
antigen. This assay was also used in the study ofCGS cases and demonstrated that
these animals could produce an immune response and that specific IgG levels to this
antigen were unaffected by the disease process, indicating that fluctuations to the
other antigens used were not due to a non-specific immune response.
Perhaps the best supporting evidence for the involvement of C. botulinum type C/D
in the aetiology of EGS is the detection of specific IgA in cases versus controls.
Despite the problems of experimental techniques (discussed in Chapter IV) there is a
clear increase in the amount of specific IgA recovered in the AGS samples than in
the controls. Specific IgA is a good indicator of recent exposure and the results from
the anti-TetSA (IgA) ELISA suggests that specific IgA is not just a result of soil
exposure. It is also shown that some of the co-grazers also possessed a relatively
significant amount of specific IgA and it would be expected that most horses in a
herd would also be exposed at the same time possibly leading to subclinical disease.
A histopathological study of clinically healthy co-grazers might be therefore useful
but extremely difficult to set up.
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Chapter VII
Investigations into canine and feline dysautonomia
7.1 Introduction
Feline dysautonomia (FD: Key-Gaskell syndrome) was first reported in 1982 (Key &
Gaskell, 1982) and the disease was seen in practices throughout the UK during the
1980s. Incidence declined in the 1990s with the largest outbreak confined to a colony
of experimental cats in 1993 (Nash et al, 1994, Symonds et al„ 1995). In 2001, an
outbreak occurred in a colony ofpet cats in Glasgow (Cave et al, 2001& 2003, Nunn
et al, 2004) and a number have since been investigated. Feline dysautonomia has
been reported throughout Europe (Edney et al, 1988) but more rarely in the US
where it was mainly confined to cats recently imported from the UK (Canton et al,
1988, Guilford et al, 1988). Incidence in the UK was estimated at 1 in 20,000 to 1 in
50,000 in 2001 although it is thought that subclinical cases may occur (Cave et al,
2003) as the aetiology of at least 43% of cats showing decreased oesophageal
motility is not resolved (Moses et al, 2000). The range ofnon-specific clinical signs,
rarity of the disorder and lack of a definitive antemortem diagnosis may lead to the
disease being under-diagnosed. No risk factors had been identified in the literature
and the disease is reported in house-kept and free-roaming animals.
Canine dysautonomia (CD) was first reported in the UK in 1983 (Roschlitz & Bennet
1983) and has been reported in Norway (Presthus & Bjerkas, 1987; Schulze et al,
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1997) although incidence in canines is much lower than in felines in Europe
(O'Brien & Johnson 2002). Increasing numbers of cases ofCD have been reported in
the US since 1988 (Wise & Lappin, 1991; Longshore et al, 1996; Berghaus et al,
2001; Harkin et al, 2002) and several risk factors for the development of the disease
have been identified. These include age (a higher susceptibility found in dogs under
two years of age), those animals living in a rural environment and those allowed to
roam freely and scavenge (Berghaus et al, 2001; Harkin et al, 2002). An association
has also been made with climatic conditions, incidence being higher in early spring
(Berghaus et al, 2001).
7.1.2 Clinical signs.
As with equids, a range of clinical signs can be observed in cats and dogs and there
are some similarities and some key differences between EGS and canine and feline
dysautonomia. Clinical signs in cats and dogs include those described previously in
horses and also include vomiting/regurgitation, prolapsed third eyelids and dysuria
and major clinical signs are shown in Table 7.1. A scoring system for FD was
proposed by Sharp et al, (1990) based on clinical signs to aid clinicians in diagnosis.
Clinical features are divided into groups based on whether they are uncommon
except in dysautonomia (Group A-see Table 7.2) or less commonly observed in
dysautonomia and/or seen in other conditions (Group B). Seen together, the features
would be suggestive of feline dysautonomia. The system also enables grading of
cases according to clinical severity.
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Jamieson et al, (2002) has proposed a similar scoring system for CD based on
clinical signs and histopathological confirmation of 25 cases, the details of which can
be seen in Table 7.3.
Table 7.1. Some major clinical signs of canine and feline dysautonomia
Clinical Sign FD CD
Dry mucous membranes +++ +++
Decreased anal sphincter tone +++ +++
Dilated pupils, poor pupillary light reflexes +++ ++*
Prolapsed third eyelids +++ +*
Anorexia +++ ++*





Abdominal pain + +++
Depression, lethargv +++ +
+/- present in 10-49% cases + present in 50-59% cases ++present in 60-70%
cases +++ present 71-100% *reported more in UK cases than US. f reported less in
the UK than in the US.




Table.7.2 Clinical Grading System for Feline Dysautonomia
Clinical Feature Score
Group A
1 Dry, crusty nose 2
2 Reduced tear secretion 2
3 Myadriasis or reduced pupillary light response 2
4 Bradycardia (rate <120 beats/min) 2
5 Regurgitation & oesophageal dysfunction* 2
Group B
6 Constipation 1
7 Proprioceptive deficits 1
8 Dry oral mucosa 1
9 Prolapsed membrana nictitans 1
10 Dysuria or bladder atony 111 Anal areflexia 1
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1997) although incidence in canines is much lower than in felines in Europe
(O'Brien & Johnson 2002). Increasing numbers of cases ofCD have been reported in
the US since 1988 (Wise & Lappin, 1991; Longshore et al, 1996; Berghaus et al,
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two years of age), those animals living in a rural environment and those allowed to
roam freely and scavenge (Berghaus et al, 2001; Harkin et al, 2002). An association
has also been made with climatic conditions, incidence being higher in early spring
(Berghaus et al, 2001).
7.1.2 Clinical signs.
As with equids, a range of clinical signs can be observed in cats and dogs and there
are some similarities and some key differences between EGS and canine and feline
dysautonomia. Clinical signs in cats and dogs include those described previously in
horses and also include vomiting/regurgitation, prolapsed third eyelids and dysuria
and major clinical signs are shown in Table 7.1. A scoring system for FD was
proposed by Sharp et al, (1990) based on clinical signs to aid clinicians in diagnosis.
Clinical features are divided into groups based on whether they are uncommon
except in dysautonomia (Group A-see Table 7.2) or less commonly observed in
dysautonomia and/or seen in other conditions (Group B). Seen together, the features
would be suggestive of feline dysautonomia. The system also enables grading of
cases according to clinical severity.
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Jamieson et al, (2002) has proposed a similar scoring system for CD based on
clinical signs and histopathological confirmation of 25 cases, the details of which can
be seen in Table 7.3.
Table 7.1. Some major clinical signs of canine and feline dysautonomia
Clinical Siun FD CD
Dry mucous membranes +++ +++
Decreased anal sphincter tone +++ +++
Dilated pupils, poor pupillary light reflexes +++ ++*
Prolapsed third eyelids +++ +*
Anorexia +++ ++*





Abdominal pain + ++t
Depression, letharuv +++ +
+/-present in 10-49% cases + present in 50-59% cases ++present in 60-70%
cases +++ present 71-100% *reported more in UK cases than US. f reported less in
the UK than in the US.




Table.7.2 Clinical Grading System for Feline Dysautonomia
Clinical Feature Score
Group A
1 Dry, crusty nose 2
2 Reduced tear secretion 2
3 Myadriasis or reduced pupillary light response 2
4 Bradycardia (rate <120 beats/min) 2
5 Regurgitation & oesophageal dysfunction* 2
Group B
6 Constipation 1
7 Proprioceptive deficits 1
8 Dry oral mucosa 1
9 Prolapsed membrana nictitans 1
10 Dysuria or bladder atony 111 Anal areflexia 1





taken from Sharp et al 1990.
*demonstrated using radiography.
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Table 7.3 Clinical grading system for canine dysautonomia
Clinical feature score
Bladder atony or dysuria 3
Dilated pupils or reduced pupillary light reflex 3
Decreased tear production 3
Dry nasal mucous membranes 3
Anal areflexia 3
Regurgitation/retching with megaoesophagus or poor
Oesophageal motility* 3









*as demonstrated by radiography





Fixed pupil dilation is often a feature of feline dysautonomia but is rarely observed in
EGS, horses are often tachycardic whilst cats and dogs with the disease are more
usually bradycardic.
7.1.3 Pathology.
Gross pathological changes in cats or dogs are not consistent and can include mega-
oesophagus, signs of aspiration pneumonia, cachexia, a full distended bladder and
colonic impaction (Symonds et al, 1995; Longshore et al, 1996; Berghaus et al, 2001;
O'Brien & Johnson, 2002).
Histopathological examination is still the only definitive way to diagnose primary
dysautonomias. Histologic findings are similar among different species with
sometimes drastic reduction in neuronal density. Abnormal-appearing neurons
demonstrate nuclear eccentricity and ragged, eosinophilic cytoplasm lacking Nissl
substance.
7.2 Materials and Methods
7.2.1 Samples: Canine Serological Study
Sera from 41 histopathologically confirmed cases of canine dysautonomia were
donated by Dr K. Harkin of Kansas State University, along with 32 control samples
from healthy dogs. The control group had an age range of (13-0.5 y, median 7.5 y)
and the case group (12.0-0.17y, median 2.0y). The ages of four case animals were
unknown.
7.2.2 Samples: Investigation into an outbreak of FD in a colony ofpet
cats.
Of a colony of eight house-kept cats, six were clinically affected. None of the cats
had access to the outdoors. The signalment of cases is shown in Table 7.4, clinical
signs and outcome are summarised in Table 7.5. The index case (Al) was admitted
to Glasgow University Veterinary School five days after the advent of clinical signs.
The remaining clinically affected cats (Bl, B2, CI) were admitted after 5 -8 days of
clinical signs. Two cats died (Al, A2) and one was euthanased in extremis (A3).
Only two cats (Al and A3) went to post-mortem and dysautonomia was diagnosed
histopathologically. Signs persisted in the surviving cats. B3 and C2 were
asymptomatic but fluoroscopy 96 days after the beginning of the outbreak, showed
subjective evidence of reduced oesophageal function. Both cases may represent a
sub-clinical form of the disease. The cats were fed a single brand of tinned food from
a communal bowl and a single brand of dry food from two communal hoppers. The
batch of dry food at the time of the outbreak had been in use for 6 days prior to the
index case. On average it took 10 days for the cats to consume all dried food
contained in the hoppers. Fresh tins of food were opened daily. Feeding practices had
not changed within the preceding 12 months.
Seven further serum samples were received from isolated cases of FD after the initial
outbreak, these were included in the serological specific IgG analysis. Of these, four
were classed as positive based on clinical signs and three classed as probable. Two of
the positive cases and one of the probable cases were subsequently confirmed as
positive by histopathology.
Blood samples (1ml) from clinical cases were collected in sterile vacutainers with no
additives and allowed to clot overnight at 4°C. Serum was collected after
centrifuging at 1000 g for 15 min and stored at -20°C until assayed. Food and faecal
samples were collected into sterile universal containers and frozen at -70°C until
processing.
Table 7.4: Signalment and genetic relationship of cats within the household
Group Cat Relationship Breed Age (years) Sex
1 1 Same parents 5 M (N)
A 2 r Same litter Birman 5 F (E)
—
J 5 F(E)
1 1 Same parents 9 M (N)
B 2 J Different litters Birman 14 F (N)
3 Shared queen with B1 & B2 but 14 F (N)
different torn & litter
1 \ Same parents Colourpoint 11 M (N)
C 2 J Same litter 11 M (N)
M = male F = female N = neutered E = entire
7.2.3 Samples: IgA and Toxin Detection Controls
Eleven adult cats (age >24 months) were used as controls. Cats were from the same
geographical area (Glasgow) and had unrestricted access to the outdoors. Cats were
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in good health according to owners (staff from Glasgow Veterinary School). Diet
history for these cats is unknown. Fresh faecal samples were collected from litter
trays into sterile universals and frozen at -70°C until processing.
7.2.4 Primary serological study
Samples were obtained from GUVS Feline Centre where samples are tested for
FeLV and T4. Samples for serology from healthy controls were classified into two
groups; indoor cats (n = 30) and those having access outdoors (n = 29) and were
randomly selected. The mean age (and range) of the indoor and outdoor populations
were 16.4 (69) months and 32 (102) months, respectively.
7.2.5 Serological study; matched case-control.
Serum samples (n = 116) were obtained as above. Samples were chosen on the basis
of information given at the time of sampling. Specifically; age, breed, health status,
free-roaming or house-kept, single or multicat household. The age range (years) of
the whole group n = 112 (15.0-0.3, median 2.46), of the free-roaming group only n =
64 (14.0-0.67, median 2.96) and of the house-kept cats n = 48 (15.0-0.33, median
2 .00). There was no significant difference between the age of the two groups (P =
0.44, Mann-Whitney U test).
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7.2.6 Sample collection and storage.
Faecal samples (2g) from cases and controls were collected immediately after
defaecation in sterile universal containers and frozen at -70°C until processed. Cases
were sampled 14 weeks after the onset of clinical signs in the index case.
Ileum and its contents were obtained from Case A3 at necropsy. Briefly, the ileum
was occluded proximally and distally using nylon suture, removed, and frozen at
-20°C until assayed.
A sample of dry food fed to cases at the start of the outbreak was stored at -70°C.
Unopened cans of tinned food fed to cases were stored at room temperature.
7.2.7 Sample preparation: Preparation of faeces with protease
inhibitors prior to IgA ELISAs.
All reagents were stored at -20°C and kept on ice during the procedure. Two parts
protease inhibitor solution (soybean trypsin inhibitor lmg/ml in PBS, 50mM EDTA
containing 0.05% Tween 20) were added to one part weighed sample (~lg).
Phenylmethylsulphonyl fluoride (PMSF; Sigma-Aldrich, 0.1M in ethanol) was added
to a final concentration of 1 mM. The mixture was vortex mixed for 30-60 sec and
then centrifuged at 3800g for lOmin.The supernate was removed and PMSF was
added to a final concentration of 1% (v/v). After mixing well it was allowed to stand
for 15min on ice. Fleat inactivated foetal calf serum (FCS) was added to a final
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concentration of 4% (v/v) and centrifuged at 15700g for 5min. The supernatant was
removed and stored at -70°C.
7.2.8 Sample preparation: Preparation of ileal tissue with saponin prior
to IgA ELISAs.
Antibody extraction from ileum was achieved with saponin as described by Berquist
(2000). One gram of frozen tissue was aseptically removed and thawed for 8 hours at
4°C in PBS containing 2% saponin (w/v), soybean protease trypsin inhibitor
(lmg/ml), EDTA; 0.05M, Tween 20 (0.05%), PMSF (2mM), sodium azide
(0.2mg/ml) and 4% FCS (v/v). A 2ml volume was added per gram of tissue. After
thawing, samples were agitated using sterile forceps and then vortexed for 30s.
Samples were centrifuged at 15,000g for 5 min and the supernatants collected and
stored at -70°C until used.
7.2.9 Preparation of faeces and food samples prior to ELISA for
BoNT/C and bacteriology.
Non-enrichment: weighed samples (~lg) were added to 10ml of phosphate buffered
saline, pH7.2, containing 0.2% gelatin, (PBS-G). Samples were incubated overnight
at 4°C.
Enrichment. Samples (~l-2g) were added to 15ml of pre-reduced NZ-CASE-CMB
medium (Hunter et al„ 1999) and incubated anaerobically at 30°C for 5 days.
After vortexing thoroughly, samples were centrifuged at 3,800g for 20min. The
supernate was collected and stored at -20°C.
7.3 ELISA
7.3.1 EDTA extraction of C. botulinum surface antigens.
Clostridium cultures (20ml) were prepared in Fastidious Anaerobe Broth (Lab M)
and incubated anaerobically at 30°C for 18h. The strain used was a toxin-negative C.
botulinum type C (NCTC 3732). EDTA extracts were prepared as described by
(Poxton 1984) and stored at -20°C. Extract protein concentration was determined as
described by Lowry et al, (1951).
7.3.2 ELISA detection of anti-BoNT/C toxoid IgA and anti-C. botuiinum
surface antigen IgA from faeces and ileal tissue.
Microwell plates (Nunc, Fisher Scientific, Loughborough, UK) were coated with
BoNT/C toxoid (Metabiologicals, Wisconsin, USA) at 5pg/ml or surface antigens at
30pg/ml diluted in coating buffer (0.05M sodium carbonate buffer, pH9.6, 0.02%
w/v sodium azide) and incubated overnight at 4°C or at room temperature
respectively. The plates were washed four times with ELISA wash buffer (1 x PBS
BR.14a tablet/1 Oxoid, Basingstoke, UK, 15mM/l NaCl, 2mM/l KCL, Tween 20
0.05%) pH7.3. Plates were blocked with PBS containing 3% teleostean gelatin
(Sigma, Poole, Dorset: PBS-TG) and 0.02% sodium azide (200pl/well) and
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incubated, with shaking, for 4h at 37°C before being washed four times with ELISA
wash buffer. They were stored in sealed polythene bags at -20°C until use.
Samples were diluted 1 in 4 with PBS-TG before the addition of lOOpl/well in
quadruplicate. They were incubated overnight at room temperature and then washed
four times in ELISA wash buffer.
Rabbit anti-cat IgA (Nordic Immunologicals, Tilberg, Netherlands) was diluted 1 in
400 with PBS-TG and lOOpl added to each well. Plates were incubated for 3h at
37°C with shaking. Plates were then washed four times with ELISA wash buffer.
Anti-rabbit IgA conjugated to alkaline phosphatase (Sigma) was diluted lin 2000
with PBS-TG. Plates were incubated for 3h at 37°C with shaking. Plates were then
washed four times with ELISA wash buffer.
Alkaline phosphatase substrate tablets (Sigma 104-105 phosphatase tablets, p-
nitrophenyl phosphate 5mg) were dissolved in 5ml substrate solvent (0.05 mol/1
sodium carbonate solution, pH 9.8, with lmmol/1 magnesium chloride) to give a
concentration of lmg/ml. Plates were then incubated at room temperature for 30min
and read with an Anthos 2001 plate reader at 405 nm referenced at 620nm.
7.3.3 ELISA detection of BoNT/C toxin from cat food, faeces and ileum.
A polyvalent guinea pig antiserum (CAMR, Porton Down, UK.) raised against
purified BoNT/C was used as a capture antibody. Optimal dilutions of the reagents
were determined using a checkerboard titration. Microwell plates (Nunc) were coated
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(100pl/well) with the antiserum diluted 1 in 10,000 in 0.05M sodium carbonate
buffer, pH9.6, 0.02% w/v sodium azide and incubated overnight at 4°C. Plates were
washed three times with ELISA wash buffer.
Plates were post-coated (PBS-TG: 200pl/well) for 2h at 37°C in a shallow water
bath, before washing three times in ELISA wash buffer.
Samples were added (lOOpl/well) neat or diluted 1 in 2 and 1 in 4 for direct samples
and 1 in 5, 1 in 25 for enriched samples in PBS-TG and were incubated for 3h at
37°C in a shallow water bath before washing 3 times in ELISA wash buffer. The
guinea-pig anti-BoNT/C horse radish peroxidase conjugate (CAMR) was diluted 1 in
300 in PBS-TG (lOOpl/well) and incubated for 3h at 37°C in a shallow water bath.
After washing 3 times in PBS-T, substrate solution ( 3,3',5,5'-tetramethyl-benzidine
dihydrochloride tablets (Sigma) dissolved in phosphate citrate buffer pH5.0 with 2pl
30% hydrogen peroxide/10 ml added, 100 pl/ml) was added, lOOpl well. The
reaction was allowed to develop at room temperature for up to 60 min and was
stopped by addition of 50pl of 2M H2S04 to each well.. A standard curve of purified
BoNT/C (from CAMR) was run on each plate.
The limits of detection of this assay were 0.8ng/ml and a standard curve of purified
neurotoxin of concentrations ranging from 200ng to 0.8 ng were included on each
plate.
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7.3.4 ELISA to detect IgG to Clostridium botulinum type C toxoid,
(primary serological study)
Coating and blocking of plates
Surface antigens were diluted to 30pg/ml in 0.05M sodium carbonate buffer (0.05M
sodium carbonate buffer, pH9.6, 0.02% w/v sodium azide) and the CI and type D
toxoid complex to 5pg/ml and added to Nunc Polysorb plates (lOOpl/well). After
overnight incubation at room temperature and 4°C respectively, plates were washed
four times in ELISA wash buffer and the toxin plates blocked for 90 min with PBS-
TG (200pl/well) at 37°C. After washing four times plates were stored at -20°C in
sealed plastic bags until used.
Plates were blocked with 200pl ofPBS-ST (phosphate buffered saline, 5% foetal
bovine serum, 0.1% Tween 20, 0.02% sodium azide) for 2 hours, with shaking, at
37°C.
Serum samples were diluted 1/50 in PBS-ST and 100pl were added in duplicate for
each sample. PBS-ST only was added to blanks and to negative controls. Plates were
then incubated for 90 mins at 37°C with shaking.
Detecting antibody, rabbit anti-cat IgG (Abeam) was diluted 1/2000 in PBS-ST and
lOOul added to all wells. Incubation was for 90mins at 37°C.
Anti-rabbit IgG conjugated to alkaline phosphatase was diluted l/2000nin PBS-ST
and lOOul added to all wells. Incubation was for 90mins at 37°C.
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Substrate was used as previously mentioned.
ODs were calculated by combining the OD from the blank wells to that of the
antigen control wells and subtracting this from the average value of the duplicated
sample wells.
After initial assays, a sample was identified that gave an OD of 1.0 and this was used
to normalise all further assays.
7.3.5 ELISA for the Detection of Specific IgG
7.3.5.1 Standard curve of canine and feline IgG
Standard curves of IgG were constructed using a Bethyl Laboratories Feline and
Canine IgG Quantication kits. The reference serum was diluted according to their
instructions in PBS containing 3% teleostean gelatin (PBS-TG).Serum was added in
duplicate wells (100 pl/well). All incubations were carried out at 37°C for 90min and
washed six times between each stage with ELISA wash buffer (1 x PBS BR 14a
tablet/1 Oxoid, Basingstoke, UK, 15mM/l NaCl, 2mM/l KCL, Tween 20 0.05%)
pH7.3. Conjugate was diluted to 1/10000 and 100 pi added to each well before
incubation and subsequent washing. Colour development was with TMB added to
phosphate-citrate buffer (100 pl/well) and the colour allowed to develop for 30 min.
Development was stopped by addition of 100 pl/well of 2M H2SO4. Plates were read
on an Anthos 2001 plate reader at 450nm, referenced at 620nm.
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7.3.5.2 ELISA for the detection of total specific IgG and specific IgG
IgG assays were all carried out using HRP conjugates from Bethyl Laboratories i.e.
goat anti-cat IgG using the same reagents and incubation conditions as used for the
generation of standard curves. Optimum dilutions of sample and conjugate were
established using checkerboard titrations and dog and cat sera was diluted 1/500 and
1/200 respectively and respective conjugates at 1/10,000. Each sample was assayed
in duplicate on two separate occasions. Positive controls are not available and initial
assays were used to identify suitable controls (median responders). These controls
were run on each plate and readings used to normalize intraplate variation, all
samples were run on the same day.
Controls and analysis
Blank wells, consisting of coating buffer were included on each plate. Negative
controls, consisting of antigen diluent in place of sample, were included on the plates
to control for nonspecific binding of antibody to the antigen. All statistical analysis
was performed on Sigmaplot or on Prism V3.03.
All univariable and multivariable logistic regression analyses was carried out by Tom
Cave, formerly ofGUVS.
7.4. Bacteriological isolation of organisms from faeces and food.
Tenfold dilutions (10"1 to 10"4) were made from the non-enriched and enriched
samples in pre-reduced nutrient broth at 24 and 48h. These were plated onto
Fastidious Anaerobe Agar (FAA, Lab M, Bury, UK) containing 5% egg yolk
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emulsion (Oxoid) and 10p.g/ml gentamicin. Plates were incubated for up to 5 days
and examined by eye for lecithinase and lipase activity. Likely colonies were re-
streaked for purity and also incubated aerobically on Columbia blood agar (Oxoid
CBA base with 5 % defibrinated horse blood) to check for aerobic growth. Colonies
were also examined by Gram stain and phase contrast microscopy.
7.5 Detection of toxin genes by PCR in clinical samples, and cat
food.
7.5.1 DNA Extraction
lg samples of faeces/ileal contents or of cat food were incubated anaerobically at
30°C in 15ml of pre-reduced NZ-CASE/CMB media. After 3 days, 1.5ml of the
enrichment was transferred to a sterile eppendorf and the DNA extraction carried out
using a Nucleospin Tissue Kit following the manufacturer's instructions.
Known toxigenic strains were used as positive controls.
DNA was diluted 1/5, 1/10 and 1/100 in molecular grade water (Sigma) and kept at -
20°C until use.
7.5.2 Primer sets
Primer sets are described in Table 7.6. PCR for toxins CI consisted of a nested PCR
reaction. PCR for all the other toxins consisted of a single PCR reaction.
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Table7.6Primersetsrde crib dinTable.PCRfotoxinsC1,Dndnovyic s stedfn tPCRre ct on. fortheC2xinconsistedfasinglPCRreaction. GeneSeque c sforT xinPrimers UpstreamDownstream ToxinNameSequenc(5'-3') type CI* C2| C2tf p** aCS-11 C2ClFf C2C2F DS-11 NovAFAAACCTCCTCGAGTTACAAGCCC AAGGAAGATA ACA AAT GCAGAAGTTT AGGTA TC GTGATCCTGTTAATGACAATG GGTGCGATTCAAGAGGCCACANameSequenc(5'-3') CS-22TAGCG TACCGGG C2C1RCCTAATGATACAAATGAAAA C2C2RCGCATTCTATAACGACCTTCTGGA DS-22TCCTTGCAATGTAAGGGATGC NovARCGCTCCTAGAGTC CGA AT GeneSeque c sforT xinPrim s(N st d) UpstreamDownstream ToxinNameSequenc(5'-3') type CI*NTCS-11GAAAATC ACCCTCTCCTACATCANameSequenc(5'-3') NTCS-22AATAAGGTCTATAGTTGGACCTCC *Williamsonetl(1999)*Tak shitl,(1996) tFujiietal,(1996)tKim rael(19 8)
7.5.3 Cycling conditions
Cycling conditions for primer Sets; DS11/DS22. CS11/CS22
Number of cycles Temperature Time
1 80°C 5min
30 95 °C lmin
55 °C lmin
72 °C 2min
1 72 °C lOmin
Conditions for type C nested primers remained the same except annealing
temperatures were altered to 52°C and 54°C respectively.
Cycling conditions for primer Set; C2C1F/C2C1R and C2C2F.C2C2R
Number of cycles Temperature Time
1 94 °C 3 min
35 94 °C 45sec
55 °C 2min
72 °C lmin
1 72 °C 5min
Cycling conditions for primer Set; NovAF/NovAR
Number of cycles Temperature Time
1 94 °C 3mins
30 95 °C lmin
48 °C lmin
72 °C lmin
1 72 °C 5mins
Conditions for C. novyi type A nested primers remained the same except annealing
temperature was altered to 55°C.
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7.5.4 PCR reaction mixtures
A 100(.il reaction was used consisting of 5pl of template DNA, lOpl PCR buffer
(lOmM), 3pi magnesium chloride (MgCl2;50mM), deoxynucleotide triphosphate
(1.6pl dNTP;12.5mM), 2pl of each primer (5pM), 2.5 Units (U) Tctq polymerase and
71,6pl molecular grade water. Negative controls consisted of above mixture but
contained no template DNA and 76.6pl water.
A master mix of these reagents was prepared and aliquoted into capped thermowell
PCR tubes and reactions were carried out in a programmable thermocycler (Genius,
Techne) PCR machine.
7.5.5 PCR product visualisation
3 pi ofPCR product was added to 2pl molecular grade water and 2pl loading buffer
and mixed. The solution was run on a 1% agarose gel containing lpl/ml ethidium




7.6.1 Canine Serological Study
Results of this study are shown in Fig.7.1 The ages and antibody levels of the control
dogs were not normally (Gaussian) distributed even after transformation,
consequently, non-parametric tests (Mann-Whitney U tests and Spearmen's
correlation) were used on these samples.
Specific IgG against BoNT/C toxoid was not significantly different between the two
groups (P = 0.42) although a significant difference was demonstrated between
specific IgG against surface antigens (P = <0.0001) (as shown in Fig. 7.1). The ages
of the two groups was also significantly different, with the control dogs being
significantly older (P = <0.0001). No correlation between age and antibody
acquisition was demonstrated in the control dogs to either antigen, however, a
correlation between antibody titre against surface antigen with age was seen when
the groups were combined (n = 69, Spearman's R = 0.3467, P= 0.0035). No
correlation was observed between anti-BoNT/C titre and anti-SA titre in controls
(n = 32, Spearman's r = 0.25, P = 0.17), cases (n = 41, Spearman's R = 0.07,















o.o L T " — '
CD Control CD Control
Graphs showing a) age differences between controls and cases of CD b)
between specific IgG levels of controls and CD cases. Red plots depict anti-
BoNT/C IgG levels and black plots depict anti-SA IgG levels.
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7.7 Investigation into feline dysautonomia outbreak
7.7.1 ELISA to detect IgA antibodies to BoNT/C toxoid and
C. botulinum surface antigens from faeces and ileal tissue.
Specific IgA antibody to BoNT/C and surface antigens was detected mainly in
affected cats and a significant difference was observed in specific IgA levels in
healthy controls and Key-Gaskell Syndrome (FD) cats. The lowest value seen in
affected cats (Fig. 7.2 a & b) is from the ileum of case A3; this sample was taken
during the outbreak (week 3) and not 14 weeks afterwards like the others.
The ELISA OD value for faecal IgA antibody BoNT/C toxoid IgA from free-
roaming control cats (median 0.23, range 0.6 - 0.03) was significantly lower than
that for surviving cases (median 1.5, range 1.7- 1.3) (p<0.001). This analysis
excludes the ileum sample from A3 this analysis as the time of sampling was much
sooner. If included in the final analysis results are still significant (median 1.45,
range 1.7-0.7) (p<0.001). Similarly, IgA against EDTA extracted surface antigens
was much lower in controls (median 0.23 (range 0.85-0.06) than in affected,
surviving cats (median 0.92 (range 1.35- 0.81) (p<0.001). Again, if the ileal sample
from A3 is included, results are still significant (median 0.865, range 1.35-0.34)
(p< 0.05).
7.7.2 Bacteriological isolation of organisms from faeces and food.
Microbiologically, faeces samples did not yield any colonies with morphology
similar to C. botulinum Group III organisms and there was no growth anaerobically
from the tinned cat food. Lecithinase and lipase positive colonies were observed on
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positive rods visible under microscope but attempts to subculture the organism into
pure culture were unsuccessful despite several attempts.
7.7.3 PCR detection of botulinum neurotoxins from faeces and food.
No faecal sample was positive for any of the PCR reactions carried out from clinical
samples. The dried cat food did show a weak band, positive for BoNT/D but this was
not repeatable either from this, or subsequent enrichments.
7.7.4 ELISA detection for BoNT/C toxin from cat food, faeces and
ileum.
Table 7.6 summarises these results and shows amounts of toxin detected using the
direct detection method. Toxin was detected in faeces via direct detection in samples
from three of the six clinical cases. Toxin was also found in faeces via direct
detection in samples from one of the two sub-clinical cases (CI). The index case
(Al) had the highest faecal toxin concentration. Toxin was not detected in control
faeces or from the cat food using this method.
Following enrichment, toxin was detected in faeces in all samples from clinical cases
with the exception of B3. Toxin remained undetectable in control faeces. Toxin was
detected in dry cat food but not in tinned cat food.
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Table 7.6. Toxin detection in food and faeces of affected cats.









Dried food ND +
Tinned food ND ND
ND = none detected, + = Present.
7.8 Feline serological studies
7.8.1 Initial serological study
Using one-way ANOVA (Kruskal-Wallis test, followed by a Dunn's post-test to
compare groups) to compare the mean ages of the three FD cats were found to be
significantly older than both the indoor-kept and free-roaming controls (P = <0.01,
P = 0.001, respectively). Free-roaming controls were not significantly older than the


























Fig. 7.3. Median comparisons of serum IgG of specific antigen of
outdoor (OD) and indoor (ID) control groups and cases against a)
BoNT/C toxoid and b) EDTA extracted surface antigens.
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Using the same test, free-roaming controls had a significantly higher IgG titre against
BoNT/C toxoid than both indoor-kept and FD cats (P = <0.0001, P = <0.05
respectively). Indoor-kept cats did not have a significantly lower IgG titre than FD
cats (P = >0.05). There was no significant difference between anti-BoNT/C toxoid
IgG of indoor controls and FD cats (P<0.005).
Free-roaming controls had a significantly higher IgG level against SA than both
indoor-kept controls and FD cats (P = <0.001, P = 0.05). There was no significant
difference between indoor-kept cats and FD cats (P = >0.05).
Correlations between age and antibody levels and between antibody levels specific
for different antigens were calculated using Prism software. The program uses
Pearson's calculation unless the sample distribution is not normally distributed
(which it tests automatically) whereby Spearman's rank correlation is performed.
Results of the correlations are shown in Table 7.7. Confidence intervals were set at
95%.
7.8.2 Matched case-control study
Specific IgG detection in cases versus matched-controls
Descriptive statistics for the control groups and case group are outlined in Table 7.8.
No significant differences between specific IgG levels of Indoor-kept and Free-
roaming controls were demonstrated (Fig.7.4). Between indoor and free-roaming
control groups, the only difference approaching statistical significance was between
IgG levels against BoNT/C (P = 0.08, MW). When comparing indoor and outdoor
controls groups against the FD group, the only significant differences observed









































Fig.7.4Boxplotsdemonstratinglevelsfsp ci icantibodyga ns)BoNT/Cb)o T/DcSA
were between IgG levels against BoNT/D; P = 0.01 and P = 0.04 versus indoor-kept
and free-roaming controls respectively.









































Using the Kruskal-Wallis and Dunn's post-test, no significant difference was
demonstrated between the groups for any antigen (Fig.7.5).
When comparing control groups with FD cats, four animals are excluded from the
next analysis (cases B2, B3, CI and C2). They are excluded on the basis of scoring
by clinical signs based on Sharp et al (1990) whereby they scored 4, 0, 2 & 1
respectively, leading to inconclusive/negative diagnosis. By excluding them from the
next analysis a suitable number of'in-contact' controls can be examined.
Kruskal-Wallis tests demonstrated that control cats had significantly higher levels of
specific IgG than cases against BoNT/D (P = <0.01) but not BoNT/C
(P = >0.05 in both cases). In contact animals demonstrated a significantly higher
specific titre than controls against BoNT/C and SA but not BoNT/D (P =< 0.05,
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Fig.7.5Comparisonfs eci icIgGlev lbetw encombinedntrols,FDcas sandin-c tactsag i t)BoNT/C, b)BoNT/Dandcsurfaceantigens.Co trolc tsdemonstratesig ific tlyhigherlevelsosp cificIgGt acasesag i t BoNT/D(P=<0.01)butnoBoNT/C>0.05i thcases).Ic tactanim lsdemo stratedsig ific n lyhigherspec fic titrehancontrolsag instBoNT/Ca dSAbun tBoNT/D.(P=<0.05,P< ,0.01respectively.).In-co t ctanim ls possessedsignificantlyhigh rIgGtitrehacaa i stllt rentig(P=<0.05,P<0.01a d=<0.01).
P = < 0.05, P = <0.01 respectively). In-contact animals possessed significantly higher
IgG levels than cases against all three antigens (P =< 0.05, P = <0.01 and P =< 0.01).
7.8.3 Multivariable modelling of canine and feline dysautonomia.
Canine
Univariable logistic regression (Tom Cave, Vale Vets) was used to identify predictor
variables for CD status and low levels of antibody levels to surface antigens and
young age were both strongly correlated with a positive CD status. Multivariable
logistic regression was then used to control for the effect of age and SA antibody titre
to look for an association between CD status and low BoNT/C antibody titre. A low
antibody titre to BoNT/C was not associated with CD status in this data group. When
linear regression was employed to look for predictors for BoNT/C levels and a
positive correlation was seen between this and SA antibody levels. Therefore, levels
against SA and BoNT/C are correlated and a low SA antibody titre is associated with
CD. However, in this data set, there is no association between CD status and anti-
BoNT/C titre that cannot be explained by them both being associated with young
age.
Feline
The effect of different variables (FD status, age, breed, sex, sick versus healthy cats,
free-roaming versus indoor and single versus multicat household) upon serological
levels for BoNT/C, BoNT/D and SA were explored using Student's t-tests and linear
regression. Continuous variables were transformed to fit a normal distribution and
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multivariable linear regression was then used to control for confounding variables
(model entry p = <0.25; model retention p = < 0.05).
Anti-SA IgG
Multivariable modelling demonstrated a significant association with increasing age
and pedigree versus domestic cats.
Anti-BoNT/C IgG
Multivariable modelling demonstrated a significant association with increasing age,
healthy versus sick and male versus female cats.
Anti-BoNT/D IgG
Multivariable modelling demonstrated a significant association only with FD status-
anti BoNT/D IgGtitre was significantly lower in cats with a diagnosis of FD than in
control cats (geometric mean 3.70 x 103 versus 10.8 x 103; p = 0.006).
Based on this model, low systemic immunity to BoNT/D is associated with FD.
7.8.4 Longitudinal sampling of affected cats.
Graphs showing changes in specific IgG are shown in Fig. 7.6
Antibodies against BoNT/C toxoid
All cases had an antibody titre above the median value of the combined control
groups with the exception of the most acutely affected cases, A1 and A2. The second
least clinically affected animal (C2-clinical score of 1) had the highest antibody titre
of the group when first sampled at Day 14 of the outbreak. Over the first 7 days of
the outbreak, marked increases in titre were observed in case B1 and a marked
decrease in CI.
Antibodies against BoNT/D toxoid
All cases assayed during the second week of the outbreak had levels below that of
the median of the combined control groups with the exception ofCI (clinical score
2) which had a comparable titre to the highest range of the control group. All
surviving cases had a titre above that of the median at day 14 of the outbreak. B1
showed a massive increase in titre when sampled at Day 163 of the outbreak and this
animal was still demonstrating clinical signs such as depression and regurgitation.
Antibodies against EDTA extracted surface antigens.
Index case, Al, demonstrated an initial titre above the median of the combined
control groups although Al and A2 were below the median. B1 and CI showed and
increase in titre between weeks 1 and 2 although B2 decreased. C2 had the highest
titre against surface antigens of any cat sampled.
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Fig.7.6 Longitudinal sampling of specific IgG against
a) BoNT/C toxoid, b) BoNT/D toxoid c) EDTA extracted surface
antigens for 8 FD affected cats. Median and ranges were calculated by











Days after onset of clinical signs in A1
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Days after onset of clinical signs in A1
Days after onset of clinical signs i A1
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7.9 Discussion
There is no record in published literature of potential causes of feline and canine
dysautonomias being investigated. Incidence of the disease is extremely rare in both
species and there are problems obtaining longitudinal serum samples due to the
general acuteness of the disease in these species and the difficulty in obtaining serum
from such ill animals. There is also difficulty in persuading owners to let their
animals go to postmortem and obtaining samples from suitable controls.
Samples from canine cases were all histopathologically confirmed and were samples
from a previously published study (Harkin et al, 2002). It was unfortunate that the
control group was unsatisfactory due to age and further control samples from the
same area would be useful. A suitable control group would require samples from
clinically healthy animals below two years of age, preferably also lifestyle matched
and would probably thus require licensing and a considerable time commitment to
involved parties. Given that the control group did not have a significant higher titre
against BoNT/C toxoid than the case group, despite being significantly older may
indicate that the toxin is rarely encountered. No correlation was demonstrated
between anti-BoNT/C and anti-SA levels in any combination of groups again
suggesting that the toxin may be rarely encountered and that anti-SA levels could be
a result of cross-reactivity between C. novyi type A surface antigens and other group
III clostridial antigens. It is reasonable to suggest also, that in a healthy gut, antibody
to surface antigens may be protective as the organisms do not get a chance to
proliferate and produce toxin. There is evidence of dietary change increasing the
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number ofClostridia in the canine gut as in cats (Sparkes et al, 1998; Baillon et al,
2004) but there is no record of recent dietary change with this group of dogs.
Comparatively few bacteriological studies of the canine and feline GI tract are
published. Most studies focus on the changes caused by the addition of fructo-
oligosaccharides (Sparkes et al, 1998) or probiotics (Baillon, et al, 2004). Clostridia
are not identified to the species level so it is unknown whether any Group III
Clostridia are found in the GI tract of healthy animals. However, dogs are susceptible
to clostridial overgrowth (Baillon et al, 2004) so environments in the canine gut may
be able to support C. botulinum type C/D at certain times. Greetham et al, (2002)
used a cultural and genotypic approach to examine bacterial populations in healthy,
adult dogs although it is not clear whether these animals were laboratory animals and
only faecal samples were collected. No Group III Clostridia were identified in this
study. Papasouliotis et al (1998) found that healthy cats carried higher numbers of
strict anaerobes than humans, with clostridial species the most frequently isolated.
Both Greetham et al, (2002) and Baillon et al, (2004) reported substantial differences
in the numbers of Clostridia detected using molecular versus traditional culture
methods.
Evidence suggests that canine dysautonomia may be linked with scavenging
behaviour in dogs in the US. There is no record of dysautonomia being investigated
or found in wildlife as here in the UK (Whitwell, 1991) and the cases of grass
sickness that have been reported are mainly restricted to horses recently imported
from the UK. However, C. botulinum type C has been implicated in numerous cases
of forage poisoning in various species including horses (Schoenbaum et al, 2000)
cattle (Galey et al, 2000) and in wild, bighorn sheep (Swift et al, 2000). Harkin et al,
(2002) reported an outbreak of canine dysautonomia in a litter of 5-week-old puppies
whose darn had been euthanased for suspected dysautonomia. The dam was two
years old and the only livestock she had had access to after giving birth were
pheasants. The puppies had no contact with any other animals other than their dam or
the owner. Two other dogs on the premises, one sibling to the dam and an older dog,
were unaffected. Unfortunately, no bacteriology was carried out during this outbreak
and one can only conjecture as to whether the dam was shedding spores or whether
toxin was contained in her milk. One puppy though, remained clinically healthy.
Testing ileal or other intestinal samples for the presence of botulinum neurotoxins or
neurotoxin genes would provide further evidence of the involvement of C. botulinum
type C/D in canine dysautonomia. However, the rarity of the disease in the UK
would make such a study impracticable.
The investigation into the outbreak of FD in the group of pet cats led to much
circumstantial evidence that lends support to the toxicoinfection hypothesis. All but
one animal (the least clinically affected) had detectable levels ofBoNT/C via antigen
capture EUISA. It is possible that this cat would have been positive for the toxin if
the mouse bioassay had been available as it is -100 times more sensitive than the
EUISA. This cat was positive for specific IgA, as were all the outbreak cats, which
indicates recent exposure.
Detection of toxin and isolation of the organism itself is extremely difficult:
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C. botulinum is highly fastidious and the toxin is unstably encoded on a
bacteriophage which is easily lost upon subculture. Presence of toxin after
enrichment does not definitively mean that toxin was present in vivo and absence of
toxin does not mean the organism was not there. Indicative colonies were observed
from an enrichment of the dried cat food but it proved impossible to isolate them.
Correspondence with the cat food manufacturer confirmed that the cat food is heated
to only 80°C which would allow the survival of clostridial spores. Unfortunately the
batch number of the particular bag was not recorded and it is impossible to say
whether the bag was contaminated before, during or after manufacture.
Taq polymerase can be inhibited by polysaccharides and various other materials
found in faecal and other enrichment cultures. Adequate DNA cleanup has been a
major hurdle in the use of molecular techniques to investigate dysautonomias. Since
this work was carried out, advances have been made in this area by other members of
the research group. DNA extraction now uses a combination ofCTAB (to bind
polysaccharides) and a bead beater to disrupt spores and Gram-positive cells.
These results demonstrate similar evidence of an association between feline
dysautonomia and a toxico-infection with C. botulinum type C as has been reported
in equine grass sickness. Hunter and others (1999) detected toxin in healthy controls
leading to the hypothesis that C. botulinum type C/D may be present in the GI tract
of healthy horses. In cats, toxin was only detected in samples from affected cats,
none was detected in healthy controls. It is interesting to note that the samples
containing the highest concentration of toxin were from the three cats most acutely
affected (Al, A2 and A3) and the one sample that was negative using both protocols
came from the least affected cat (B3). Toxin has been detected before in high
percentages of dysautonomic cats (Hunter, 2001). Given the very different diets and
GI physiology of equines and felines it is possible that indoor-kept cats are not
normally exposed to C. Botulinum type C/D via canned food. The dried food was
positive for toxin after enrichment. It may be that cereal in dried food harbours
C. Botulinum (and other Clostridia) and provides an environment in the gut that
permits their proliferation.
Local mucosal immunity may be important in protection against the disease,
especially in free-roaming cats that may be exposed to C. Botulinum type C/D
through hunting. However, in house-kept cats that are not naturally exposed to the
organism, specific IgA may be a good indicator of exposure. It was evident from
these results that affected cats had some levels of specific IgA and if healthy controls
possessed specific IgA, that it was below the levels of detection of the assay used.
The control group were all free-roaming but only 3 of these showed a (much lower)
positive signal to BoNT/C toxoid compared to all of the affected cats. However this
indicates that certain cats are exposed to the toxin at certain times. No positive
control for specific IgA is available and some concentration of IgA in samples from
affected cats may have been seen due to dehydration although they were not
clinically dehydrated at the time. Also, due to availability of reagents at the time, the
assay was not quantitative. The numbers used in the study were small and a matched
case-control study, matching age, lifestyle and diet would be useful.
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It is not known whether gut stasis is caused by production of the toxin or is a
consequence of it. However, detection of specific IgA in gut samples from acute
cases of grass sickness (Hunter 2001), indicate that there has been exposure to the
organism before the onset of clinical signs and that gut stasis may be an effect rather
than a cause of the disease.
Generally, dysautonomias occur in younger animals (Doxey et al„ 1991; Berghaus et
al, 2001; Harkin et al, 2002) and a young age is a recognised risk factor in both
horses and dogs. A correlation between BoNT specific antibodies and age has been
demonstrated in horses (McCarthy et al, 2004).
The cats involved in the Glasgow outbreak were all adult although the three most
acutely affected cats (Al, A2 & A3) were also the youngest in the colony. There is
some anecdotal evidence of a genetic susceptibility in felines (Symonds et al„ 1995)
and these three animals were also littermates.
The idea that indoor-kept cats may be more susceptible due to naivety was an
attractive one although the disease is reported in free-roaming cats also. Previous
serological work in horses had shown significantly lower specific antibody levels in
sick horses compared with controls (Hunter et al,, 2001) although age-matching of
controls had not been possible.
Initial serological results were promising, free-roaming animals having a higher titre
against BoNT/C and SA than indoor-kept and FD animals. Although the FD group
268
had significantly higher IgG titre against BoNT/C this might have been partially
explained by recent exposure or because outbreak cats were not sampled until at least
seven days after onset of clinical signs in the index case. Multiple comparisons of
groups means are inadvisable due (Motulsky 1996) due to the increased likelihood of
finding significant differences so one-way ANOVA was also employed (Kruskal-
Wallis, non-parametric test followed by a Dunn's post-test for multiple
comparisons). This test demonstrated significant differences between free-roaming
controls, indoor controls and FD cats for both BoNT/C toxoid and surface antigens
for each antigen. However, significant differences were not observed between indoor
controls and FD cats for either antigen.
Correlation was performed to check for a positive correlation between antibody
acquisition and age. The only positive correlation demonstrated in individual control
groups was between free-roaming controls and anti-BoNT/C IgG. However, when
the two control groups were combined, a positive correlation was seen against both
antigens.
Correlation between antibody levels (anti-BoNT/C versus anti-SA) is not always
observed in horses which may be due to greater exposure to neurotoxin-negative
Group III strains than to neurotoxin positive strains or because a good antibody titre
against SA indicates a good immune response to the organism, helping prevent C.
botulinum type C/D growth in the gut and therefore prevents toxin production. In co-
grazing horses, an inverse correlation between SA and anti-BoNT/C antibody has
been demonstrated. Although a negative correlation was not observed in the free-
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roaming controls, a much smaller correlation was demonstrated than in indoor-kept
controls. A strong positive correlation was observed between anti-BoNT/C and anti-
SA IgG levels in the indoor-kept control groups, possibly due to lower levels of anti-
SA antibodies (due to less exposure to the organism) allowing more toxin production
in this group of animals.
Due to the differences in age of the case and control groups and the chance of
obtaining age-matched controls, it was decided to repeat the study. By this time, a
BoNT/D toxoid had also become available and a commercial ELISA kit to quantify
feline IgG.
Multivariate analysis was employed to control for confounding variables-most
importantly age and lifestyle, i.e. free-roaming versus indoor-kept cats. The only
significant finding was the association between low anti-BoNT/D titre and FD.
A recognised clinical scoring system was used to exclude certain cases although this
is arguably subjective. Definitive diagnosis can only be by histopathological
examination of ganglia and the excluded animals could have had FD and therefore
not be counted as 'healthy' in-contact animals. The presence of specific IgA in all
cases and toxin in most demonstrates recent exposure. However, these animals
survived although its impossible to say whether this is due to less exposure to the
toxic insult or due to a better immune response that limited neuronal damage.
The three most acutely affected cats demonstrated initial specific IgG levels below or
equivalent to the median IgG of the control cats against BoNT/C and BoNT/D. Bl,
the only surviving cat not excluded on the basis of clinical scoring, showed a low
initial titre against all three antigens that rose sharply when sampled on day 14. C I
demonstrated a drop in specific IgG against BoNT/C and BoNT/D over the same
time period although it demonstrated a rise in anti-SA. A drop in specific IgG is seen
in some horses, thought to relate to the IgG being used up against the antigen. The
initial levels of the surviving cats may have limited the disease/prevented it and the
dramatic rise in titre produced by B1 may have been too late to prevent the neuronal
damage that caused the presenting clinical signs. Chronic GS cases often
demonstrate fluctuations of specific IgG and it remains unclear as to whether the
animal is being re-exposed to the antigens due to compromised gut motility or
whether the neuronal damage leads to problems in cytokine production. Sampling at
30 days in the case of the cats would have been useful to see whether the levels had
increased again. It is interesting to note that the levels of the cats at 164 days were
roughly approximate to their initial levels-particularly anti-toxoid levels. The
obvious exception to this is the anti-BoNT/D titre of case B1. Numbers of cases are
too small to draw conclusions in this longitudinal analysis but due to the rarity of
such studies, interesting in themselves.
In conclusion, similar supportive but circumstantial evidence indicating C. botulinam




Aktories, K., Barmann, M., Ohishi, I., Tsuyama, S., Jakobs, K.H. and
Habermann, E. (1986). Botulinum C2 toxin ADP-ribosylates actin. Nature,
322: 390-392.
Aktories, K., Mohr, C. and Koch, G. (1992). Clostridium botulinum C3 ADP-
ribosyltransferase. Current Topics in Microbiology and Immunology 175: 115-
131.
Aktories, K., Schmidt, G. and Just, I. (2000). Rho GTPases as targets of
bacterial protein toxins. Biological Chemistry. 381: 421-426.
Aktories, K., Wille, M. and Just, I. (1992). Clostridial actin-ADP-ribosylating
toxins. Current Topics in Microbiology and Immunology, 175: 97-113.
Aktories, K. Molecular. (1992). Mechanisms of the cytopathic action of actin-
ADP-ribosylating toxins. Microbiology 6: 2905-2908.
Anon (1927). Grass disease in horses and botulism. Lancet 2 1084.
Baillon, M., Marshall-Jones ZV, Butterwick RF (2004). Effects of probiotic
Lactobacillus acidophilus strain DSM13241 in healthy adult dogs. American
Journal of Veterinary Research 65: 338-43.
Barash, J. R., Arnon, S.S. (2004). Dual toxin - producing strain of Clostridium
botulinum type Bf isolated from a California patient with infant botulism.
Journal of Clinical Microbiology 42: 1713-5.
Barlow, R. M. (1969). Neuropathological observations in grass sickness of
horses. Journal of Comparative Pathology 79: 407-411.
Barratt, D. C., Taylor, F.G.R., Morgan, K.L. (1992). A telephone - based
questionnaire of fatal equine colics in Wales during 1988 with particular
reference to grass disease. Preventive Veterinary Medicine 12: 205-215.
Barsanti, J. A., Walser, M., Hatheway, C.L., Bowen, J.M., Crowell, W. (1978).
Type C botulism in American foxhounds. Journal of the American Veterinary
Medical Association. 172: 809-13.
Barth, H., Blocker, D., Behlke, J., Bergsma-Schutter, W., Brisson, A., Benz,
R. and Aktories, K. (2000). Cellular uptake of Clostridium botulinum C2 toxin
requires oligomerisation and acidification. Journal of Biological Chemistry
275:18704-18711.
272
Barth, H., Hofmann, F., Olenik, C., Just, I. and Aktories, K. (1998). The N-
terminal part of the enzyme component (C2I) of the binary Clostridium
botulinum C2 toxin interacts with the binding component C2II and functions
as a carrier system for a Rho ADP-ribosylating C3-like fusion toxin. Infection
and Immunity 66: 1364-1369.
Barth, H., Preiss, J.C., Hofmann, F. and Aktories, K. (1998). Characterisation
of the catalytic site of the ADP-ribosyltransferase Clostridium botulinum C2
toxin by site-directed mutagenesis. Journal ofBiological Chemistry 273:
29506- 29511.
Begg, G. W. (1936). Grass disease in horses. Veterinary Record 48: 655-
662.
Benavides, E., Ortiz, D., Benavides, J. (2000). Association of botulism and
tetanus as causative agents of an outbreak of bovine paraplegic mortality in
the Eastern plains of Colombia. Annals New York Academy of Sciences'.
646-649.
Bendixen, H. (1946). Grass sickness in Denmark. Maanedsskift for
Drylaegger 58: 41-62.
Bengston, I. A. (1922). Preliminary note on a toxin-producing anaerobe
isolated from the larvae of Lucilia caesar. Public Health Report, 37: 164-170.
Berghaus, R. O' Brien., D P. Johnson, G.C. and Thome, J.T. (2001). Risk
factors for development of dysautonomia in dogs. Journal of the American
Veterinary Medical Association. 218: 1285-1290.
Berghaus, R. O' Brien., D P. Johnson, G.C. and Thome, J.T., Buening, G.M.
(2002). Incidence of canine dysautonomia in Missouri, USA, between
January 1996 and December 2000. Preventive Veterinary Medicine 54: 291-
300.
Bernard, W., Divers, T.J., Whitlock, R.H., Messick, R.H., Tulleners, E. (1987).
Botulism as a sequel to open castration in a horse. Journal of the American
Veterinary Medical Association. 191: 73-4.
Berquist, C. M.-R., Anna. Lonroth, Hans. Svennerholm, Ann-Mari (2000).
Development of a new method for the determination of immune responses in
the human stomach. Journal of Immunological Methods 234: 51-59.
Black, J. D. (1986). Interaction of 1251-labelled botulinum neurotoxins with
nerve terminals. II. Autoradiographic evidence for its uptake into motor
nerves by acceptor-mediated endocytosis. Journal of Cell Biology 103: 535-
544.
273
Blasi, J., Chapman, E.R., Link, E., Binz, T., Yamasaki, S., DeCamilli,
P.,Sudhof, T.C., Niemann, H. and Jahn, R. (1993a). Botulinum neurotoxin A
selectively cleaves the synaptic protein SNAP-25. Nature New Biology 365:
160-163.
Blasi, J., Chapman, E.R., Yamasaki, S., Binz, T., Niemann, H. and Jahn, R.
(1993b). Botulinum neurotoxin C1 blocks neurotransmitter release by means
of cleaving HPC-1/syntaxin. EMBO Journal 12: 4821-4828.
Blaustein, R. O., Germann, W.J., Finkelstein, A. and Das Gupta, B.R. (1987).
The N-terminal half of the heavy chain of botulinum type A neurotoxin forms
channels in planar phospholipid bilayers. FEBS Letters 226: 115-120.
Blocker, D., Barth, H., Maier, E., Benz, R., Barbieri, J.T. and Aktories, K.
(2000). The C terminus of component C2II of Clostridium botulinum C2 toxin
is essential for receptor binding. Infection and Immunity 68: 4566-4573.
Blood, D. C., Studdert, V P. (1999). Saunders Comprehensive Veterinary
Dictionary, W B Saunders.
Broughton, J., Parsons, L. (1985). Botulism in horses fed big bale silage.
Veterinary Record 117(25-26): 674.
Brownlee, A. (1959). Neuronophagia in the coeliaco - mesenteric ganglia of
horses affected with grass sickness. Veterinary Record 77: 323 - 4.
Canton, D., Sharp N.J., Aguirre G.D., (1988). Dysautonomia in a cat. Journal
of the American Veterinary Medical Association. 192(9): 1293-6.
Cave, T. K., C. Mellor, D. Liddon, M. & Reid, S. (2001). Feline dysautonomia
in a closed colony of pet cats. Veterinary Record 123: 451-452.
Cave, T. K., C. Mellor, D., Nunn, F., Nart, P. & Reid, S. (2003). Outbreak of
feline dysautonomia (Key - Gaskell syndrome) in a closed colony of pet cats.
Veterinary Record 153(13): 387-92.
Chia, J. K., Clark, J.B., Ryan, C.A., Pollack, M.(1986). Botulism in an adult
associated with food-borne intestinal infection with Clostridium botulinum.
New England Journal Medicine 315: 239-241.
Cobb, S. P., Hogg, R.A., Challoner, D.J., Brett, M.M., Livesey, C.T., Sharpe,
R.T., Jones, T O. (2002). Suspected botulism in dairy cows and its
implications for the safety of human food. The Veterinary Record 150: 5-8.
274
Coffield, J. A., Bakry, N., Zhang, R.D., Carlson, J., Gomella, L.G. and
Simpson, L.L. (1997). In vitro characterisation of botulinum toxin types A, C
and D action on human tissues: combined electrophysiologic, pharmacologic
and molecular biologic approaches. Journal of Pharmacology and
Experimental Therapeutics 280: 1489-1498.
Collins, M. D. and. East., A.K. (1998). Phylogeny and taxonomy of the food-
borne pathogen Clostridium botulinum and its neurotoxins. Journal of Applied
Microbiology 84: 5-17.
Cottrell, D. F., McGorum, B.C., Pearson, G.T. (1999). The neurology and
enterology of equine grass sickness: a review of basic mechanisms.
Neurogastroenterology Motility. 11: 79-92.
Darke, P. G., Roberts, T.A., Smart, J.L., Bradshaw, P R. (1976). Suspected
botulism in foxhounds. Veterinary Record 99: 98-9.
Davidson, A. J., Edwards, G.B., Proudman, C.J., Cripps, P.J., Matthews, J.B.
(2002). Cytokine mRNA expression pattern in horses with large intestinal
disease. Research in Veterinary Science 72 177-185.
Davidson, A. J., Hodgkinson, J.E., Proudman, C.J., Matthews, J.B. (2005).
Cytokine responses to Cyathostominae larvae in the equine large intestinal
wall. Research in Veterinary Science 78: 169-176.
Dohman, K., Wagner, B., Horohov, D.W., Leibold, W. (2000). Expression and
characterisation of equine interleukin -2 and interleukin - 4. Veterinary
Immunology and Immunopathology 77: 243-256.
Doxey, D. L., Gilmour, J.S. and Milne, E.M. (1991). A comparative study of
normal equine populations and those with grass sickness (dysautonomia) in
eastern Scotland. Equine Veterinary Journal 23: 365-369.
Doxey, D. L., Gilmour, J.S. and Milne, E.M. (1991). The relationship between
meterological features and equine grass sickness (dysautonomia). Equine
Veterinary Journal 23: 370-373.
Doxey, D. L., Johnston, P., Hahn, C., Reynolds, J. (2000). Histology in
recovered cases of grass sickness. The Veterinary Record 146: 645-646.
Doxey, D. L., Milne, E.M., Ellison, J. and Curry, P.J.S. (1998). Long-term
prospects for horses with grass sickness (dysautonomia). Veterinary Record
142: 207-209.
275
Doxey, D. L., Milne, E.M., Gilmour, J.S. (1997). Experimentally induced
lesions in dysautonomia (GS). Proceedings of the First International
Workshop on grass sickness, equine motor neurone disease and related
disorders., Bern, Switzerland, Equine Veterinary Journal Ltd, Newmarket,
Suffolk, UK.
Doxey, D. L., Milne, E.M., Gwilliam, R. and Sandland, J. (1999). Prediction of
long-term outcome following grass sickness (equine dysautonomia).
Veterinary Record 144: 386-387.
Doxey, D. L., Milne, E.M., Woodman, M.P., Gilmour, J.S., Chisholm, H.K.
(1995). Small intestine and small colon neuropathy in equine dysautonomia
(grass sickness). Veterinary Research Communications 19: 529-543.
Doxey, D. L., Milne, E.M. and Harter, A. (1995). Recovery of horses from
dysautonomia (grass sickness). The Veterinary Record 137: 585-588.
Doxey, D. L., Milne, Gilmour, J.S., and Pogson, D M. (1991). Clinical and
biochemical features of grass sickness (equine dysautonomia). Equine
Veterinary Journal 23: 360-364.
Doxey, D. L., Pogson, D.M., Milne, E.M. (1992). Clinical equine
dysautonomia and autonomic neuron damage. Research in Veterinary
Science 53: 106-109.
Eckhardt, M., Barth, H., Blocker, D. and Aktories, K. (2000). Binding of
Clostridium botulinum C2 toxin to asparagine-linked complex and hybrid
carbohydrates. Journal of Biological Chemistry 275: 2328-2334.
Edney, A., Gaskell CJ. (1988). Feline dysautonomia around the world.
Veterinary Record. 123: 451-2.
Edwards, G. B. (1987). Equine dysautonomia. Grass sickness of horses:
clinical picture and management. Journal of Small Animal Practice 28: 364-
373.
Ekiund, M. W., Poysky, FT., Oguma, K., lida, H. and Inoue, K. (1987).
Relationship of bacteriophages to toxin and haemagglutinin production by
Clostridium botulinum types C and D and its significance in avian botulism
outbreaks., Thomas, Springfield, Illinois.
Ekiund, M. and Poysky, F. (1974). Interconversion of type C and D strains of
Clostridium botulinum by specific bacteriophages. Applied Microbiology 27:
251-258.
Ekiund, M., Poysky, F.T., and Reed, S.M. (1972). Bacteriophage and the
toxigenicity of Clostridium botulinum type D. Nature New Biology 235: 480-
482.
276
Eklund, M., Poysky, F.T., Reed, S.M. and Smith, C.A. (1971). Bacteriophage
and the toxigenicity of Clostridium botulinum type C. Science 172: 480-482.
Eklund, M. W. Poysky, F T., Mseitif, L.M. and Strom, M.S. (1988). Evidence
for plasmid - mediated toxin and bacteriocin production in Clostridium
botulinum type G. Applied and Environmental Microbiology 54: 1405-1408.
Elad, D., Yas-atan, E., Aroch, I., Shamir, MH., Kleinbart, S., Hadash, D.,
Chaffer, M., Greenberg, K., Shlosberg, A. (2004). Natural Clostridium
botulinum type C toxicosis in a group of cats,. Journal of Clinical Microbiology
42(11): 5406-8.
Eleopra, R., Tugnoli, V., Rossetto, O., Montecucco, C. and De Grandis, D.
(1997). Botulinum neurotoxin serotype C: a novel effective botulinum toxin
therapy in humans. Neuroscience Letters 224: 91-94.
Farrow, B. M., W.G.Revington, M L.,Stewart, B.J., Zuber, R.M. (1983). Type
C botulism in young dogs. Australian Veterinary Journal 60: 374-377.
Fintl, C., McGorum, B.C. (2002). Evaluation of three ancillary treatments in
the management of equine grass sickness. Veterinary Record 151: 381-3.
Fintl, C., Milne, E M. and McGorum, B.C. (2002). Evaluation of urinalysis as
an aid in the diagnosis of equine grass sickness. Veterinary Record 151:
721-4.
Fintl, C., Pearson, G.T., Ricketts, S.W., Mayhew, I.G. and Hudson, N.P.H.
(2004). The development and distribution of the instertital cells of Cajal in the
intestine of the equine fetus and neonate. Journal of Anatomy 205: 35-44.
Foran, P., Lawrence, G.W., Shone, C.C., Foster, K.A., and Dolly, J.O. (1996).
Botulinum neurotoxin C1 cleaves both syntaxin and SNAP-25 in intact and
permeabilised chromaffin cells:Correlation with its blockade of catecholamine
release. Biochemistry 35: 2630-2636.
Foster, P.S., Hogan, S.P., Matthai, K.I., (Interleukin - 4 and interleukin - 5 as
targets for the inhibition eosinophilic inflammation and allergic airways
hyperreactivity).
Fujii, N., Kubota, T., Shirakawa, S., Kimura, K. Ohishi, I. Moriishi, «., Isogai,
E. and Isogai, H. (1996). Characterisation of component-l gene of botulinum
C2 toxin and PCR detection of its gene in clostridial species. Biochemical
and Biophysical Research Communications 220,: 353-359.
Fujinaga, Y., Inoue, K., Watanabe, S., Yokota, K., Hirai, Y., Nagamachi, E.
amd Oguma K. (1997). The haemagglutinin of Clostridium botulinum type C
277
progenitor toxin plays an essential role in binding of toxin to the epithelial
cells of guinea pig small intestine, leading to the efficient absorption of the
toxin. Microbiology 143: 3841-3847.
Galey, F.,Terra, R., Walker, R., Adaska, J., Etchebarne, M.A., Puschner, B.
Fisher, E., Whitlock, R.H., Rocke, T., Willoughby, D., Tor, E. (2000). Type C
botulism in dairy cattle from feed contaminated with a dead cat. Journal of
Veterinary Diagnostic Investigations. 12: 204-9.
Garrett, L. A.,Brown, R., Ian R. Poxton (2002). A comparative study of the
intestinal microbiota of healthy horses and those suffering from equine grass
sickness. Veterinary Microbiology 2319.
Gilmour, J. S. (1973). Experimental reproduction of the neurological lesions
associated with grass sickness. The Veterinary Record.
Gilmour, J. S. (1973). Observations on neuronal changes in grass sickness
of horses. Research Veterinary Science 15: 197-200.
Gilmour, J. S. (1976). Accumulations of nor-adrenaline associated with
axonal changes in autonomic ganglia in grass sickness. Neuropathology and
Applied Neurobiology. 389-394.
Gilmour, J. S. (1987). Epidemiology and pathology. Journal of Small Animal
Practice 28: 373-378.
Gilmour, J. S., Brown, R and Johnson, P. (1981). A negative serological
relationship between cases of grass sickness in Scotland and Clostridium
perfringens type A enterotoxin. Equine Veterinary Journal 13: 56-58.
Gilmour, J. S. and. Jolly., G.M. (1974). Some aspects of the epidemiology of
equine grass sickness. Veterinary Record 95: 77-81.
Gilmour, J. S. and. Mould., D.L. (1977). Experimental studies of neurotoxic
activity in blood fractions from acute cases of grass sickness. 22: 1-4.
Gordon, W. S. (1934). Enterotoxemia in herbivorous animals - its possible
bearing on grass sickness in horses. Veterinary Record 14: 1016-1032.
Greet, T. R. and. Whitwell., K.E. (1986). Barium swallow as an aid to the
diagnosis of grass sickness. Equine Veterinary Journal 18: 294-7.
Greetham, H., Giffard C, Flutson R.A., Collins M.D., Gibson G.R., (2002).
Bacteriology of the Labrador dog gut: a cultural and genotypic approach.
Journal ofApplied Microbiology 93(4): 640-6.
Gregory, A. E., Jubb, T.F., Nickels, R.J and Cousins, D.V. (1996). Use of
enzyme-linked immunoassays for antibody types C and D botulinum toxins
278
for investigations of botulism in cattle. Australian Veterinary Journal 73: 55-
61.
Greig, J. R. (1928). Acute "grass sickness", an interpretation of the clinical
symptoms. Veterinary Record 8: 31-34.
Greig, J. R. (1942). Grass sickness in horses. A review of present knowledge
of the disease with particular reference to the nature of the causal agent.
Transactions of the Royal Highland Agricultural Society of Scotland. 54: 1-28.
Griffin, P. M., Hatheway, C.L., Rosenbaum, R.B. and Sokolow, R. (1996).
Endogenous antibody production to botulinum toxin in an adult with intestinal
colonisation botulism and underlying Crohn's disease. Journal of Infectious
Diseases 175: 633-637.
Griffiths, I. R., Kyriakides, E., Smith, S., Howie, F. and Deary, A.W. (1993).
Immunocytochemical and lectin histochemical study of neuronal lesions in
autonomic ganglia of horses with grass sickness. Equine Veterinary Journal
25: 446-452.
Griffiths, I. R., Smith, S., Doxey, D.L., Whitwell, K. and Love, S. (1994).
Evidence that the agent of equine grass sickness may reach neurons by
retrograde axonal ransport. The Veterinary Record 135: 520-523.
Griffiths, I. R. a. W., K.E. (1993). Leporine dysautonomia: further evidence
that hares suffer from grass sickness. Veterinary Record 132: 376-377.
Guilford, W., O'Brien D.P., AllertA., Ermeling, H.M., (1988). Diagnosis of
dysautonomia in a cat by autonomic nervous system function testing. Journal
of the American Veterinary Medical Association. 193: 823-8.
Guthrie, W. J. (1940). Grass sickness in horses. Journal of the Royal
Agricultural Society 100: 50-59.
Haagsma, J. (1987). Laboratory investigation of botulism in wild birds. Avian
Botulism: An International Perspective. J. M.W. Eklund and V.R. Dowell.
Springfield, Illinois, Thomas: 283-293.
Hahn, C. A., Mayhew, I.G. (2000). Phenylephrine eyedrops as a diagnostic
test in equine grass sickness. The Veterinary Record. 603-606.
Hall, J. D., McCroskey, L.M., Pincomb, B.J. and and Hatheway, C.L. (1985).
Isolation of an organism resembling Clostridium barati which produces type F
botulinal toxin from an infant with botulism. Journal of Clinical Microbiology
21:654-655.
279
Harkin, K., Nietfeld J, Fischer JR. (2002). Dysautonomia in a family of
German shorthaired pointers. Journal of American Animal Hospital
Association. 38: 55-9.
Harkin, K. R., Andrews, G. A., Nietfield, J. C. (2002). Dysautonomia in
dogs:65 cases (1993-2000). Journal of the American Veterinary Medical
Association. 220: 633-639.
Harley, R., Gruffydd-Jones, T., Day, M. (1998). Determination of salivary and
serum immunoglobulin concentrations in the cat. Veterinary Immunology and
Immunopathology 65: 99-112.
Hatheway, C. L. (1989). Bacterial sources of clostridial neurotoxins,
Academic Press.
Hatheway, C. L. (1990). Toxigenic Clostridia. Clinical Microbiological Reviews
3: 66-98.
Hatheway, C. L. and. McCroskey., L.M. (1987). Examination of faeces and
serum for the diagnosis of infant botulism: experience in 336 patients.
Journal of Clinical Microbiology 25: 2334-2338.
Hauser, D. G., M, Boquet, P. and Popoff, M R. (1992). Plasmid localisation of
a type E botulinal neurotoxin gene homologue in toxigenic Clostridium
butyricum strains and absence of this gene in non-toxigenic C. butyricum
strains. FEMS Microbiological Letters 99: 251-256.
Hauser, D. G., M., Marvaud, J.C.,Eklund, M.W. and Popoff, M R. (1995).
Botulinal neurotoxin C1 complex genes, clostridial neurotoxin homology and
genetic transfer in Clostridium botulinum. Toxicon 33: 515-526.
Hayashi, T., Mcmahon, H., Yamasaki, S., Binz, T., Hata, Y., Sudhof, T.C. and
Niemann, H. (1994). Synaptic vesicle membrane fusion complex: action of
clostridial neurotoxins on assembly. EMBO Journal 13: 5051-5061.
Heider, L. C., McClure, J.T., Leger, E.R. (2001). Presumptive diagnosis of
Clostridium botulinum type D intoxication in a herd of feedlot cattle. Canadian
Veterinary Journal 42: 210-212.
Hooper - McGrevy, W., B.M., Prescott, J.F. (2003). Immunoglobulin G
subisotype responses of pneumonic and healthy exposed foals and adit
horses to Rhodococcus equi virulence - associated proteins. Clinical and
Diagnostic Laboratory Immunology 10: 345 - 351.
Horohov, D. W. (2000). Equine T -cell cytokines. Immunology 16: 1-14.
280
Hudson, N. P., Pearson, G.T., Kitamura, N. and Mayhew, I.G. (1999). An
immunohistochemical study of interstitial cells of Cajal (ICC) in the equine
gastrointestinal tract. Research in Veterinary Science 66: 265-271.
Hunter, L. C. (2001). The role of Clostridium botulinum type C in the
pathology of equine grass sickness. PhD Thesis. University of Edinburgh.
Hunter, L. C., Miller, J.K., Poxton, I.R. (1999). The association of Clostridium
botulinum type C with equine grass sickness: a toxicoinfection? Equine
Veterinary Journal 31: 492-499.
Hunter, L. C., Poxton, I.R. (2001). Systemic antibodies to Clostridium
botulinum type C: do they protect horses from grass sickness
(dysautonomia)? Equine Veterinary Journal 33: 547-553.
Hunter, L. C., Poxton, I.R. (2002). Clostridium botulinum types C and D and
the closely related Clostridium novyi. Reviews in Medical Microbiology 13:
75-90.
Hutson, R. A., Thompson, D.E., Lavvson, P.A., Schocken-ltturino, R.P.,
Bottger, E.C. and Collins, M.D. (1993). Genetic interrelationships of
proteolytic Clostridium botulinum types A,B and F and other members of the
Clostridium botulinum complex as revealed by small - subunit rRNA gene
sequences. Antonie van Leeuwenhoek 64: 273-283.
Ihara, H., Kohda, T., Morimoto, F., Tsukamoto, K., Karasawa, T., Nakamura,
Mukamoto, M., Kozaki, S. (2003). Sequence of the gene for Clostridium
botulinum type B neurotoxin associated with infant botulism, expression of
the C - terminal heavy chain and its binding activity. Biochim Biophys Acta
1625: 19-26
Inoue, K., and lida, H. (1968). Bacteriophages of Clostridium botulinum.
Journal of Virology. 537-540.
Inoue, K., Fujinaga, Y., Honke, K., Yokota, K., Ikeda, T., Ohyama, T.,
Takeshi, K., Watanabe, T. and Oguma, K. (1999). Characterisation of
haemaglutinin activity of Clostridium botulinum type C and D 16S toxins and
one subcomponent of haemaglutinin (HA1). Microbiology 145(2533-2542).
Inoue, K., Sobhany., M., Transue, T.R., Oguma, K., Pederson, L.C. and
Negishi, M. (2003). Structral analysis by X-ray crystallography and
calorimetry of a haemaglutinin component (HA1) of the progenitor toxin toxin
from Clostridium botulinum. Microbiology 149: 3361-3370.
Inoue, K. and. lida., H. (1971). Phage conversion of toxigenicity in
Clostridium botulinum types C and D. Japanese Journal of Medical Science
24: 53-56.
281
Jacobsen, C. N., Aasted, B., Broe, M.K. and Petersen, J.L. (1993).
Reactivities of 20 anti-human monoclonal antibodies with leucocytes from ten
different animal species. Veterinary Immunology and Immunopathology 39:
461-466.
Jamieson, P., Scudamore CL, Ruppert CE, Mauchline S, Simpson JW
(2002). Canine dysautonomia: two clinical cases. Journal of Small Animal
Practice 43: 22-6.
Jean, D., Fecteau, G., Scott, D., Higgins, R., Quessy, S. (1995). Clostridium
botulinum type C intoxication in feedlot steers being fed ensiled poultry litter.
Canadian Veterinary Journal 36: 626-628.
Jensen, W. I. and. P., J.I. (1987). The global importance of type C botulism in
wild birds. Springfield, Illinois, Thomas.
John, H. A., Gilmour, J.S., Baird, A., Milne, E.M., Doxey, D.L., Whitwell, K.,
Holdstock, N.B., Rossdale, P.D. (1997). Retrospective in vitro toxicity testing
of plasma from equine dysautonomia (grass sickness) cases previously used
in in vitro studis. Proceedings of the First International Workshop on grass
sickness, equine motor neurone disease and related disorders. Bern,
Switzerland., Equine Veterinary Journal Ltd, Newmarket, Suffolk.
John, H. A., Laffling, A., Mayhew, I.G., Whitwell, K., Holdstock, N.B.,
Rossdale, P.D. (1997). Variable susceptibility of autonomic nerve cell lines
established from different horses to toxic plasma from equine dysautonomia
cases. Proceedings of the First International Workshop on grass sickness,
equine motor neurone disease and related disorders. Berne, Switzerland.,
Equine Veterinary Journal, Newmarket.
Johnson, P. (1985). Unusual compound of small molecular weight in the
serum of horses with acute grass sickness. Research in Veterinary Science
38: 329-333.
Johnson, P., Dawson, A., Mould, D.L. (1983). Serum protein changes in
grass sickness. Research in Veterinary Science 35: 165-170.
Key, T. J. A. and. Gaskell., C.J. (1982). Puzzling syndrome in cats
associated with pupillary dilatation. Veterinary Record 110: 160.
Kimura, K., Kubota, T., Ohishi, IJsogai, H. and Fujii, N. (1998). The gene for
component-ll of botulinum C2 toxin. Veterinary Microbiology 62: 27-34.
282
Kinde, H., Bettey, R.L., Ardans, A., Galey, F.D, Daft, B.M., Waler, R.L.,
Eklund, MW, Byrd, J.W. (1991). Clostridium botulinum type C intoxication
associated with consumption of processed alfalfa hay cubes in horses.
Journal of the American Veterinary Medical Association. 199: 724-6.
Klei, T. R., French, D.D., Chapman, M R. (1989). Protection of yearling
ponies against Strongylus vulgaris by foalhood vaccination. Equine
Veterinary Journal Suppl. 75: 2-5.
Knight, K. L., Burnett, R.C., McNicholas, J.M. (1985). Organisation and
polymorphism of rabbit immunoglobulin heavy chain genes. Journal of
Immunology 134: 1245.
Kobayashi, H., Fujisawa, K., Saito, Y., Kamijo, M., Kubo, M., Eto, Y. (2003).
A botulism case of a 12 - year old girl aused by intestinal colonisation of
Clostridium botulinum type Ab. Japanese Journal of Infectious Disease 56:
73-4.
Kohn, C. W., Knight, D., Ftueston, W., Jacobs, R., Reed, S.M. (1989).
Colostral and serum IgG, IgA and IgM concentrations in Standardbred mares
and their foals at partuition. Journal of the American Veterinary Medical
Association. 195: 64-68.
Kozaki, S., Sakaguchi, G., Nishimura, M., Iwamori, M. and Nagai, Y.(1984).
Inhibitory effect of ganglioside GT1b on activities of Clostridium botulinum
toxins. FEMS Microbiology Letters: 219-223.
Kurokawa, Y., Oguma, K., Yokosawa, N., Syuto, B., Fukatsu, R. and
Yamashita, I. (1987). Binding and cytotoxic effects of Clostridium botulinum
type A, C1 and E toxins in primary neuron cultures from foetal mouse brains.
Journal of General Microbiology, 133: 2647-2657.
Lacy, D. B., Tepp, W., Cohen, A C., DasGupta, B.R. and Stevens, R.C.
(1998). Crystal structure of botulinum neurotoxin type A and implications for
toxicity. Nature Structural Biology 5: 898-902.
Lamanna, C. (1987). The scope of the avian botulism problem. Avian
Botulism: An International Perspective. J. M.W. Eklund and V.R. Dowell.
Springfield, Illinois, Thomas: 5-11.
Lannek, N., Lindberg, P., Persson, F., Obel, A.L., Sevelius, F. (1961). A
grass disease enzoonotic in stable - fed horses with an investigation of the
aetiological role of the food. Veterinary Record 73: 601-603,
Lee, W. FL a. R., Ft. (1970). Correlation of toxic and non-toxic strains of
Clostridium botulinum by DNA composition and homology. Journal of
General Microbiology 60: 117-123.
283
Llhomme, C., Collobert - Laugier, C., Amardeilh, M.F., Delverdier, M. (1996).
Equine dysautonomia : an anatomoclinical study of 8 cases. Revue de
Medicine Veterinaire 147: 805-812.
Lindstron, M., Nevas, M., Kurki, J., Sauna-aho, R., Latvala - Kiesila, A.,
Polonen, I., Korkeala, H. (2004). Type C botulism due to toxic feed affecting
52,000 farmed foxes and mink in Finland. Journal of Clinical Microbiology 42:
4718-25.
Livesey, C. T., Sharpe, R.T., Flogg, R.A. (2004). Recent association of cattle
botulism with poultry litter. Veterinary Record 154: 734-5.
Longshore, R., O'Brien D.P., Johnson G.C., Grooters A.M., Kroll R.A. (1996).
Dysautonomia in dogs: a retrospective study. Journal of Veterinary Internal
Medicine. 10: 103-9.
Lowry, O H., Rosebrough, N.J., Farr, A.L. and Randall, R.J. (1951). Protein
measurement with the Folin phenol reagent. Journal ofBiological Chemistry
193: 265-275.
Lunn D.P., H. M., Schram B, Duffus W.P. (1995). Monoclonal antibodies
specific for equine IgG sub-isotypes including an antibody which recognizes
B lymphocytes. Veterinary Immunology and Immunopathology 47: 239-51.
Lunn, D. P., Holmes, M.A., Antczak, D.F., Agerwal, N., Baker, J., Bendali-
Ahcene, S., Blanchard-Channell, M., Byrne, K.M., Cannizzo, K., Davis, W.,
Hamilton, M.J., Hannant, D., Kondo, T., Kydd. J.H., Monier, M.C., Moore,
P.F., O'Neil, T., Schram, B.R., Sheoran, A., Stott, J.L., Sugiura, T. and
Vagnoni, K.E. (1998). Report of the Second Equine Leucocyte Antigen
Workshop, Squaw Valley, California, July 1995. Veterinary Immunology and
Immunopathology 62: 101 -143.
MacKay, R. J., Berkhoff, G.A. (1982). Type C toxicoinfectious botulism in a
foal. Journal of the American Veterinary Medical Association. 180: 163-4.
MacPherson, R. (1978). Selenium deficiency. Veterinary Record 103: 60.
Mahaffey, L. M. (1959). Ganglionic lesions in grass sickness of horses.
Veterinary Record 71: 170-1.
Mahmut, N., Inoue, K., Fujinaga, Y., Arimitsu, H., Sakaguchi, Y., Hughes, L.,
Hirst, R., Murphy, T., Tsuji, T., Watanabe, T., Ohyama, T., Karasawa, T.,
Nakamura,S., Yokota, K., and Oguma, K. (2002). Mucosal immunisation with
Clostridium botulinum type C 16S toxoid and its non-toxic component.
Journal of Medical Microbiology 51: 813-820.
Main, D. C.,Gregory, A.R. (1996). Serological diagnosis of botulism in dairy
cattle. Australian Veterinary Journal 73: 77-78.
284
Maksymowych, A. B. and. Simpson.,L. (1998). Binding and transcytosis of
botulinum neurotoxin by polarized human colon carcinoma cells. The Journal
of Biological Chemistry 273: 21950-21957.
Marrs, J., Small, J., Milne, E.M. and John, H.A. (2001). Liver and biliary
system pathology in equine dysautonomia (grass sickness). Journal of
veterinary Medicine 48: 243-255.
Marti, E., Horohov, D.W., Antzak, D.F., Lazary, S., Lunn, D.P. (2003).
Advaces in equine immunology: Havemeyer workshop reports from Sante
Fe, New Mexico, and Hortobagy, Hungary. Veterinary Immunology and
Immunopathology 91: 233 - 243.
Mauss, S., Chaponnier, C., Just, I., Aktories, K. and Gabbiani, G.(1990).
ADP-ribosylation of actin isoforms by C. botulinum C2 toxin and C.
perfringens iota toxin. European Journal of Biochemistry, 194: 237-241.
McCarthy, H. E., C.J. Proudman, N.P. French. (2001). Epidemiology of
equine grass sickness:a literature review (1909-1999). Veterinary Record
149: 293-300.
McCarthy, H. E., French, N.P., Edwards, G.B., Miller, K. and C.J. Proudman.
(2004). Why are certain premises at increased risk of equine grass sickness?
A matched case - control study. Equine Veterinary Journal 36: 130-134.
McCarthy, H. E., French, N.P., Edwards, G.B., poxton, I.R., Kelly, D.F.,
Payne-Johnson, C.E., Miller, K. and C.J. Proudman. (2004). Equine grass
sickness is associated with low antibody levels to Clostridium botulinum-. a
matched case - control study. Equine Veterinary Journal 36: 123-129.
McCroskey, L. M. and. Hatheway., C.E. (1988). Laboratory findings in four
cases of adult botulism suggest colonisation of the intestinal tract. Journal of
Clinical Microbiology 26: 1052-1054.
McGorum, B. C., and Anderson, R.A. (2002). Biomarkers of exposure to
cyanogens in horses with grass sickness. The Veterinary Record 151: 442-
445.
McGorum, B. C., and Kirk, J. (2001). Equine dysautonomia (grass sickness)
is associated with altered plasma amino acid levels and depletion of plasma
sulphur amino acids. Equine Veterinary Journal 33: 473-477.
McGorum, B. C., Fry, S.C., Wallace, G., Coenen, K., Robb, J., Williamson,
G., Aruoma, O.I. (2000). Properties of herbage in relation to equine
dysautonomia: biochemical composition and antioxidant and pro-oxidant
actions. Journal ofAgricultural Food Chemistry. 48: 2346-2352.
285
McGorum, B. C., Pirie, S and Mayhew, I.G. (1998). Is equine grass sickness
(EGS) a consequence of oxidative stress? Summary report of the 10th
Anniversary Symposium of the Equine Grass Sickness Fund.
McGorum, B. C., Wilson, R., Pirie, R.S., Mayhew, I.G., Kaur, H. and Aruoma,
O.I. (2003). Systemic concentrations of antioxidants and biomarkers of
macromolecular oxidative damage in horses with grass sickness. Equine
Veterinary Journal 35: 121 -126.
McKay, W. M. (1958). Grass sickness in horses. British Veterinary Journal
114: 433-451.
McLoughlin, M. F., Mcllroy, S.G., Neill, S.D. (1989). A major outbreak of
botulism in cattle being fed ensiled poultry litter. Veterinary Record 124: 558 -
60.
Midura, T. F. and. Arnon, S.S. (1976). Infant botulism: identification of
Clostridium botulinum and its toxin in faeces. Lancet ii: 934-936.
Milne, E., Doxey, D.L., Woodman, M.P., Cuddeford, D. and Pearson, R.A.
(1996). An evaluation of the use of cisapride in horses with chronic grass
sickness (equine dysautonomia). British Veterinary Journal 152: 537-549.
Milne, E., Doxey, D.L. and Gilmour, J.S. (1990). Analysis of peritoneal fluid
as a diagnostic aid in grass sickness (equine dysautonomia). The Veterinary
Record 127: 162-165.
Milne, E., Doxey, D.L. and Kent, J.E. (1991). Acute phase proteins in grass
sickness (equine dysautonomia). Research in Veterinary Science 50: 273-
278.
Milne, E., Woodman, M. P. and Doxey, D.L. (1994). Use of clinical
measurements th predict the outcome in chronic cases of grass sickness
(equine dysautonomia). Veterinary Record 134: 438-440.
Mitchell, W. R. and. Rosendal., S. (1987). Type C botulism: the agent, host
susceptibility, and predisposing factors. Avian Botulism: An International
Perspective. J. M.W. Eklund and V.R. Dowell. Springfield, Illinois, Thomas:
55-71.
Mitten, L. A., Hinchcliff, W., Ftolcombe, S.J., Reed, S.M. (1994). Mechanical
ventilation and management of botulism secondary to an injection site
abcess in an adult horse. Equine Veterinary Journal 26: 420 -3.
286
Mizukoshi, F., Maeda, K., Flamano, M., Iwata, H., Matsumuta, T., Kondo, T.,
Sugiura, T. (2002). IgG antibody subclass response against equine
herpesvirus type 4 in horses. Veterinary Immunology and Immunopathology
88:97-101.
Montecucco, C., and Schiavo, G.(1993). Tetanus and botulism neurotoxins: a
new group of zinc proteases. Trends in Biochemical Sciences 18: 324-327.
Montecucco, C., Papini, E. and Schiavo, G. (1994). Bacterial protein toxins
penetrate cells via a four-step mechanism. FEBS Letters 346: 92-98.
Moriishi, K., Syuto, B., Saito, M., Oguma, K.,Fujii, N., Abe, N., and Naiki, M.
(1993). Two different types of ADP-ribosyltransferase C3 from Clostridium
botulinum type D lysogenised organisms. Infection and Immunity 61: 5309-
5314.
Mosedale, B., Felstead, K.J., Parke, (1968). The effect of anti-lymphocyte
serum on the response of human and mouse lymphocytes to PHA. Nature
218: 983-984.
Moses, L., Harpster, N.K., Beck, K.A., Plartzband, L. (2000). Oesophageal
motility dysfunction in cats: a study of 44 cases. Journal of American Animal
Hospital Association. 36: 309-12.
Motulsky, PI. (1996). Intuitive Biostatistics, Oxford University Press, USA.
Mowatt, M. M., and Viney, J.L. (1997). The anatomical basis of intestinal
immunity. Immunological Reviews 156: 145-166.
Murray, A., Cottrell, D.F. and Woodman, M.P. (1994). Cholinergic activity of
intestinal muscle in vitro taken from horses with and without equine grass
sickness. Veterinary Research Communications 18: 199-207.
Nakimura, S., Kimura, I., Yamakawa, K., Nishidi, S., Kozaki, S. and
Sakaguchi, G. (1978). Sporulation and C2 toxin production by Clostridium
botulinum producing no C1 toxin. Microbiology and Immunology 22 591-596.
Nash, A., Griffiths IR, Sharp NJ. (1982). Key-Gaskell syndrome. Veterinary
Record. 111: 564.
Nash, A., Griffiths IS, Sharp NJ (1982). The Key-Gaskell syndrome-an
autonomic polyganglionopathy. Veterinary Record. 111: 307-8.
Nash, A., Thompson H, Rosengurt N, Symonds HW, Gaskell CJ, Flughes KS
(1994). Feline dysautonomia in group-housed cats. Veterinary Record 134:
175-6.
287
Neill, S. D., McLoughlin, M.F., Mcllroy, S.G. (1989). Type C botulism in cattle
being fed ensiled poultry litter. Veterinary Record 124: 558 -60.
Nelson, K. M., Schram, B.R., McGregor, M.W. (1998). Local and systemic
isotype - specific antibody responses to equine influenza virus infection
versus conventional vaccination. Vaccine 16: 1306-1313.
Newton, J. R., Hedderson, E.j., Adams, V.J., McGorum, B.C., Proudman,
C.J. (2004). An epidemiological study of risk factors associated with the
recurreence of grass sickness. Equine Veterinary Journal 36: 105-12.
Niemann, H. (1991). Molecular biology of clostridial neurotoxins. London,
Academic Press.
Norgauer, J., Kownatzki, E., Seifert, R. and Aktories, K. (1988). Botuinum C2
toxin ADP-robosylates actin and enhances O2" production and secretion but
inhibits migration of activated human neutrophils. Journal of Clinical
Investigations 82: 1376-1382.
Nunn, F. G., Cave, T.A., Knottenbelt, C. and Poxton, I.R. (2004). Association
between Key-Gaskell syndrome and infection by Clostridium botulinum type
C/D. The Veterinary Record 154:111 -5.
Nusrat, A., Giry, M., Turner, J R., Colgan, S.P., Parkos, C.A., Carnes, D.,
Lemichez, E., Boquet, P. and Madara, J.L. (1995). Rho protein regulates tight
junctions and perijunctional actin organisation in polarised epithelia.
Proceedings of the National Academy of Science USA 92: 10629-10633.
Obel, A. L. (1955). Studies on grass disease. The morphological picture with
special reference to the vegetative nervous system. Journal of Comparative
Pathology 65: 334-346.
O'Brien, D.P., and Johnson GC (2002). Dysautonomia and autonomic
neuropathies. Veterinary Clinics of North America: Small Animal Practice 32:
251-65.
Ochoa, R. a. de Valendia., S. (1978). Equine grass sickness:serologic
evidence of association with Clostridium perfringens type A enterotoxin.
American Journal of Veterinary Research 39: 1049-1051.
Oguma, K., Agui, T., Syuti, B.,lida, H. and Kubo, S. (1982). Four different
monoclonal antibodies against type C1 toxin of Clostridium botulinum.
Infection and Immunity 38: 14-20.
Oguma, K., Murayama, S., Syuti, B.,lida, H. and Kubo, S. (1984). Analysis of
antigenicity of Clostridium botulinum type C1 and D toxins by polyclonal and
monoclonal antibodies. Infection and Immunity 43: 584-588.
288
Oguma, K., Syuto, B., lida, A. and Kubo, S. (1981). Homogeneity and
heterogeneity of toxins produced by Clostridium botulinum type C and D
strains. Infection and Immunity 34: 382-388.
Oguma, K., Syuto, B.,lida, H. and Kubo, S. (1980). Antigenic similarity of
toxins produced by Clostridium botulinum types C and D strains. Infection
and Immunity 30: 656-660.
Oguma, K., Yamaguchi, T., Sudou, K., Yokosawa, N. and Fujikawa, Y.
(1986). Biochemical classification of Clostridium botulinum type C and D
strains and their nontoxigenic derivatives. Applied and Environmental
Microbiology 51: 256-260.
Ohiishi, I. (1983). Response of mouse intestinal loop to botulinum C2 toxin:
enteric activity induced by cooperation of non-linked protein components.
Infection and Immunity 40: 691-695.
Ohiishi, I., and Ogagiri, Y. (1984). Histopathological effect of botulinum C2
toxin on mouse intestines. Infection and Immunity 43: 54-58.
Ohiishi, I., Iwasaki, M. and Sakaguchi, G. (1980). Purification of botulinum C2
toxin. Infection and Immunity 30: 668-673.
Ohiishi, I., Miyake, M. (1985). Binding of the two components of C2 toxin to
epithelial cells and brush borders of mouse intestine. Infection and Immunity
48: 769-775.
Ohiishi, I. and Das Gupta., B.R. (1987). Molecular structure and biological
activities of Clostridium botulinum C2 toxin. Illinois, Springfield.
Ohiishi, I., Iwasaki, M,. Sakaguchi, G. (1980). Oral toxicities of Clostridium
botulinum type C and D toxins of different molecular weights. Infection and
Immunity 28: 303-309.
Ortiz, N. E. a. S., G.R. (1994). Landfill sites, botulism and gulls. Epidemiology
and Infection, 112: 385-391.
Ortolani, E. L., Brito, L.A.B., Mori, C.S., Schalch, U., Pacheco, J. and
Baldacci, L. (1997). Botulism outbreak associated with Poultry litter
consumption in three Brazilian cattle herds. Toxicon 39: 89-92.
Osen-Sand, A., Staple, J.K., Naldi, E., Schiavo, G., Rossetto, O. Petitpierre,
S., Malgaroli, A., Montecucco, C. Catsicas, S. (1996). Common and distinct
fusion proteins in axonal growth and transmitter release. Journal of
Comparative Neurology 367: 222-234.
289
Overesch, G., Wagner, B., Radbruch, A and Leibold, W. (1998). Organisation
of the equine immunoglobulin constant heavy genes. II. equine c gamma
genes. Veterinary Immunology and Immunopathology 66: 273.
Papasouliotis, K., DVM, PhD. A H. Sparkes, BVetMed, PhD; G.Werrett; K,
Egan; E.A. Gruffydd-Jones; T.J. Gruffydd-Jones, BVetMed, PhD. (1998).
Assessment of the bacterial flora of the proximal part of the small intestine in
healthy cats, and the effect of sample collection method. American Journal of
Veterinary Research 59: 48-51.
Pemberton, A. D., Hodgson, J.C. and Gilmour, J.S. (1990). Characterisation
of compounds isolated from the sera of horses with acute grass sickness.
Research in Veterinary Science 49: 315-318.
Perkins, J. D., Bowen, I.M., Else, R.W., Marr, C.M. and Mayhew, I.G. (2000).
Functional and histopathological evidence of cardiac parasympathetic
dysautonomia in equine grass sickness. The Veterinary Record 146: 246-
250.
Pierce, N. F. and. Cray. J., W.C. (1982). Determinants of the localisation,
magnitude, and duration of a specific mucosal IgA plasma cell response in
enterically immunised rats. Journal of Immunology 128: 1311-1315.
Pinsent, P. J. N. (1989). Grass sickness of horses (grass disease: equine
dysautonomia). Veterinary Annual. 29: 169-174.
Pogson, D. M., Doxey, D.L., Gilmour, J.S., Milne, E.M. and Chisholm H.K.
(1992). Autonomic neurone degeneration in equine dysautonomia (grass
sickness). Journal of Comparative Pathology 107: 271-283.
Pollin, M. M. a. G., I.R. (1992). A review of the primary dysautonomias of
domestic animals. Journal of Comparative Pathology 106: 99-119.
Pool, W. A. (1928). 'Grass disease' in horses. Veterinary Record'. 23-30.
Poxton, I. (1984). Demonstration of the common antigens of Clostridium
botulinum, C. sporogenes and C. novyi by an enzyme linked immunosorbent
immunoassay and electroblot transfer. Journal of General Microbiology 130:
975-981.
Poxton, I. a. Byrne., M.D. (1984). Demonstration of shared antigens in he
genus Clostridium by an enzyme-linked immunosorbent assay. Journal of
Medical Microbiology 17: 171 -176.
Poxton, I. R., Hunter, L.C., Brown, R., Lough, H.G. and Miller, J.K. (1997).
Clostridia and equine grass sickness. Reviews in Medical Microbiology 8,
Supplement 1: S49-S51.
290
Presthus, J., Bjerkas I. (1987). Canine dysautonomia in Norway. Veterinary
Record 120: 463-4.
Prince, D., Corcoran, B.M., Mayhew, I.G. (2003). Changes in nasal mucosal
innervation in horses with grass sickness. Equine Veterinary Journal 35: 60-
66.
Richmond, R. N., Hatheway, C., Kaufman, A.F. (1978). Type C botulism in a
dog. Journal of the American Veterinary Medical Association. 173: 202-3.
Ricketts, S. W., Greet, T.R., Glyn, P.J., Ginnett, C D., McAllister, E.P.,
McCaig, J., Skinner, P.H., Webbon, P.M., Frape, D.L., Smith, G.R. et al.
(1984). Thirteen cases of botulism in horses fed big bale silage. Equine
Veterinary Journal 16: 515 - 8.
Robb, J., Doxey, D.L. and John, H.A. (1997). Effects of fungal extracts on
equine autonomic nerve cells in vitro. Proceedings of the First International
Workshop on grass sickness, equine motor neurone disease and related
disorders. Bern, Switzerland., Equine Veterinary Journal Ltd, Newmarket,
Suffolk.
Robb, J., Doxey, D.L., Milne, E.M., Whitwell, K.E., Robles, C.A., Uzal, F.A.
and John, H. (1997). The isolation of potentially toxigenic fungi from the
environment and horses with grass sickness and mal seco. Proceedings of
the First International Workshop on grass sickness, equine motor neurone
disease and related disorders. Bern, Switzerland., Equine Veterinary Journal
Ltd, Newmarket, Suffolk.
Rochlitz, I., and Bennett, A.M. (1983). Key-Gaskell syndrome in a bitch.
Veterinary Record 112: 614-615.
Rossetto, O., Schiavo, G., Montecucco, C., Poulain, B., Deloye, F., Lozzi, L.
amd Shone, C.C. (1994). SNARE motif and neurotoxins. Nature New Biology
372: 415-416.
Sandor, G., Korach, S., Mattern, P. (1964). 7S globulin, immunologically
identical to 19S gamma - 1(beta)- M-globulin, a new protein of horse serum.
Nature 204: 795 -796.
Schiavo, G., Poulain, B., Benfenati, F. and DasGupta, B.R. (1993). Novel
targets and catalytic activities of bacterial protein toxins. Trends in
Microbiology. 1: 170-174.
Schiavo, G., Shone, C.C., Rossetto, O., Alexander, F.C.G. and Montecucco,
C. (1993). Botulinum neurotoxin serotype F is a zinc endopeptidase specific
for VAMP/synaptobrevin. Journal of Biological Chemistry{268)'. 11516-11519.
291
Schiavo, G., Shone, C.C., Rossetto, 0., Alexander, F.C.G. and Montecucco,
C. (1993). Botulinum neurotoxin serotype F is a zinc endopeptidase specific
for VAMP/synaptobrevin. Journal of Biological Chemistry 268: 11516-11519.
Schiavo, G. B.,Poulain, B., Rossetto, O., Polverino de Laureto.P., DasGupta,
B.R. and Montecucco, C. (1992). Tetanus and botulinum-B neurotoxins block
neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature
New Biology 359: 832-835.
Schiavo, G.M., and Montecucco, C. (2000). Neurotoxins affecting
neuroexocytosis. Physiological Reviews 80: 717-766.
Schiavo, G.M., Catsica, S., Polverino de Laureto, DasGupta, B.R., Benfenati,
F. and Montecucco, C. (1993). Identification of the nerve terminal targets of
botulinum neurotoxin serotypes A, D and E. Journal ofBiological Chemistry
268: 23784-23787.
Schiavo, G. S., Bennett, M.K., Scheller, R.H. and Montecucco, C. (1995).
Botulinum neurotoxin type C cleaves a single lys-ala bond within the carboxy-
terminal region of syntaxins. Journal of Biological Chemistry 270: 10566-
10570.
Schoenbaum, M., Hall, SM., Glock, RD., Grant, K.,Jenny, AL., Schiefer, TJ.,
Sciglibaglio, P., Whitlock, RH. (2000). An outbreak of type C botulism in 12
horses and a mule. Journal of the American Veterinary Medical Association.
217(365-8): 340.
Scholes, S. F. E., Vaillant, C., Peacock, P., Edwards, G.B., Kelly, D.F.
(1993). Diagnosis of grass sickness by ileal biopsy. The Veterinary Record
133: 7-10.
Scholes, S. F. E., Vaillant, C., Peacock, P., Edwards, G.B., Kelly, D.F.
(1993). Enteric neuropathy in horses with grass sickness. The Veterinary
Record 132: 647-651.
Schultz, R. D., Scott, F.W., Duncan, J.R., Gillespie, J.H. (1974). Feline
immunoglobulins. Infection and Immunity 9: 391-393.
Schulze, C., Schanen H, Pohlenz J. (1997). Canine dysautonomia
resembling the Key-Gaskell syndrome in Germany. Veterinary Record 141:
496-7.
Seddon, H. R. (1922). Bulbar paralysis in cattle due to the action of a
toxigenic bacillus with a discussion on the relation of the condition to forage
poisoning (botulism). Journal of Comparative Pathology and Therapeutics 35:
147-190.
292
Sharp, N. J. (1990). Feline dysautonomia. Seminars in Veterinary Medecine
and Surgery (Small Animal). 5: 67-71.
Sharp, N. J. N., Nash, A S. and Griffiths, I.R. (1984). Feline dysautonomia
(the Key-Gaskell syndrome): a clinical and pathological study of forty cases.
Journal of Small Animal Practice 25: 599-615.
Sheoran, A., Lunn, D P., Holmes, M.A. (1998). Monoclonal antibodies to
subclass - specific antigenic determinants on equine immunoglobulin gamma
chains and their characterisation. Veterinary Immunology and
Immunopathology 62: 153.
Sheoran, A., Sponseller, B.T., Holmes, M.A., Timoney, J.F. (1997). Serum
and mucosal antibody isotype responses to M-like protein (SeM) of
Streptococcus equi in convalescent and vaccinated horses. Veterinary
Immunology and Immunopathology 59: 239-251.
Sheoran, A., Timoney, J.F.Holmes, M.A.,Karzenski, S.S., Crisman, M.V.
(2000). Immunoglobulin isotypes in sera and nasal mucosal secretions and
their nenatal transfer and distribution in horses. American Journal of
Veterinary Research 61:1099-1105.
Sheoran, A. a. Holmes., M.A. (1996). Separation of equine IgG subclasses
(IgGa, IgGb and IgG(T)) using their differential binding characteristics for
staphylococcal protein A and streptococcal protein G. Veterinary Immunology
and Immunopathology 55: 33-43.
Simpson, L.L (2000). Identification of the characteristics that underlie
botulinum toxin potency:Implications for designing novel drugs. Biochemie
82: 943-953.
Simpson, L. L. (1982). A comparison of the pharmacological properties of
Clostridium botulinum type C1 and C2 toxins. The Journal ofPharmacology
and Experimental Therapeutics 223: 695-701.
Simpson, L. L. (1989). Peripheral actions of the botulinum toxins. New York,
Academic Press.
Smart, J. L., Jones, T.L., Clegg, F.G., McMurtry, M.J. (1987). Poultry waste
associated Type C botulism in cattle. Epidemiology and Infection, 98(1): 73 -
9.
Smith, G. R. a. T., A. (1988). The production of Clostridium botulinum toxin in
mammalian, avian and piscine carrion. Epidemiology and Infection, 102: 467-
471.
Smith, L. D. (1975). Clostridium botulinum. The Pathogenic Anaerobic
Bacteria. A. T. Balows, C.C. Illinois: 203-229.
293
Sollner, T., Whiteheart, S.W., Brunner, M., Erdjument-Bromage, H.,
Geromanos, S., Tempst, P. and Rothman, J.E. (1993). SNAP receptors
implicated in vesicle targeting and fusion. Nature New Biology 362: 318-324.
Sparkes, A., Papasouliotis K, Sunvold G, Werrett G, Clarke C, Jones M,
Gruffydd-Jones TJ, Reinhart G (1998). Bacterial flora in the duodenum of
healthy cats, and effect of dietary supplementation with fructo-
oligosaccharides. American Journal of Veterinary Research 59: 431-5.
Sparkes, A., Papasouliotis K, Sunvold G, Werrett G, Gruffydd-Jones EA,
Egan K, Gruffydd-Jones TJ, Reinhart G. (1998). Effect of dietary
supplementation with fructo-oligosaccharides on fecal flora of healthy cats.
American Journal of Veterinary Research 59: 436-40.
Steinbach, F., Deeg, C., Mauel, S., Wagner, B. (2002). Equine immunology:
offspring of the serum horse. Trends in Immunology 23: 223- 226.
Steinbach, F., Mauel, S., Beier, I., (2002). Recombinant equine interferons:
expression cloning and biological activity. Veterinary Immunology and
Immunopathology 84(83 - 95).
Stewart, P. B., Bell, R. (1970). Selective suppression of cell mediated
immunity by equine anti - rabbit lymphocyte serum. Nature 227: 279.
Stewart, W. J. (1977). A case of suspected grass sickness in a thoroughbred
mare. Australian Veterinary Journal 53: 196.
Stiles, B. G., Blocker, D., Hale, M.L., Guetthoff, M.A. and Barth, H. (2002).
Clostridium botulinum C2 toxin: binding studies with flourescence - activated
cytometry. Toxicon 40: 1135-1140.
Sunagawa, H. I., K (1991). Isolation and characterisation of converting and
non-converting phages, harbored in the strains of Clostridium botulinum
types C and D isolated in Japan. Journal of Veterinary Medical Science 53:
951-954.
Sunagawa, H. I., K (1992). Biological and biophysical characteristics of
phages isolated from Clostridium botulinum type C and D strains, and
physiochemical properties of the phage DNAs. Journal of Veterinary Medical
Science 54: 675-684.
Swerczek, T. W. (1980). Experimentally induced toxicoinfectious botulism in
horses and foals. American Journal of Veterinary Research 41: 348-350.
Swerczek, T. W. (1980). Toxicoinfectious botulism in foals and adult horses.
Journal ofAmerican Veterinary Medical Association 176: 217-220.
294
Swift, P. K., Wehausen, J.D., Ernst, H.B., Singer, R.S., Pauli, A.M., Kinde, H.,
Rocke, T.E., Bleich, V.C. (2000). Desert bighorn sheep mortality due to
presumptive type C botulism in California. Journal ofWildlife Disease 36(1):
184-9.
Symonds, H. W., McWilliams, P., Thompson, H., Nash, A.,Sanchez, S. &
Rozengurt, N. (1995). A cluster of cases of feline dysautonomia (Key-Gaskell
syndrome) in a closed colony of cats. Veterinary Record 136: 353-355.
Tocher, J. F. (1924). Grass sickness in horses. Transactions of the Royal
Highland and Agricultural Society of Scotland 36: 65-83.
Tocher, J. F., Tocher, W. Brown, W. and Buton, J.B. (1923). Grass sickness
investigation report. Veterinary Record 3: 37-45 and 75-89.
Uzal, F. A., and Robles, C.A. (1993). Mai seco, a grass sickness - like
syndrome of horses in Argentina. Veterinary Research Communications 17:
449-457.
Uzal, F. A., Woodman, M P., Giraudo, C.G., Robles, C.A. and Doxey, D.L.
(1996). An attempt to reproduce 'mal seco' in horses by feeding them
Festuca argentina. The Veterinary Record 139: 68-70.
Uzal, F. A. a. R., C.A. (1995). Epidemiology and aetiological features of mal
seco, a grass sickness-like syndrome of horses. First International Workshop
on grass sickness, equine motor neurone disease and related disorders.
Bern, Switzerland, Equine Veterinary Journal Ltd, Newmarket, Suffolk, UK.
Vanderkerckhove, J., Schering, B., Barman, M., Aktories, K. (1988).
Botulinum C2 toxin ADP - ribosylates cytoplasmic beta / gamma actin in
arginine 177. The Journal of Biological Chemistry 263: 696-700.
Wagner, B., Miller, D.C., Lear, T.L., Antczak, D.F. (2004). The complete map
of the Ig heavy chain constant gene region reveals evidence for seven IgG
isotypes and for IgD in the horse. The Journal of Immunology 173: 3230 -
3242.
Weir, R. C., Porter, R.R., Givol, D. (1966). Comparison of the C-terminal
amino - acid sequence of two horse immunoglobulins IgG and IgG(T). Nature
212:205-206.
Whitlock R.H., Buckley., C. (1997). Botulism. Veterinary Clinics of North
America: Equine Practice 13: 107-128.
Whitwell, K. (1991). Do hares suffer from grass sickness? Veterinary Record
128: 395-396.
295
Whitwell, K. (1997). Histopathology of grass sickness - comparative aspects
of dysautonomia in various species (equine, feline, canine, leporids).
Proceedings of the First International Workshop on grass sickness, equine
motor neurone disease and related disorders, Berne, Switzerland, Equine
Veterinary Journal, Newmarket.
Whitwell, K., Needham, J. (1996). Mucoid enteropathy in UK rabbits;
dysautonomia confirmed. Veterinary Record 139: 323-324.
Williamson, L. C., and Neale, E.A. (1998). Syntaxin and 25kDa
Synaptosomal-associated protein: differential effects of botulinum
neurotoxins C1 and A on neuronal survival. Journal of Neuroscience
Research 52: 569-583.
Williamson, L. C., Halpern, J. Dunlap, V. and Neale, E.A. (1995). Botulinum
neurotoxin C acts on syntaxin and SNAP-25 and is cytotoxic to neurons.
Molecular Biology of the Cell. 6(61 a).
Williamson, L. C., Halpern, Montecucco, C.,Brown, J.E. and Neale, E.A.
(1996). Clostridial neurotoxins and substrate proteolysis in intact neurons.
The Journal ofBiological Chemistry 271: 7694-7699.
Wise, L., Lappin M.R. (1991). A syndrome resembling feline dysautonomia
(Key-Gaskell syndrome) in a dog. Journal of the American Veterinary Medical
Association. 198: 2103-6.
Wood, J. L., Milne, E.M., and Doxey, D.L. (1998). A case-control study of
grass sickness (equine dysautonomia) in the United Kingdom. Veterinary
Journal 156: 7-14.
Wood, J. A. and. Gilmour., J.S. (1991). A suspected case of grass sickness
in the Falkland Islands. 128: 359-60.
Yamakawa, K., Nishida, S. and Nakamura, S. (1983). C2 toxicity in extract of
Clostridium botulinum type C spores. Infection and Immunity 41: 858-860.
Yokosawa, N., Kurokawa, Y., Tsuzuki, K., Syuto, B., Fujii, N., Kimura, K. and
Oguma, K. (1989). Binding of Clostridium botulinum type C neurotoxin to
different neuroblastoma cell lines. Infection and Immunity 57: 272-277.
Zhao Y, K. I., Pan Q, Liberies DA, Geli J, Davis SK, Rabbani H,




Association between Key-Gaskell syndrome
and infection by Clostridium botulinum
type C/D
F. Nunn, T. A. Cave, C. Knottenbelt, I. R. Poxton
There is growing evidence that equine dysautonomia is a toxicoinfection with Clostridium botulinum type c.
The possibility that feline dysautonomia has the same aetiology was investigated by attempting to detect
botulinum type c neurotoxin in the food, faeces and the contents of the ileum of affected cats, and by
serology. The toxin was detected directly in four of eight affected cats and after enrichment in seven of
them, and in their dried food. No toxin was detected in healthy control cats or in their tinned food. Recent
exposure to the organism was assessed by the detection of immunoglobulin A (IgA) in the faeces of
healthy control cats and affected cats. The levels of IgA antibodies to the toxin and to surface antigens of
C botulinum type c in the faeces of the affected cats 14 weeks after the outbreak were significantly higher
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FELINE dysautonomia is a disease characterised by extensive
degeneration of the autonomic nervous system (Key and
Gaskell 1982), and dysautonomia has also been reported in
horses, dogs, rabbits and hares. Most of the cases of feline,
equine and leporine dysautonomia have been reported in the
UK (Whitwell 1991, Whitwell and Needham 1996), whereas
most case? of canine dysautonomia have been reported in the
USA (Berghaus and others 2001).
In hnrsps with gms? sickness, CI neurotoxin from
Clostridium botulinum type C (BoNT/c) has been detected in
74 per cent of acute cases and 67 per cent of both subacute
and chronic cases, but in only 10 per cent of control horses
(Hunter and others 1999). During an outbreak of dysautono¬
mia in cats, the same toxin was detected indirectly from ileal
samples from 11 of the 16 affected cats, and after enrichment
from nine of them. The levels of specific immunoglobulin A
(IgA) to both EDTA-extracted C botulinum surface antigens
and a BoNT/c-toxoid complex have also been found to be sig¬
nificantly higher in hnrsps with grass sickness than in con
trol horses (Hunter 2001).
In November 2001, there was an outbreak of feline dys¬
autonomia in a closed non-breeding colony of eight pet cats
(Cave and others 2001) which was investigated to test the
hypothesis that the aetiology of feline dysautonomia might
be similar to that of equine grass sickness, and that it is
caused by toxicoinfection by C botulinum type C/D. The pro¬
cedures used to investigate equine grass sickness were
applied: the detection of the toxin in food, faeces and gut
contents by ELlSA; the isolation of C botulinum from food and
faeces; and the detection of specific IgA antibodies in the




Six of a colony of eight house-kept cats, none of which had
access to the outdoors, were clinically affected. The charac¬
teristics of the cases are shown in Table 1, and the clinical signs
and outcomes are summarised in Table 2. The index case (A1)
was admitted to Glasgow University Veterinary School five
days after first showing clinical signs, and cats Bl, B2 and Cl
were admitted five to eight days after first showing clinical
signs. Cats A1 and A2 died and A3 was euthanased in
extremis. Only A1 and A3 were examined postmortem, and
dysautonomia was diagnosed histopathologicaliy. Clinical
signs persisted in the surviving cats (B1, B2 and Cl). Cats B3
and C2 showed no clinical signs, but a fluoroscopic cxami
nation 96 days after the beginning of the outbreak showed
subjective evidence of reduced oesophageal function; they
may have suffered a subclinical form of the disease. The cats
were fed a single brand of tinned food from a communal bowl
and a single brand of dry food from two communal hoppers.
At the time of the outbreak the batch of dry food had been
in use for six days before the index case. On average it took 10
days for the cats to consume all the dried food contained in
the hoppers. Fresh tins of food were opened daily. The cats'
food and pattern of feeding had not changed during the pre¬
ceding 12 months.
Control cats
Eleven cats over two years old were used as controls. They
were from the same geographical area (Glasgow) and had
unrestricted access to the outdoors. They were owned by staff
from Glasgow Veterinary School, who considered that they
were in good health; their dietary history was unknown.
Sample collection and storage
Faecal samples of 2 g from the cases and controls were
collected in sterile universal containers immediately after
defecation and frozen at -70°C until processed. The cases
were sampled 14 weeks after the onset of clinical signs in the
index case.
The ileum and its contents were obtained from case
A3 postmortem; the ileum was tied off proximally and
distally with nylon suture, removed and frozen at-20°C until
assayed.
A sample of the dry food fed to the cases at the start of the
outbreak was stored at -70°C, and unopened cans of the
tinned food fed to them were stored at room temperature.
Sample preparation
Preparation of faeces with protease inhibitors for the
IgA ELISAs All reagents were stored at -20°C and kept on ice
during the procedure. Two parts protease inhibitor solution
(soybean trypsin inhibitor 1 mg/ml in phosphate-buffered
saline [pbs], 50mM edta containing 0-05 per cent Tween 20)
were added to one part weighed sample (approximately 1 g).
Phenylmethylsulphonyl fluoride (pmsf; Sigma-Aldrich),0TM
in ethanol, was added to a final concentration of ImM. The
mixture was vortexed for 30 to 60 seconds and then cen-
trifuged at 3800 g for 10 minutes. The supernatant was
removed and pmsf was added to a final concentration of 1 per
cent (v/v). After mixing well, the mixture was allowed to stand
for 15 minutes on ice. Heat-inactivated fetal calf serum (fcs)
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was added to a final concentration of 4 per cent (v/v) and the
mixture was centrifuged at 15,700 g for five minutes. The
supernatant was removed and stored at -70°C.
Preparation of ileal tissue with saponin for the IgA
ELISAs Antibody was extracted from the ileum with saponin
as described by Bergquist and others (2000); 1 g of frozen
tissue was removed aseptically and thawed for eight hours
at 4°C in 2 ml pbs containing 2 per cent saponin (w/v),
1 mg/ml soybean protease trypsin inhibitor, 50mM edta, 0 05
per cent Tween 20, 2mM pmsf, 0-2 mg/ml sodium azide
and 4 per cent fcs (v/v). After thawing, the samples were agi¬
tated with sterile forceps and then vortexed for 30 seconds.
The samples were centrifuged at 15,000 g for five minutes and
the supernatants were collected and stored at -70°C until
used.
Preparation of faeces and food samples for the ELISA
for BoNT/C and bacteriology For non-enriched samples,
approximately I g of the sample was added to 10 ml of pbs,
pH 7-2, containing 0-2 per cent gelatin (pbs-g), and the sam¬
ples were incubated overnight at 4°C.
For enriched samples, approximately 1 to 2 g was added
to 15 ml of prereduced nzcasecmb medium (Hunter and
others 1999) and incubated anaerobically at 30°C for
five days. After vortexing thoroughly, the samples were
centrifuged at 3800 g for 20 minutes and the supernatant was
collected and stored at -20°C.
EDTA extraction of C botulinum surface antigens Cul¬
tures of C botulinum (20 ml) were prepared in Fastidious
Anaerobe Broth (LabM) and incubated anaerobically at 30°C
for 18 hours. The strain used was a toxin-negative C botu¬
linum type C (nctc 3732). edta extracts were prepared as
described by Poxton (1984) and stored at -20°C, and their
protein concentration was determined as described by Lowry
and others (1951).
ELISA detection of anti-BoNT/c toxoid IgA and
anti-C botulinum surface antigen IgA from faeces
and ileal tissue
Microwell plates (Nunc; Fisher Scientific) were coated with
BoNT/c toxoid (Metabiologicals) at 5 pg/ml or surface antigens
at 30 pg/ml diluted in coating buffer (0-05M sodium carbon¬
ate buffer, pH 9-6,0-02 per cent w/v sodium azide) and incu¬
bated overnight at 4°C or at room temperature, respectively.
The plates were washed four times with elisa wash buffer
(one pbs br14a tablet/litre [Oxoid], 15mM sodium chloride,
2mM potassium chloride, 0 05 per cent Tween 20, pH 7-3).
The plates were blocked with pbs containing 3 per cent
teleostean gelatin (Sigma) (pbs-tg) and 0-02 per cent sodium
azide (200 pi per well) and incubated while being shaken for
four hours at 37°C, before being washed four times with elisa
wash buffer. They were stored in sealed polythene bags at
-20°C until used.
TABLE 1: Characteristics and genetic relationships of the eight affected cats
Group Cat Relationship Breed Age (years) Sex
Same parents, same litter Birman
Same parents, different litters Birman
Shared queen with B1 and B2
but different torn and litter

















M Male, F Female, N Neutered, E Entire
Samples were diluted 1 in 4 with pbs-TG before the addi¬
tion of 100 pl/well in quadruplicate. They were incubated
overnight at room temperature and then washed four times
in elisa wash buffer.
Rabbit anti-cat IgA (Nordic Immunologicals) was diluted 1
in 400with pbs-TG and 100 pi was added to each well. The plates
were incubated for three hours at 37°C while being shaken, and
were then washed four times with elisa wash buffer.
Anti-rabbit IgA conjugated to alkaline phosphatase
(Sigma) was diluted 1 in 2000 with pbs-TG and 100 pi was
added to each well. The plates were incubated for three hours
at 37°C while being shaken, and were then washed four times
with elisa wash buffer.
Alkaline phosphatase substrate tablets (104-105 phos¬
phatase tablets, p-nitrophenyl phosphate 5 mg/ml; Sigma)
were diluted 1 in 10,000 with substrate solvent (0-05M
sodium carbonate solution, pH 9-8, with ImM magnesium
chloride) to give a concentration of 1 mg/ml and 100 pi of this
solution was added to each well. The plates were then incu¬
bated at room temperature for 30 minutes and read with an
Anthos plate reader at 405 nm, referenced at 620 nm.
Bacteriological isolation of organisms from
faeces and food
Tenfold dilutions (10"' to 10^) were made from the non-
enriched and enriched samples in pre-reduced nutrient broth
after 24 and 48 hours, and plated on to fastidious anaerobe
agar (faa) (Lab M) containing 5 per cent egg yolk emulsion
(Oxoid) and 10 pg/ml gentamicin. The plates were incubated
for up to five days and examined for lecithinase and lipase
activity. Likely colonies were re-streaked for purity and also
incubated aerobically on Columbia blood agar (Oxoid cba
base with 5 per cent defibrinated horse blood) to check for
aerobic growth. The colonies were also examined by Gram
stain and phase-contrast microscopy.
ELISA detection of BoNT/C toxin from cat food,
faeces and ileum
A polyvalent guinea pig antiserum (camr) raised against
purified BoNT/c was used as a capture antibody. Optimal dilu¬
tions of the reagents were determined by using a checker-
TABLE 2: Major clinical signs shown by the eight affected cats and the outcome of the disease 1
Cat Lethargy
Regurgitation/ Urinary Bilateral Histopathological
vomiting Appetite Dysphagia Constipation retention pupillary dilatation Outcome confirmation
A1 + + Anorexic + + + + Died +
A2 + + Anorexic + + + + Died _
A3 + + Anorexic + + + + Euthanased +
Bl + + Reduced - - + Survived _
B2 + + Anorexic - + + Survived _
B3 + Normal - - - - Survived _
CI + Normal - - _ Survived _
C2 - Normal - - - Survived -
+ Present, - Absent
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(a)
FIG 1: Box and whiskers
plots of faecal
mmunoglobulin A (IgA)
expressed in terms of
the optical density (OD)
in the ELISA against
(a) botulinum type C
neurotoxin toxoid




C botulinum type C
strain. The affected cats
were sampled 14 weeks
after the onset of
clinical signs (with the
exception of the lowest
ralue, which was from
an ileal sample from
a cat which was
euthanased in the third
week of the outbreak).
Ihe control group
consisted of 11 healthy,
free-roaming cats. The
affected group of cats
tiad significantly higher





TABLE 3: Detection of the botulinum type C neurotoxin in the








board titration. Microwell plates (Nunc) were coated with
100 pi per well of the antiserum diluted 1 in 10,000 in 0-05M
sodium carbonate buffer, pH 9-6, 0 02 per cent w/v sodium
azide, and incubated overnight at 4°C. The plates were then
washed three times with elisa wash buffer.
They were then postcoated with PBS-TG (200 pi per well)
for two hours at 37°C in a shallow water bath, and washed
three times in eusa wash buffer.
The non-enriched samples were added (100 pi per well)
either neat or diluted 1 in 2 and 1 in 4 in PBS-TG, and the
enriched samples (100 pi per well) were added neat or diluted
1 in 5 and 1 in 25 in PBS-TG, and incubated for three hours
at 37"C in a shallow water bath, and then washed three times
in elisa wash buffer. The guinea pig anti-BoNT/C horse¬
radish peroxidase conjugate (camr) was diluted 1 in 300 in
PBS-TG, added to the plates (100 pi per well) and incubated
for three hours in a shallow water bath. After washing three
times in PBS containing 0-05 per cent Tween 20, substrate
solution (3,3', 5,5'-tetramethyl-benzidine dihydrochloride
tablets (Sigma) dissolved in phosphate citrate buffer, pH 5 0,
with 2 pi of 30 per cent hydrogen peroxide per 10 ml) was
added at 100 pi per well. The reaction was allowed to develop
at room temperature for up to 60 minutes and was stopped
by the addition of 50 pi of 2M sulphuric acid to each well.
A standard curve of purified BoNT/C (camr) was run on each
plate. The limits of detection of this assay were 0-8 ng/ml
and a standard curve of purified neurotoxin with concen¬
trations ranging from 200 ng to 0-8 ng was included on each
plate.
Controls and statistical analysis
No positive control sera were available, but positive signals
were identified in the initial assays and these were used as



























ND Not detected, + Present
controls and to normalise the results in later assays. Negative
controls consisted of coated wells with no sample but
with conjugate, and coated wells with sample but no con¬
jugate.
The results were analysed by using SPSS software (SPSS
Science) and the Mann-Whitney U test. Significance was set
at the 5 per cent level.
RESULTS
ELISA to detect IgA antibodies to BoNT/C toxoid
and C botulinum surface antigens from faeces
and ileal tissue
Specific IgA antibody to BoNT/C and surface antigens was
detected mainly in the affected cats which had significantly
higher mean specific IgA levels than the healthy control cats.
The lowest value in the affected cats (Fig 1) was observed in
the ileum of case A3, in a sample taken during the outbreak
(week 3) and not 14 weeks afterwards like the others.
The elisa values for IgA antibody to BoNT/c toxoid in the
free-roaming control cats (median 0-23, range 0-6 to 0-03)
were significantly lower than in the surviving cases (median
1-5, range 1-7 to 1-3) [P<0-001 ]). This analysis excludes the
ileum sample from A3, but if it is included the results are
still significant (median 1-45, range 1-7 to 0-7 [P<0-001 ]).
Similarly, the levels of IgA against EDTA-extracted surface anti¬
gens were much lower in the control cats (median 0-23, range
0-85 to 0-06) than in the surviving affected cats (median 0-92,
range 1-35 to 0-81 [P<0-001 ]). Again, if the ileal sample from
A3 is included, the results are still significant (median 0-87,
range 1-35 to 0-34 [P<0-05]).
Bacteriological isolation of organisms from
faeces and food
On the basis of the colony morphology the faecal samples did
not yield any likely colonies, and there was no growth anaer-
obically from the tinned cat food. Likely colonies did appear
in the cultures of the dry food, but subculture was unsuc¬
cessful despite several attempts.
ELISA detection of BoNT/c toxin in cat food, faeces
and ileum
Toxin was detected without enrichment in faecal samples
from three of the six clinical cases, and one of the two sub¬
clinical cases (CI). The index case (Al) had the highest fae¬
cal concentration of toxin. No toxin was detected in the faeces
of the control cats or in the cat food by this method. After
enrichment, toxin was detected in faecal samples from all the
clinical cases except B3, but none was detected in faeces from
the control cats. Toxin was detected in the dry cat food but
not in the tinned cat food. Table 3 summarises these results
and shows the amounts of toxin detected by the direct detec¬
tion method.




There is evidence that equine dysautonomia, or grass sickness,
is caused by a toxicoinfection with C botulinum group III phe-
♦ notype (serotype C/D) (Hunter and others 1999, Hunter
2001).
1 C botulinum type C mainly affects animals and can pro¬
duce three toxins: CI (BoNT/c) is a bacteriophage-encoded
neurotoxin that inhibits the release of neurotransmitters by
• specifically proteolysing syntaxin (Schiavo and others 1995)
and snap-25 (Foran and others 1996) at cholinergic nerve
terminals; C2 and C3 toxins both have adp-ribosylating
activity, and C2 can disrupt the ultrastructure of the
cytoskeleton (Mauss and others 1990). C botulinum type D
is very similar to C botulinum type C and is distinguishable
only by the bacteriophage-encoded type D neurotoxin.
Mosaic toxins consisting of type C and type D subunits also
occur (Morrishi and others 1989). Of these toxins, only
BoNT/c has been shown to be cytotoxic in vitro (Kurokawa
and others 1987) and could be the cause of the pathology
observed in dysautonomias.
It is very difficult to isolate the organism and to detect
the toxin. C botulinum is highly fastidious and the toxin is
encoded on an unstable bacteriophage which is easily lost
upon subculture. The presence of toxin after enrichment does
not necessarily mean that toxin was present in vivo and the
absence of toxin does not necessarily mean that the organism
was not there. These results provide evidence that there is
an association between feline dysautonomia and a toxico¬
infection with C botulinum type C similar to that reported
in equine grass sickness. Hunter and others (1999) detected
toxin in healthy horses leading to the hypothesis that C botu¬
linum type C/D may be present in the gastrointestinal tract of
healthy horses. In these cats, the toxin was detected only in
samples from the affected cats, and the samples containing
the highest concentrations of toxin were from the three most
< acutely affected cats (Al, A2 and A3); the one negative sam¬
ple came from the least affected cat (B3). The toxin assay is
highly specific and does not detect BoNT/D or any of the other
botulinum neurotoxins.
Given the very different diets and gastrointestinal physi¬
ology of horses and cats it is possible that cats kept indoors
are not normally exposed to C botulinum type C/D in their
canned food. The dried food was positive for toxin after
"
enrichment, and it is possible that contamination with cereal
or soil in dried food may harbour C botulinum (and other
Clostridia) and provide an environment in the gut that allows
. them to proliferate. Dry food is heated only to 80°C during
processing, theoretically allowing C botulinum spores to sur-
4
vive. Since the investigation, the dried and tinned foods of dif¬
ferent brands fed to three other cats with Key-Gaskell
syndrome have been assayed for toxin and all have been neg¬
ative. These cats were allowed access to the outdoors, and
Berghaus and others (2001) and Harkin and others (2002)
have shown that free-roaming dogs, known to forage, are
more likely to develop dysautonomia.
Local mucosal immunity may be important in protecting
animals against the disease, especially free-roaming cats that
may be exposed to C botulinum type C/D through hunting.
However, in house-kept cats that are not naturally exposed to
the organism, specific IgA may be a good indicator of their
exposure. The affected cats had detectable levels of specific
IgA whereas the healthy controls did not. The control cats
were free-roaming but only three of them showed a positive
signal to BoNT/c toxoid, compared with all of the affected cats.
No dietary history was available for the control cats. No pos¬
itive control for specific IgA is available and the concentration
of IgA in the samples from the affected cats may have been
increased by dehydration, although they were not clinically
dehydrated when sampled. The assay used was not quantita¬
tive, and there were only a small number of cats; a case-
control study would be useful, particularly of animals fed
similar diets.
It is not known whether the gut stasis is caused directly
by the production of the toxin. However, the detection of spe¬
cific IgA in gut samples from acute cases of grass sickness
(Hunter 2001) indicates that the horses had been exposed to
the organism before the clinical signs developed, and that the
gut stasis may be an effect rather than a cause of the disease.
The levels of specific serum IgG have been found to be
significantly lower in horses with grass sickness than in
healthy controls (Hunter and Poxton 2001), suggesting that
weakly immune animals may be more susceptible to grass
sickness.
The results of this investigation provide strong circum¬
stantial evidence of an association between feline dysautono¬
mia and C botulinum type C. The toxin and specific IgA were
detected in samples from the affected cats, and the toxin was
also detected in samples of the dried food fed to the cats. Only
a small number of samples from the affected and control cats
were available, but the results warrant further investigation of
any new cases of feline dysautonomia.
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Two koi (Cyprinus carpio) from the same pond developed similar lesions of scoliosis. Radiographic
examinations showed that their spines had become malaligned as a result of vertebral compression
fractures involving T14 to T16. The vertebrae in both fish were stabilised with screws, k-wire and
polymethylmethacrylate. They both appeared to improve after surgery, but they began to decline and
died within three months. A postmortem examination revealed multi-organ inflammation that was
not associated with the surgical implants.
SCOLIOSIS, or'bent-back', in koi (Cyprinus carpio) is being
reported more often. Many causes have been suggested,
including vitamin C deficiency (John and others 1979, Halver
and Hardy 1994); electrocution as a result of either lightning
strike (Barlow 1993), faulty submersible pumps (Johnson
1997) or clcctrofishing (Sharber and Carothers 1988); tryp
tophan deficiency (Halver and Shanks 1960, Kloppel and Post
1975, Poston and Rumsey 1983,Walton and others 1984, Post
1993); trauma; organophosphates (Couch and others 1977,
Alam and Maughan 1993, Waddington 1995); and bacterial
cold water disease (Noga 1996). Although some fish continue
to do well with a noticeable curvature of the spine, others
become debilitated and intervention becomes necessary This
paper describes the progression of the condition and the sur
gical stabilisation of scoliosis in two koi.
CASE HISTORY 1
In July 2001, an approximately two-year-old, 56 cm, 1314 g,
female doitsu sanke koi developed a 3 cm chevron-shaped
ulcer, dorsal to its right pectoral fin. The fish shared a 56,775
litre pond, with a maximum depth of 137 cm, with 30 other
koi and 10 goldfish (Carassius auratuc). Thewater quality had
been good, but in the previous three months some of the fish
had developed ulcerative skin disease, and when this koi
began separating itself from its school the ulcer was first
noticed. The koi had been treated by the owner with a series
of three injections of 5-7 mg/kg amikacin sulphate (Ami
glyde-V, 50 mg/ml; Fort Dodge) administered intracoelomi
cally every 48 hours.When the injections were given, the ulcer
was cleansed with 10 per cent povidone iodine solution
(Betadine; Purdue Frederick) and then treated with a topical
triple antibiotic ointment (Neosporin; Warner Lambert). All
the fish in the pond were provided with paste food contain¬
ing 0-5 mg/g enrofioxacin (Baytril 2-27 per cent; Bayer
Corporation) at a dose of 10 mg enrofloxacin/kg/day. When
there was no improvement, the paste food was instead
impregnated with 2 mg/g trimethoprim-sulphadiazine
(Tribrissen; Schering Plough) and fed to provide a dose of 30
mg/kg/day, upon a veterinarian's recommendation.
Clinical and radiographic findings
The ulcer was hyperaemic but healing, and there was mild
scoliosis, with a left lateral deviation of the tail at the level of
the anal fin.
A biopsy taken from the tip of the right pectoral fin
had no evidence of microscopic changes A skin scrape taken
from the ulcerative lesion contained a few unidentified non
pathogenic protozoal organisms and one free-living nema¬
tode. The fish was anaesthetised in 200 mg/litre of buffered
tricane methanesulphonate (MS222) (Finquel; Argent
Chemical Laboratories) for the purpose of radiographic
examination (Love and Lewbart 1997) and maintained by
delivering the anaesthetic-containing water through a syringe
over its gills as needed. Dorsoventral radiographs revealed a
right laterodorsal angulation involving the 14th, 15th and
16th trunk vertebrae (T14 to T16) at the level of the caudal
swimbladder. The vertebrae at this site appeared to be
ostcopenic and the intervertebral spaces were not well delin
eated (Fig 1). Lateral views revealed a dorsolateral subluxa¬
tion of the spinal column just caudal to the last rib, involving
T14 and T15. The lateral angulation was considered to be due
to a combination of a fracture and a subluxation. Several cal
lused, mid body fractures were apparent in the caudal ribs.
The koi recovered uneventfully in fresh dechlorinated water;
it resumed swimming with the group of fish and the ulcer
started to heal; it was treated with trimethoprim sulpha
diazinc for two more weeks, but no further treatment was
considered necessary.
The Veterinary Record, July 24, 2004 115
